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Abstract 
Streptokinase (SK), expressed by Lancefield Group A, C and G β-haemolytic Streptococci and 
Staphylocoagulase (SCG), expressed by S. aureus, are bacterial virulence factors which 
belong to a family of proteins known as Zymogen-activator and adhesion proteins (ZAAPs). 
SK and SCG are responsible for the non-proteolytic activation of plasminogen and 
prothrombin, respectively. Understanding of SK activity is exclusively based on the Group C 
(GCS) S. equisimilis H46a SK, a ‘clot buster’ or thrombolytic used in the treatment of 
Myocardial Infarction (MI), which exhibits no fibrin specificity. SK is the most used thrombolytic 
worldwide. 
Here, detailed kinetic studies in purified assay systems explored the mechanistic variation 
between a recombinant H46a SK (rSK H46a) and a Group A Streptococcal SK (M1GAS), most 
typically isolated in invasive human infection. This work demonstrates a fibrin specific 
mechanism for M1GAS SK and proposes a kinetic model for M1GAS SK plasminogen 
activation, to compliment the “Trigger and Bullet” hypothesis for H46a SK by Bock and 
colleagues. 
This work has relevance to the use of SK variants, with enhanced fibrin specificity, for 
improvement of thrombolytic therapies. Cardiovascular diseases such as myocardial 
infaraction and ischaemic stroke are significant casues of mortality, particularly in the 
developing world. Access to Alteplase, an expensive recombinant tPA and the only licensed 
treatment for stroke, is limited and there is interest in the use of SK for this purpose. 
Furthermore, microbial resistance is an increasing health burden, as demonstrated by 
programs such as the Longitude prize. Exploring the mechanisms of bacterial virulence factors 
at the molecular level such as this could provide rationale for the development of much-needed 
new antimicrobial technologies.  
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Chapter 1: Introduction 
1.1 An overview of haemostasis and fibrinoysis 
Haemostasis, the prevention of blood loss, and fibrinolysis (clot breakdown) are a delicate 
equilibrium necessary to ensure continuous blood flow, thus preventing ischaemia and 
maintaining a functional vascular system, whilst avoiding excess blood loss following blood 
vessel damage (Marder, 2012). Haemostasis is generally divided into primary and secondary 
haemostasis. Primary haemostasis is the formation of a platelet plug, the initial step to prevent 
blood loss, with secondary haemostasis the act of blood coagulation (Clemetson, 2012). There 
are two main triggers of coagulation - the extrinsic and the intrinsic pathways. The extrinsic 
pathway is initiated by tissue damage which causes tissue factor release, whereas the intrinsic 
pathway is initiated by contact with negatively charged surfaces, including the surface of 
platelets (Marder, 2012). 
Many steps in the coagulation and fibrinolysis pathways involve conversion of inactive 
zymogens to active serine proteases, thus forming an amplifying cascade; an idea first 
proposed in 1964 (Davie and Ratnoff, 1964). Overall, the main intention of the coagulation 
cascade is the generation of thrombin, which among other functions such as FXIII and platelet 
activation catalyses the hydrolysis of fibrinogen to form fibrin, the protein framework of blood 
clots (Figure 1.1) (Davie, 2003).  
Fibrinolysis, initiated by plasminogen conversion to plasmin, counteracts the effect of the 
coagulation cascade, to subsequently breakdown the fibrin clot (Cesarman-Maus and Hajjar, 
2005). The sophisticated feedback loops of the coagulation and fibrinolysis factors maintain 
healthy blood flow with essential input from platelets providing further regulation.  
As well as maintaining blood flow and preventing blood loss, coagulation is critical for 
mammalian response to pathogenic invasion. Fibrin clots help to trap pathogens preventing 
their entry into the blood (see section 1.8 for further information). 
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Figure 1.1   A simplified coagulation cascade.  The coagulation cascade culminates in the activation of prothrombin, to the serine protease 
thrombin, and thus the initiation of fibrin formation. Thrombin also activates FXIII to FXIIIa which cross-links fibrin to stabilise the clot. Plasminogen 
is activated to the serine protease plasmin by physiological plasminogen activators tPA and uPA to promote fibrinolysis, the dissolution of fibrin 
into fibrin degradation products.  
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1.2 Fibrinogen and fibrin formation 
Fibrinogen is a large (340 kDa) soluble glycoprotein dimer circulating in human blood and 
extracellular fluids (Chapin and Hajjar, 2015). Though considered inert in circulation, 
fragments made in a variety of ways can enhance plasminogen activation, and fibrinogen has 
been shown to enhance the activity of urokinase (uPA) and tPA (Thelwell and Longstaff, 2007, 
Bringmann et al., 1995a).  
Fibrinogen consists of three polypeptide chains termed Aα, Bβ and γ (Henschen et al., 1983) 
which fold to form a central E structural domain, two D regions and αC domains (Medved and 
Nieuwenhuizen, 2003). The E domain contains fibrinopeptide A and fibrinopeptide B. 
Thrombin initially cleaves at Arg17-Gly18 on the Aα chain and then at Arg14-Gly15 on the Bβ 
polypeptide, to releases fibrinopeptide A first, and then fibrinopeptide B, from the fibrinogen 
molecule to initiate fibrin formation (Medved and Nieuwenhuizen, 2003). This cleavage 
exposes knobs ‘A’ and ‘B’ located on the E domain, allowing them to fit into holes ‘a’ and ‘b’ 
respectively, located in the D region, of other fibrinogen molecules. It is the removal and 
arrangement of fibrinopeptide A first that promotes protofibril formation and their lateral 
overlapping (Medved and Nieuwenhuizen, 2003).  The cleavage to release fibrinopeptide B, 
which occurs subsequently, promotes lateral association of protofibrils (Yang et al., 2000). 
The release of fibrinopeptide B is combined with dissociation of the αC domains within the 
molecule from the central domain, promoting aggregation (Nieuwenhuizen, 2001, Undas and 
Ariens, 2011). 
Aside from cleaving fibrinogen, thrombin can activate the transglutaminase factor XIII (FXIIIa), 
which cross-links the fibrin polymers during fibrin formation via a ε(γ-glutamyl)lysine bond thus 
supporting the fibrin structure and elasticity (Chapin and Hajjar, 2015, Undas and Ariens, 
2011, Duval et al., 2014, Hethershaw et al., 2014). FXIIIa also cross-links the plasmin inhibitor 
α2-antiplasmin to fibrin strands during fibrin clot formation, to further protect from fibrinolysis 
(Pisano et al., 1968, Fraser et al., 2011).   
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1.3 Plasminogen, plasmin and fibrinolysis 
Fibrinolysis is the process of fibrin breakdown to promote clot dissolution. A key event in 
fibrinolysis is the activation of plasminogen to plasmin, a broad-specificity serine protease 
responsible for fibrin hydrolysis (Chapin and Hajjar, 2015). Plasminogen, a 92 kDa zymogen, 
consists of an amino-terminal peptide sequence, five structural domains known as kringles 
and a catalytic domain (serine protease) (Longstaff and Kolev, 2015). 
The zymogen circulates in human plasma at high concentrations (180-200 µg/ml), in a soluble 
form, termed Glu-Pg owing to the amino-terminal glutamic acid residue (Lahteenmaki et al., 
2001). Glu-Pg is closed conformation and thus resistant to activation (Horrevoets et al., 1995). 
Published crystal structures of full-length human Glu-Pg have recently become available, 
providing further insight into the intramolecular interactions involved (Law et al., 2012, Xue et 
al., 2012). The kringle domains of plasminogen contain lysine binding sites (LBS) which 
facilitate binding with fibrin and helps to incorporate plasminogen into clots as they form (Lucas 
et al., 1983). Fibrin binding also alters Glu-Pg conformation to a more open and easily 
activated form (Horrevoets et al., 1995). Limited exposure of inactive plasminogen to plasmin 
upon activation, results in cleavage of the Lys76-Lys77 peptide bond and release of the amino-
terminal peptide sequence. This newly formed plasminogen, known as Lys-Pg, is more readily 
activated (Horrevoets et al., 1995, Lucas et al., 1983).  
Plasmin consists of two-chains, a heavy chain (65 kDa), and a light chain (25 kDa) which 
contains the active site, linked by two disulfide bonds (Cesarman-Maus and Hajjar, 2005). The 
active serine protease initially catalyses the generation of C-terminal lysine residues to 
increase binding of plasminogen and the plasminogen activator, tPA to further promote 
plasmin generation (Cesarman-Maus and Hajjar, 2005). Hydrolysis of fibrin through cleavage 
of several sites generates multiple degradation products including D-dimer, leading to clot 
dissolution (Figure 1.1). Plasmin activity is inhibited by α2-antiplasmin, but binding to fibrin 
protects plasmin from α2-antiplasmin inactivation (Schneider and Nesheim, 2004).  
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1.4 Physiological plasminogen activators and their regulation of fibrinolysis 
Physiological plasminogen activators include the proteases tissue-type plasminogen activator 
(tPA) and urokinase (uPA). tPA and uPA function via proteolytic cleavage of the Arg561-Val562 
bond of plasminogen,  allowing Val562 to form a salt bridge with Asp740 and creating the active 
plasmin enzyme (Wang et al., 1999). As with plasminogen, lysine binding sites in the kringle 
domains, and also a finger domain, promote tPA binding to fibrin (Longstaff et al., 2011). 
Fibrinogen has been demonstrated to bind and stimulate tPA activation of plasminogen in 
several studies (Lucas et al., 1983, Thelwell and Longstaff, 2007, Bringmann et al., 1995b). 
Additionally, tPA activation of plasminogen in the presence of fibrinogen has been shown to 
exhibit a template profile (Thelwell and Longstaff, 2007). However, other studies have seen 
stimulation of activity in the presence of fibrin only, concluding that fibrinogen does not bind to 
plasminogen or the plasminogen activator, tPA. It is therefore hypothesised that tPA and 
plasminogen binding sites are only exposed through the conversion of fibrinogen to fibrin 
(Nieuwenhuizen, 2001, Nieuwenhuizen et al., 1988).  
Plasmin generation is promoted by a positive feedback mechanism whereby the active 
protease cleaves single-chain tPA (sctPA) and singe-chain uPA (scuPA) to generate two chain 
versions (tctPA and tcuPA respectively), thereby enhancing plasminogen activation in solution 
(Cesarman-Maus and Hajjar, 2005). Studies have demonstrated though that in the presence 
of fibrinogen and fibrin, tctPA and sctPA exhibit similar activities (Thelwell and Longstaff, 2007) 
It is important to note the different mechanisms by which plasminogen activation can occur. 
Although the vast majority of intravascular fibrinolysis is catalysed by tPA, mouse models have 
demonstrated that uPA may also play a role (Bugge et al., 1996). Binding of the lysine 
analogue tranexamic acid to lysine binding sites on the plasminogen molecule serves to open 
up the closed conformation of Glu-Pg and enhance its activation by uPA, suggesting uPA is 
more sensitive to the open conformation. This effect is not observed with tPA, whose 
mechanism as outlined above relies more on its colocalisation with fibrin or fibrinogen (Silva 
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et al., 2012). Under physiological conditions, plasminogen activation by both tPA and uPA is 
inhibited by plasminogen activator inhibitor 1 (PAI-1) (Thelwell and Longstaff, 2007).  
1.5 Bacterial plasminogen activators 
To counter host defence systems, bacteria have evolved mechanisms to hijack mammalian 
haemostasis in order to enable their dissemination. Many pathogenic bacteria employ the use 
of bacterial-derived or host physiological plasminogen activators (Sun, 2006). 
The key importance of plasminogen and it’s activation to plasmin, in the degradation of fibrin, 
is exploited by several bacteria who have evolved to produce plasminogen activators. For 
example, the Pla protein is a plasminogen activator protease, like the serine proteases tPA 
and uPA (Bergmann and Hammerschmidt, 2008). It is found on the outer membrane of 
Yersinia pestis, the bacteria responsible for the bubonic plague. Pla is shown to be critical in 
Y. pestis virulence; dramatically reducing the number of bacteria required to kill the host 
(Degen et al., 2007).  
In contrast to this, streptokinase (SK) is an indirect non-proteolytic activator of plasminogen 
secreted by Lancefield gram-positive group A, C and G β-haemolytic Streptococci (Huang et 
al., 1989). The SK protein consists of 414 amino acid residues and is divided into three 
domains termed α (residues 1-146), β (147-290) and γ (291-414) (Wang et al., 1998). Our 
understanding of SK functionality comes exclusively from studies on the well-characterised 
mechanism of the group C H46a S. equisimilis SK, which behaves very differently from the 
physiological and bacterial plasminogen activators described before. The protein has no 
intrinsic enzymatic activity of its own, instead binding to plasminogen to form a 1:1 
stoichiometric complex (Wang et al., 1999). Upon binding and complex formation, Ile1 is 
theorised to act as a substitute for Val562 of plasminogen, working as a counterion and forming 
a salt bridge to Asp740, which induces a conformational change generating an active site in the 
bound plasminogen molecule (Wang et al., 2000).  
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The N-terminal region of SK is shown to be critical for SK activity and SK mutants lacking 
residues 1-59 are incapable of plasminogen activation in solution, becoming fibrin specific 
(Sazonova et al., 2004, Reed et al., 1999).   
However, overall H46a SK demonstrates no fibrin specificity or stimulation, and thus 
understanding of the mechanism of SK activity is based upon this view. In particular, Ile1 of 
SK is necessary for the conversion of the inactive SK-Pg complex to SK-Pg* (active 
plasminogen activator complex) (Wang et al., 2000, Wang et al., 1999). SK also forms a tight 
complex with plasmin, for which it has a higher affinity than plasminogen (Boxrud et al., 2000). 
The formation of the SK-Pm* active complex modifies the substrate specificity of plasmin 
towards the activation loop of free plasminogen (Bajaj and Castellino, 1977). The SK-Pg* and 
SK-Pm* complexes are both plasminogen activators, converting free plasminogen into 
plasmin, through cleavage of the Arg561-Val562 bond; as with the physiological plasminogen 
activators (Figure 1.4). This ability to act as plasminogen activators is not a property 
possessed by plasminogen or plasmin when not in complex with SK, and both SK-Pg* and 
SK-Pm* activity cannot be regulated by physiological plasmin inhibitors α2-antiplasmin 
(D'Costa and Boyle, 2000, Cole et al., 2011). Coevolution of SK and plasminogen in a battle 
of survival between host and pathogen has ensured that SK’s are extremely species specific, 
with variants from human pathogens exhibiting poor activation potential of other animal 
plasminogens (Gladysheva et al., 2003). 
Staphylokinase (SAK), secreted by Staphylococcal bacteria, is another non-proteolytic 
plasminogen activator with many similarities in mechanism to SK. SAK also forms a 
plasminogen activator complex, inducing a conformational change, and generating an active 
site in the bound plasminogen molecule through insertion of its N-terminal residues. However, 
unlike H46a SK, SAK requires binding to fibrin for its activity, (Bergmann and Hammerschmidt, 
2008).  
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Figure 1.2 A schematic of Streptokinase (SK) interactions with Plasminogen (Pg) and 
Plasmin (Pm). A) Representative schematic for SK interaction with plasminogen and plasmin. 
B) SK binds plasminogen in a 1:1 stoichiometric complex inducing a conformational change 
and generating an active site. The active site can bind and cleave further plasminogen 
molecules converting them to the active serine protease plasmin. C) SK preferentially binds 
plasmin and the SK-Pm* complex acts as a plasminogen activator too. The plasmin generated 
hydrolyses fibrin to promote clot breakdown (fibrinolysis). 
 
 
  
    A)      SK + Pg              SK-Pg* + SK-Pg*Pg + Pg + Pm +SK              SK-Pm* 
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1.6 Zymogen activator adhesion proteins (ZAAP’s) and molecular sexuality 
The plasminogen activators SK, and SAK, secreted by Staphylococcus bacteria including S. 
aureus, belong to a family of bacterial proteins and virulence factors known as the zymogen-
activator and adhesion proteins (ZAAPs) (Panizzi et al., 2004). This group includes the 
prothrombin activator staphylocoagulase (SCG), also secreted by S. aureus (Friedrich et al., 
2003).  
ZAAPs interactions with the human host fibrinolytic (SK, SAK) and blood coagulation (SCG) 
systems, respectively, have been demonstrated to help establish infection (Figure 1.3) 
(Panizzi et al., 2004). The family of proteins function to promote the activation of their 
respective zymogens through the mechanism of ‘molecular sexuality’, where activation is non-
proteolytic and achieved by complex formation inducing a conformational change and the 
generation of an active site (Panizzi et al., 2004). The concept of ‘molecular sexuality’ was 
first proposed by Bode and Huber in 1976 (Bode and Huber, 1976). ZAAP’s share conserved 
N-terminal sequences which mimic sequences crucial for activation in trypsin (Ile-Val-Gly) and 
chymotrypsin (Ile-Val-Asn). These N-terminal sequences insert into activation pockets on their 
respective zymogens to promote activation (Panizzi et al., 2004, Bode and Huber, 1976).  The 
best characterised of these is the mechanism of plasminogen activation by SK (Figure 1.3). 
1.7 Staphylocoagulase and prothrombin activation  
SCG, a zymogen activator-adhesion protein (ZAAP), is an indirect, non-proteolytic activator of 
prothrombin secreted by Staphylococcus aureus (Panizzi et al., 2004). The SCG protein is 
divided into N-terminal D1-D2 domains which bind prothrombin, a linker region and the 
fibrinogen-binding C-terminal domain (Friedrich et al., 2003, McAdow et al., 2012). In a 
manner analogous to plasminogen activation by SK, the N-terminal Ile1-Val2-Thr3 of SCG is 
shown to insert into the Ile16 ‘activation’ pocket of prothrombin and form a salt bridge with 
Asp194, as demonstrated by X-ray crystallography (Friedrich et al., 2003). The formation of this 
salt bridge acts as a substitute for the N-terminal Ile formed following physiological cleavage 
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of prothrombin, and is the fundamental concept of the molecular sexuality mechanism 
(Friedrich et al., 2003, Bode and Huber, 1976).  
SCG binding to prothrombin causes a conformational change in the zymogen, inducing a 
functional active site. Like SK, the N-terminal of SCG is important for zymogen activation with 
Ile1 and Val2 shown to be critical (Friedrich et al., 2003), and the bacterial protein has no 
intrinsic enzymatic activity of its own. SCG has been shown to form active ‘staphylothrombin’ 
complexes with both prothrombin (SCG-prothrombin) and thrombin (SCG-thrombin) to 
specifically cleave fibrinogen to make fibrin (Panizzi et al., 2004). The SCG-prothrombin 
complex demonstrates ~2 fold greater amidolytic activity than SCG-thrombin, but overall the 
efficiency against fibrinogen is indistinguishable compared to human thrombin (Friedrich et al., 
2006). As with SK and SAK, S. aureus SCG activity is species specific, with poor potential as 
a bovine prothombin activator (Friedrich et al., 2006). The key difference between SK function 
and SCG is that the staphylothrombin complexes act directly on the thrombin substrate 
fibrinogen, whereas SK-Pm* and SK-Pg* complexes act as plasminogen activators.  
Staphylothrombin does not activate Factor V, Factor VIII or many other physiological 
substrates of thrombin (Hendrix et al., 1983), but there is conflicting evidence wih regard to 
staphylothrombin interaction with FXIII (McAdow et al., 2012, Panizzi et al., 2004). 
Staphylothrombin do not appear to be regulated by physiological thrombin inhibitors 
(Kawabata et al., 1986) with the formation of the activator complex shielding thrombin from 
antithrombin inhibition (Hendrix et al., 1983). However, the therapeutic thrombin inhibitors 
argatroban (Hijikata-Okunomiya and Kataoka, 2003) and dabigatran have been shown to 
inhibit SCG-prothrombin activity (Vanassche et al., 2010). Dabigatran has also been 
demonstrated to reduce S. aureus virulence and sepsis in in vivo models (Vanassche et al., 
2011, McAdow et al., 2011), as well as staphylothrombin initiated platelet aggregation 
(Vanassche et al., 2013).  
Both SCG-prothrombin and SCG-thrombin bind to fibrinogen with high affinity via an 
alternative mechanism from that of thrombin alone, forming a pentameric complex consisting 
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of two SCG-(pro)thrombin complexes and one fibrinogen molecule (Panizzi et al., 2006). 
Despite understanding of staphylothrombin interaction with fibrinogen and the mechanism of 
fibrin formation, there is little understanding of the properties of the fibrin product formed.  
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Figure 1.3 The interaction of SCG and SK with the mammalian haemostasis system. 
SCG secreted by S. aureus binds to prothrombin and thrombin to form staphylothrombin 
complexes that promote fibrin formation to enable bacterial immune evasion. SK from 
Streptococcal species bind plasminogen and plasmin to form plasminogen activator 
complexes that promote the generation of plasmin. The plasmin generated by SK activity 
hydrolyses the fibrin clot to promote bacterial dissemination in the host. 
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1.8 Haemostasis, mammalian defences and bacterial virulence 
Coagulation plays an important part in mammalian defence against invading pathogens. The 
fibrin networks of clots encapsulate, kill and block entry of invading pathogens, providing a 
physical barrier to pathogenic entry and dissemination (Loof et al., 2014, Shannon et al., 
2010). There is extensive evidence detailing the interaction between pathogenic bacteria and 
the coagulation system of their human host. In particular, the binding of peptides released 
during thrombin catalysis of fibrinogen to bacterial fibrinogen-binding surface receptors has 
been demonstrated to reduce the number of colony forming units (CFU’s) and aid the killing 
of Group A Streptococci, Group B Streptococci and S. aureus (Pahlman et al., 2013). Whilst 
the presence of FXIIIa has been demonstrated to facilitate entrapment of E. coli and S. aureus, 
with FXIIIa-deficient clots losing this capacity (Wang et al., 2010) as well as the killing and 
trapping of S. pyogenes within the fibrin networks of the clot, through cross-linking of the 
bacterial fibrinogen-binding surface protein M1 to fibrin strands (Wang et al., 2010, Loof et al., 
2011). FXIII has also been shown to prevent establishment of S. pyogenes infection in a 
murine model. Here the bacteria were localised to within fibrin clots in wild-type mice (i.e. in 
the presence of FXIII), but had disseminated beyond the initial site of infection in FXIII-deficient 
mice (Loof et al., 2012).   
To counteract host defences, evolutionary advantage has ensured that many bacterial species 
including Staphylococci and Streptococci studied in this work, display cell surface proteins that 
bind coagulation factors, including plasminogen and fibrinogen, as well as secrete 
plasminogen activators to influence haemostasis and fibrinolysis (Sun, 2006). These 
interactions with fibrinogen or plasminogen are an effective way to localise plasmin activity to 
the bacterial surface (Takada and Takada, 1989a). They also allow bacteria to degrade host 
fibrinogen, extracellular matrix and tissues to facilitate dissemination and establish invasive 
infection (Bergmann and Hammerschmidt, 2008).  
Understanding the interaction between bacterial proteins and haemostatic proteins at the 
molecular level could also prove useful for the development of new antimicrobial technologies 
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to help fight infection. There is an increasingly pressing need for advancements in this area 
given the rising instance of microbial resistance to available antibiotics, and few suitable 
developments (Longitude Prize Open, 2015). 
1.8.1 Haemostasis and Streptococcal virulence 
Both Group C  (GCS) and Group A Streptococci (GAS) are capable of human diseases but it 
is GAS, in particular the M1GAS serotype, that is the predominant isolate in severe invasive 
Streptococcal infections (Steer et al., 2009, Ekelund et al., 2005, Cole et al., 2011). S. 
pyogenes, an M1GAS, is a strict human pathogen, responsible for diseases such as impetigo 
and pharyngitis, as well as life-threatening conditions including Streptococcal toxic shock 
syndrome (STSS) and necrotizing fasciitis (Walker et al., 2005). It has an extensive portfolio 
of interaction with the human coagulation and fibrinolysis, reviewed recently by (Loof et al., 
2014, Bisno et al., 2003). 
S. pyogenes displays several surface proteins which bind human coagulation factors including 
plasminogen, fibrinogen, FV, FXI and FXII and hijack the human coagulation system to 
promote infection (Herwald et al., 2003). The interaction of streptococcal strains with the host 
plasminogen activation system is particularly important in establishing invasive systemic 
disease (Cole et al., 2006), and bacterial virulence is increased by SK-dependent interaction 
with plasminogen (Khil et al., 2003).  
Subgroups of M1GAS are known to have different plasminogen activation characteristics 
whereby some strains require the presence of fibrinogen in order to both bind and activate 
plasminogen (McArthur et al., 2008, McKay et al., 2004a). Group A Streptococci fall distinctly 
into three phylogenetic clusters, cluster 1, cluster 2a and cluster 2b, with distinctive surface 
proteins (Figure 1.4) (McArthur et al., 2008). Cluster 2b can bind plasminogen through the 
surface-bound PAM molecule. PAM is not present in cluster 2a bacteria, including the S. 
pyogenes strain studied in this project, which instead have evolved fibrinogen binding potential 
through expression of the M1 protein, the M protein most commonly connected with invasive 
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Streptococcal infection (Steer et al., 2009). Cluster 1 Group A Streptococci produce both 
fibrinogen and plasminogen binding receptors different from PAM and M1 (McArthur et al., 
2008). A hypothesis by the McArthur group suggests that with all GAS bacteria, regardless of 
which cluster, SK and plasminogen can interact with fibrinogen to form a tri-molecular complex 
(Figure 1.4, (McArthur et al., 2008)). However, there is no direct evidence studying these 
proteins in isolation to support this. Plasminogen acquisition to GAS via plasminogen and 
fibrinogen binding to cell surface receptors, is shown to be a crucial factor of establishing 
systemic infection (McKay et al., 2004). (Sun et al., 2012) inhibited SK gene expression in 
GAS bacteria to demonstrate that SK deficiency improves the survival of infected mice. 
The relationship between GAS interaction with human haemostasis and their pathogenesis 
has never been investigated with regard to mechanistic details of SK functionality. It is entirely 
plausible that the mechanistic variety of the specific receptors of each Streptococcal strain 
which bind haemostatic proteins contributes at least in part to differences in their observed 
pathogenesis.  
1.8.2 Haemostasis and S. aureus virulence 
S. aureus is responsible for diseases including infective endocarditis, sepsis and osteomyelitis 
as well superficial soft tissue infections (McAdow et al., 2012). SCG is a known virulence factor 
contributing to the survival of S. aureus in the bloodstream, implemented in the promotion of 
sepsis, colonisation of tissues and abscess formation, a defining feature of S. aureus infection 
(Cheng et al., 2010, DeDent et al., 2012). Specifically, S. aureus mediated fibrin formation 
through SCG activation of prothrombin has been shown to reduce activation of leucocytes 
(Vanassche et al., 2011) and promote platelet aggregation and S. aureus platelet interactions 
(Vanassche et al., 2012). SCG interaction with fibrinogen is known to be crucial in abscess 
formation (Cheng et al., 2009) and has been detected in the pseudocapsule of mouse renal 
abscess models (Cheng et al., 2010). Murine endocarditis model have also demonstrated that 
prothrombin binding to SCG serves to incorporate the zymogen into the bacterial vegetations 
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(Panizzi et al., 2011). SCG distribution is restricted to the host facing peripheral layers of the 
structures in both instances. SCG has also been implemented in the establishment of catheter 
related S. aureus infections (Vanassche et al., 2013). It has been proposed that S. aureus 
may use the fibrin produced via SCG activity as a protective coat allowing immune evasion as 
it disseminates throughout its host (Vanassche et al., 2011, McAdow et al., 2012, Cheng et 
al., 2011). Despite detailed understanding of SCG in virulence models, little attention has been 
paid to understanding the protein and it’s interaction with the haemostastic system at the 
molecular level.  
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Fig 1.4 Proposed mechanisms for the cell surface acquisition of plasmin activity by Group A Streptococcal Clusters 1, 2a and 2b 
(adapted from (McArthur et al., 2008). Phylogenetic analysis of group A streptococcal bacteria revealed three distinct clusters (1, 2a and 2b). 
Each displays a characteristic cell surface proteins that bind plasminogen and/or fibrinogen. A) Cluster 2b display PAM, a plasminogen receptor. 
B) Cluster 2a display M1, a fibrinogen receptor. C) Cluster 1 display plasminogen and fibrinogen receptors but not PAM or M1. 
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1.9 Myocardial infarction and history of thrombolytics 
Cardiovascular disease, including myocardial infarction (MI) or heart attack, is the leading 
cause of death in the world (McKay et al., 2004b). The disease is often a result of blood clots, 
and so ‘clot buster’s’ or thrombolytics are employed as therapeutics administered for the 
dissolution of blood clots in the treatment of acute myocardial infarction (Collen and Lijnen, 
2005). The efficiency of SK as a plasminogen activator resulted in its use as a first generation 
thrombolytic drug along with the physiological plasminogen activator, uPA (Parry et al., 2000). 
SK is still the most widely used thrombolytic in the world (Armstrong and Collen, 2001).  
The SK protein used in the therapeutic is derived exclusively from the Group C H46a S. 
equisimilis strain. This strain was originally chosen for the production of therapeutic SK 
because it expressed high levels of SK but no erythrogenic toxins. This was an advantage 
when fermenting large culture volumes as required to manufacture the thrombolytic, proving 
much safer than more pathogenic alternatives (Kunamneni et al., 2007). However, H46a SK 
has no proven advantage over other SK strains with regard to plasminogen activation 
potential. In particular, first generation thrombolytics, are not fibrin specific, causing systemic 
plasminogen activation, and depletion of many coagulation factors (Longstaff and Thelwell, 
2005). This is a major concern with thrombolytics, often resulting in bleeding complications 
(Dundar et al., 2003).  
Accordingly, the rationale for the development of second generation thrombolytics was fibrin 
specificity. The objective of more fibrin-targeted plasminogen activation was to improve the 
clot-busting potential and reduce the incidence of bleeding complications seen with systemic 
SK and uPA (Verstraete, 2000). Recombinant tPA (Alteplase) with fibrin-binding domains 
replaced the use of first generation alternatives after demonstrating improvements compared 
to SK for haemorrhagic stroke and mortality in the international randomised GUSTO trial 
(Investigators, 1993). However, the short half life meant large therapeutic doses were needed, 
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and as such systemic activation and bleeding complications were still a problem, and better 
alternatives were needed (Collen and Lijnen, 1991, Verstraete, 2000).  
To further enhance the fibrin specificity of tPA, improve the half life and increase resistance to 
inhibitors, recombinant variants with domain deletions such as reteplase and tenectaplase 
were designed, and the third generation of thrombolytics was founded (Longstaff and Thelwell, 
2005). This group also includes desmotoplase, a plasminogen activator, discovered in 
Vampire bat saliva, that shares similarities with tPA but offers increased fibrin specificity 
(Medcalf, 2012, Verstraete, 2000). 
Overall, despite improved technologies and significant effort, thrombolytics have not 
performed as well as would have been expected with reducing bleeding complications and 
mortality (Armstrong and Collen, 2001, Verstraete, 2000). As such, the treatment of MI has 
largely moved beyond thrombolytics in developed countries, with percutaneous coronary 
intervention (PCI) considered vastly superior (Armstrong et al., 2003). 
Whilst the treatment of myocardial infarction has moved away from the use of SK in developed 
countries, its use is licensed in Europe. It also remains an inexpensive and easily produced 
thrombolytic for use in less developed nations, where cardiovascular disease is an 
increasingly significant concern (Feigin, 2007). Thrombolytics are an essential treatment for 
ischaemic stroke, with Alteplase (tPA) the only licensed therapeutic available (Longstaff and 
Kolev, 2015). Investigating the mechanism of SK variants from bacterial strains other than S. 
equisimilis, for which very little understanding exists, may provide understanding which could 
improve the effectiveness of the thrombolytic.  
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1.10 Project aims 
The aim of this project is to investigate the details of the ‘molecular sexuality’ mechanisms by 
which the ZAAPs, SK and SCG activate the zymogens, plasminogen and prothrombin, 
respectively.  
For SK, this includes characterisation of plasminogen binding, determination of activation 
kinetics, and study of regulation of activity by fibrinogen and fibrin. In particular, this work will 
investigate the mechanism of plasminogen activation and fibrinolysis by M1GAS SK, as 
relative to H46a SK from GCS, used in the thrombolytic, very little is known about the M1GAS 
SK structure/function relationship. The SK from S. pyogenes shares 88.4% amino acid 
sequence identity with the GCS SK used in the thrombolytic but it is only recently that 
differences in plasminogen activation between SK from Streptococcal strains has been 
investigated. Increased understanding of the mechanistic variation between SK from different 
Streptococcal species will aid our understanding of bacterial virulence, potentially providing 
rationale for new improved antmicrobial therapeutics. It will also aid improvement of 
thrombolytic therapies, for the treatment of myocardial infarction and ischaemic stroke. 
With regard to SCG, the aim is to clone and express a full-length native N-terminal 
recombinant SCG protein and investigate the physical properties of the fibrin product and its 
fibrinolysis, by both physiological and bacterial plasminogen activators of which very little is 
known. There is currently limited understanding of the benefit to S. aureus in producing both 
staphylokinase, which aims to degrade fibrin clots, and staphylocoagulase which serves to 
induce fibrin formation. It is therefore an aim of this project to begin to understand the interplay 
between the two virulence factors and how their interaction with the human host haemostatic 
system may promote their dissemination and establishment of infection.  
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Chapter 2: Investigating plasminogen activation by rSK H46a and rSK MIGAS 
2.1 Introduction 
Until recently understanding of activation of plasminogen by SK was based almost exclusively 
on kinetic studies of the SK from H46a strain of S. equisimilis, which displays no fibrin 
specificity (Chibber et al., 1985, Takada and Takada, 1989b). This SK is used in the 
therapeutic treatment of myocardial infarction. Accordingly, all SK was considered to have no 
fibrin specificity. Recent studies into SK from cluster 2b have begun to elucidate differences 
in mechanisms (Zhang et al., 2012, Zhang et al., 2013). However, there is still limited 
understanding of the association between differences in Streptococcal pathogenicity and 
mechanistic variation among SK.  
Group A Streptococci (GAS) are more commonly associated with invasive disease in humans 
than Group C Streptococci (Ekelund et al., 2005, Cole et al., 2011). Furthermore, the M protein 
serotype most typically associated with invasive GAS disease is M1, a fibrinogen binding 
surface receptor (Johansson et al., 2010). Despite the pathogenicity of GAS, very little is 
known about the structure/function relationship of GAS SK, a known virulence factor.  
To begin to address this, the work herein investigates the activity of GCS S. equisimilis H46a 
strain SK and SK from GAS M1 type S. pyogenes using recombinant variants.  In particular, 
given the expression of M1, examining the effect of fibrinogen and fibrin may provide some 
useful insights into the mechanism of plasminogen activation by M1GAS SK, particularly in 
comparison to H46a SK. Furthermore, a recent study by (Loof et al., 2012), demonstrated that 
the trapping of S. pyogenes within fibrin clots was linked to the FXIIIa-mediated cross-linking 
of M1 to fibrinogen. FXIIIa is also known to cross-link the plasmin inhibitor α2-antiplasmin to 
fibrin strands within the clot (Fraser et al., 2011). However, the fibrinolysis of FXIIIa cross-
linked fibrin by S. pyogenes SK and the combined effect of FXIIIa and α2-antiplasmin on this 
M1GAS SK is unknown, and hence is a focus of this mechanistic study. 
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Previous work has shown that the conserved N-terminal residues of SK are critical for 
plasminogen activation (Wang et al., 2000, Wang et al., 1999). Many expression systems in 
E. coli require the addition of a Met ‘start’ codon at the N-terminus to enable protein 
expression. However, this residue is inefficiently cleaved in E. coli post-translation 
modifications and has been demonstrated to affect SK function, leaving it unable to activate 
plasminogen (Thelwell and Longstaff, 2014). With this in mind, a SUMOstar fusion protein 
expression system was used to express rSK H46a and rSK M1GAS. A SUMOstar expression 
system allows preservation of the native N-terminal sequence in the final product, thus 
minimising any changes in function. Cleavage of the SUMOstar tag by SUMOstar protease 
recognises the tertiary structure of the SUMOstar tag ensuring no unwanted residues are left 
at the N-terminus preserving the native SK sequence (Malakhov et al., 2004). Other 
advantages of the system include simple purification from cell lysate and removal of the 
SUMOstar protease, and SUMOstar tag following cleavage, by Ni-affinity chromatography 
utilising the 6xHis tag within the SUMOstar fusion protein and protease. 
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2.2 Experimental Procedures  
2.2.1 Materials, equipment and software for recombinant protein expression and purification 
LB media powder, B-per, Lysozyme, DNAse I (Thermo Scientific, Massachusetts, USA) 
0.5-3 ml Dialysis cassettes, Coomassie Plus reagent (Pierce, Rockford, IL) 
NuPAGE Novex precast gel system, 4-12% Bis-Tris polyacrylamide gel, MES running buffer, 
Sample reducing agent, Sample buffer, Molecular weight standard, SimplyBlue safety stain, 
His-Trap columns (Life Technologies, Renfrewshire, UK) 
SUMOstar Expression kits (LifeSensors, Pennsylvania, USA) 
T7 Express lysY E. coli (New England Biolabs, Hertfordshire, UK) 
Amino-acid analysis (Alta-Bioscience, Birmingham, UK)  
0.2 micron filters, Ampicillin, IPTG, Imidazole, DTT, NiNTA agarose (Sigma Aldrich, St Louis, 
Missouri, USA)  
Propylene columns (Qiagen, Manchester, UK) 
AKTA Purifier (GE Healthcare, Buckinghamshire, UK) 
Vector NTI (Thermo Fisher, Paisley, UK) 
 
38 | P a g e  
 
2.2.2 Recombinant protein expression and purification  
Recombinant SK (rSK) rSK H46a, rSK M1GAS were expressed as N-terminal SUMOstar 
fusion proteins from transformed glycerol stocks (15% (v/v)) of T7 Express lysY E. coli 
provided by C. Thelwell (personal communication). Cells were transformed with a construct of 
pETBlue-1, a vector for T7 lac promoter IPTG-inducible expression of proteins, the sequence 
for SUMOstar fusion protein (including a 6xHis affinity tag) and the appropriate SK variant 
(Figure 2.1). 
2.2.2A Expression of recombinant proteins in E. coli 
 Overnight cultures of E. coli containing the expression plasmid were diluted 1:50 into fresh 
LB media supplemented with 100 µg/ml ampicillin, and incubated at 37°C with shaking to an 
OD 600 nm of 0.4-0.6.  Protein expression was induced by the addition of IPTG to a final 
concentration of 0.4 mM for a further 2-3 hours.  Cells were harvested by centrifugation (3000 
x g for 15 min) then lysed chemically using 4 ml of B-PER reagent per gram of cells. The B-
PER was supplemented with DNase I (2 µl per ml of B-PER to give a final concentration of 5 
U/ml), lysozyme (2 µl per ml of B-PER to give a final concentration of 0.1 mg/ml) and 1x Halt 
protease inhibitor cocktail according to the manufacturer’s instructions.  The soluble protein 
fraction was recovered by centrifugation (20000 x g for 20 min).  
2.2.2B Purification of his-tagged proteins 
His-tagged proteins were purified from culture lysates by Ni-affinity chromatography using a 1 
ml HisTrap HP column equilibrated with 20 mM Tris-HCl, 0.5 M NaCL, 40 mM imidazole, 
pH 7.7 at room temp on an AKTA Purifier.  All buffers and culture lysates were vacuum filtered 
through a 0.2 µM filter and degassed before use, and applied to the column at a flow rate of 
1 mL min-1.  Culture lysates were supplemented with 40 mM imidazole to limit non-specific 
binding of bacterial proteins and applied to the HisTrap column.  The column was washed with 
15 ml equilibration buffer supplemented with 40 mM imidazole and bound proteins were eluted 
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from the column in 0.5 ml fractions against a 10 ml imidazole gradient of 40 mM – 600 mM.   
Protein elution was monitored using a UV detector (280 nm) and fractions containing the 
recombinant fusion protein (assessed visually using SDS page) were pooled. 
2.2.2C Cleavage of SUMOstar fusion tag 
Pooled fractions of purified proteins were dialysed against protease cleavage buffer (20 mM 
Tris-HCL, pH 8.0. containing 1.5 M NaCl) using 0.5-3ml dialysis cassettes. Dialysis was at 
4 °C initially for 4 hours in 1 L, followed by 2 L overnight, with continuous stirring.  The 
SUMOstar fusion tag was cleaved using SUMOstar protease according to the manufacturer’s 
protocol. Cleavage was typically achieved over 4 hours at 30°C in the presence of 2 mM DTT 
and was confirmed by SDS-PAGE, although overnight incubation were sometimes necessary 
for rSK H46a.  The SUMOstar tag and protease were bound to Ni-NTA agarose by mixing for 
1 hour at room temperature and the cleaved purified protein was recovered by filtration through 
an empty column. 
2.2.2D SDS-page and coomassie staining 
Presence of recombinant proteins in peak fractions following Ni-affinity chromatography, 
molecular weights of proteins, estimations of purity and confirmation of SUMOstar cleavage, 
were checked visually by SDS-PAGE and Coomassi’e staining relative to molecular weight 
markers.   Visualisation of proteins by SDS PAGE was performed using the NuPAGE Novex 
precast gel system.  Proteins were incubated with sample buffer and reducing agent at 70 °C 
for 10 min according to the manufacturer’s instructions. Samples were loaded and run on 4-
12% Bis-Tris polyacrylamide gel alongside SeeBlue Plus2 pre-stained molecular weight 
marker (10 µl) as directed by the manufacturer using NuPAGE MES buffer.  Gels were stained 
with SimplyBlue SafeStain for 1 hour and destained overnight in H2O.   
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2.2.2E Determining protein concentration 
Protein concentrations were determined by amino-acid analysis or using Coomassie Plus 
reagent relative to a standard curve of full-length SK quantified by amino acid analysis.  
2.2.2F Batch pooling 
Several preparations were made and pooled together for each recombinant protein and all 
assays carried out on the same pooled batch. 
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Figure 2.1 Expression vector construct pET Blue- 1 SumoSK H46a. Map of example 
expression vector construct created in Vector NTI (Invitrogen) showing the T7 promoter, the 
ribosome binding site (RBS), ampicillin resistance gene (AmpR), the SUMOstar SK H46a 
fusion protein sequence (SUMO-SK H46a) and 6 x His-tag used for purification. An equivalent 
construct was designed for expression of SUMOstar SK M1GAS, SUMOstar SK H46a del1-
59 and SUMOstar SK M1GAS del1-59. 
 
 
 
                    
pET Blue-1 SumoSK H46a
5045 bp
SUMO-SK H46a
SK H46a
AmpR
6X His Tag
T7 Promoter
RBS
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2.2.3 Material and software for SK activity assays 
2.2.3A Materials 
Buffer A - 0.5 M Tris pH 8.4 at 37 °C. Stored at 2-8 °C for 6 months. 
Buffer B – 10 mM Tris HCL 100 mM NaCl 0.01% Tween 20. Store at 2-8 °C for 1 week. 
Buffer C – Buffer B + 1mg/ml Human Serum Albumin (HSA). Store at 2-8 °C for 3 days.  
Buffer D – 40 mM Tris-HCL 100 mM NaCl 0.01% Tween 20. Store at 2-8 °C for 1 week. 
Blocking buffer – 0.05M Tris HCL, 0.01% Tween 20, pH 8.4 at 37 °C.   
All laboratory chemicals used to make buffers were from Sigma Aldrich, St Louis, Missouri, 
USA.  
Fibrinogen (Calbiochem, Merck Millipore, Billerica, Massachusetts, USA) - reconstituted in 
Buffer B to give stock solution of 50 mg/ml, and flash frozen in liquid nitrogen in small aliquots 
and stored at -40 °C. All dilutions for reaction set ups were in buffer B also. 
Glu-Plasminogen (Glu-Pg) (Quadratech, Surrey, UK) - Reconstituted to 1mg/ml in H20, flash 
frozen in small aliquots in liquid nitrogen and stored at -40 °C. All dilutions for reactions were 
made in buffer C. 
Lys-Plasminogen (Lys-Pg) (Immuno, Vienna, Austria) – Reconstituted to 1 mg/ml in H20, flash 
frozen in small aliquots in liquid nitrogen and stored at -40 °C. All dilutions for reactions were 
made in buffer C. 
WHO 2nd IS Thrombin (01/578) – Reconstituted in 1 ml H20, flash frozen in small aliquots in 
liquid nitrogen and stored at -40 °C. All dilutions for reactions were made in buffer C. 
WHO 3rd IS SK (00/464) – reconstituted in 1ml H20, flash frozen in small aliquots in liquid 
nitrogen and stored at -40 °C. All dilutions for reactions were made in buffer C. 
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rSK H46a, rSK M1GAS, rSK H46a (del1-59), rSK M1GAS (del 1-59) (see section 2). Flash 
frozen in liquid nitrogen and stored in small aliquots at -40 °C. All dilutions for reaction set up 
were made in buffer C. 
S-2251, H-D-Val-L-Leu-L-Lys-pNA (Chromogenix, Milan, Italy) – reconstituted in 15 ml H2O, 
to give a 3 mM stock solution. Stored at 2-8 °C, stable for several months.  
Microtitre plates (Greiner,  Kremsmunster, Austria) – all microtitre plates were blocked with 
200 µL blocking buffer for 2 hours at 37 °C and washed 2x with 200 µL H20 before use. 
2.2.3B Software Packages 
GraphPad Prism (GraphPad Software, San Diego, California, USA) 
SoftMax Pro v5.0 (Molecular Diagnostics, Sunnydale, California, USA) 
Microsoft Excel (Redmood, Washington, USA) 
R script (R Foundation, Vienna, Austria) 
Combistats (EDQM, Strasbourg, France)  
2.2.4 SK Activity Assays 
The methods below describe the measurement of SK activation of plasminogen in the Glu- 
and Lys- forms in solution and in the presence of fibrinogen and fibrin. Initially, the variants 
were investigated in each assay system with fixed concentrations of Plasminogen, thrombin 
and fibrinogen. The assays were then adapted to look at the effect of fibrinogen concentration, 
plasminogen concentration, FXIIIa cross-linked fibrin, tranexamic acid and α2-antiplasmin.  
2.2.4A Plasminogen activation by SK in solution (Figure 2.2A) 
Rates of plasminogen activation by recombinant SK variants were determined using the 
chromogenic substrate for plasmin, S-2251 based on the European Pharmacopeoial method 
for assigning potencies to therapeutic SK (Europe, 2008b).  A range of SK dilutions made in 
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buffer C were mixed with a solution of Glu- or Lys- Pg and S-2251, in blocked 96 well microtitre 
plates. The SK concentrations were such that the rates for rSK H46a and rSK M1GAS activity 
were similar to the WHO 3rd IS SK (00/464) and produced a linear dose response. Final 
concentrations were Glu- or Lys- Pg (100 nM) and S-2251 (0.6 mM) in a total reaction volume 
of 100 µl. The plasmin generated cleaves S-2251 to release p-nitroaniline (pNA) which was 
monitored by measuring absorbance change at 405 nm in 30 s intervals, for 90 min at 37 C.  
Each assay included 4 SK doses with 4 replicates for each sample. Initial rates of plasminogen 
activation were calculated from the slopes of plots where the substrate (S-2251) and 
plasminogen were less than 10% consumed absorbance versus time squared using an R 
program (The R Foundation) script (Silva et al., 2012) written by C. Longstaff (personal 
communication) based on equations (1), (2) and (3) (Longstaff et al., 1995).  
OD405 =
ϵ
2
βνt2 (1) 
β =
kcat(S˗2251)[S˗2251]
KM(S˗2251) + [S˗2251]
 (2) 
ν =
kcat[SK][Pg]
KM + [Pg]
 (3) 
2.2.4B Plasminogen activation by SK in the presence of fibrinogen (Figure 2.2B) 
Rates of plasminogen activation were determined as in 2.2.4A, but with the addition of 
fibrinogen (3.0 mg/ml).  
2.2.4C Plasminogen activation by SK in the presence of fibrin (Figure 2.2C)  
Fibrin clots (60 µl) were made in blocked microtitre plates by incubating thrombin (20 nM) with 
fibrinogen (3.0 mg/ml) containing Glu- or Lys- Pg (100 nM), for 30 mins at 37°C. 40 µl solution 
containing SK and S-2251 (reaction concentration 0.6 mM) were added to the surface of pre-
formed fibrin clots, thus SK activates plasminogen on the surface of the clot, bound to fibrin 
(Longstaff and Whitton, 2004). All dilutions were made in buffer D, so as to produce clear clots 
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which would not affect the absorbance readings from pNA generation. As with the 
chromogenic solution assay, pNA generation was monitored by measuring absorbance at 
405 nm at 30 s intervals for 90 mins at 37 C, and rates of plasminogen activation were 
calculated from transformed plots of absorbance versus time squared using an R program 
script written by Colin Longstaff, personal communication.  
2.2.4D Fibrinolysis (Figure 2.2D) 
Fibrin clots were made in blocked microtitre plate wells by adding a solution of fibrinogen (3.0 
mg/ml) containing Glu- or Lys- Pg (100 nM) (60 µl) to a 40 µl solution of thrombin (20 nM) and 
SK (refer to Figure 2.3). Each assay contained 4 doses and 4 replicates for each SK variant. 
Absorbance at 405 nm was measured at 30 s intervals for 5 hours at 37 C using plate reader 
software SoftMax Pro v5.0 to monitor clotting and lysis through changes in fibrin clot opacity.  
The raw, kinetic data was exported from Softmax Pro plate reader software as a text file. An 
R program script, written by Colin Longstaff (Personal communication, see appendix 1) was 
used to determine the time at maximum absorbance (complete clotting) and time at lowest 
absorbance (complete lysis), to allow calculation of the time to 50% lysis (Figure 2.3). The 
script is capable of determining several parameters from the raw kinetic data such as max 
absorbance, time to max absorbance, time to complete lysis, time to % lysis.  Time to 50% 
lysis from start of reaction is commonly used as a measure of fibrinolysis and as such was 
chosen in this instance as a parameter by which to compare the variants.  
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Figure 2.2 Assay systems used to determine rates of plasminogen activation and 
fibrinolysis by rSK H46a and rSK M1GAS. Assays were performed in 96 well microtitre 
plates, with each image representing the reaction in one well for each of the four assay 
systems (2.2.4A-D). Plasminogen activation by SK against the chromogenic substrate for 
plasmin (S-2251) was measured by monitoring absorbance change at 405 nm in solution (a), 
in the presence of fibrinogen (b) and at the surface of a pre-formed fibrin clot to measure the 
activity in the presence of fibrin (c). Fibrinolysis rates were measured by absorbance change 
at 405 nm in the absence of a chromogenic substrate (d). In this instance, the change in 
absorbance corresponds to the changes in clot turbidity as the fibrin clot forms and lyses.  
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Figure 2.3 Typical clot lysis profile from a fibrinolysis assay (Section 2.2.4D and Figure 
2.2D). Change in absorbance at 405 nm represents lysis and clotting and was used to 
calculate the time at maximum absorbance at 405 nm (complete clotting) and time at lowest 
absorbance (complete lysis), to determine the time to 50% lysis from the start of the reaction, 
as a measure of SK activity. 
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2.2.4E Data analysis – parallel line bioassay  
rSK activity in each assay system was calculated in International Units (IU) relative to the 
WHO 3rd International Standard for SK (00/464), a commercial thrombolytic SK from H46a 
strain. In these assay systems, multiple SK dose responses for all variants were successfully 
fitted to a parallel line bioassay according to chapter 5.3 of the European Pharmacopoeia with 
the software Combistats (EDQM) (Europe, 2008a). Combistats is a statistical analysis 
program for biological dilution or potency assays. Thus, potencies (IU/ml) were reported with 
95% confidence limits and statistical assessment of linearity of dose responses and 
parallelism between standard (00/464) and test SK dose responses. If non-linearity and non-
parallelism were determined to be significant at the 5% significance level, the assay was 
deemed invalid and potency could not be determined. Protein concentrations determined by 
amino acid analysis were used to calculate specific activities, expressed in terms of IU/g 
protein for each SK variant.  
2.2.5 Investigating the effect of fibrinogen concentration on plasminogen activation by rSK 
H46a and rSK M1GAS  
To investigate the effect of fibrinogen further, the solution assay with fibrinogen (Section 
2.2.4B and Figure 2.2B) was adapted to measure plasminogen activation rates by rSK H46a 
and rSK M1GAS over a fibrinogen concentration range (0 -10 mg/ml). 4 replicates of each 
fibrinogen concentration and at least 3 independent experiments were carried out for each of 
the plasminogen activators. SK doses for the variants were determined so as to produce the 
same rates of pNA generation based on activity in solution i.e. in the presence of 100 nM Glu-
Pg and 0.6 mM S-2251, without fibrinogen. All reaction volumes were 100 µl.    
Rates were calculated as in 2.2.4A. Percentage activity compared to in solution (i.e. no 
fibrinogen) was determined in Microsoft Excel and plotted against a log fibrinogen 
concentration range in GraphPad prism, to establish the stimulatory effect of fibrinogen on the 
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rSK variants. The activity for rSK H46a with Lys-Pg was also subtracted from all activities to 
account for the stimulation by formation of a SK-Pg complex and thus determine the effect of 
fibrinogen.  
2.2.6 Investigating the combined effect of fibrinogen and plasminogen on plasminogen 
activation by rSK H46a and rSK M1GAS 
To investigate the effect of fibrinogen further, the solution assay with fibrinogen (as described 
in Section 2.2.4B and Figure 2.2B) was adapted to measure plasminogen activation rates by 
rSK H46a and rSK M1GAS over a fibrinogen/ plasminogen concentration matrix. 12 fibrinogen 
concentrations (0 -10 mg/ml) increasing across a 96 well microtitre plate and 8 concentrations 
of Glu-Pg (0 – 1.6 µM) down the plate, were incubated with 0.6 mM S-2251 and a fixed 
concentration of plasminogen activator, to produce a matrix of 96 different reactions. All 
reactions were 100 µL and a minimum of 3 independent experiments were carried out for each 
of the plasminogen activators, tPA (included to allow comparison), rSK H46a and rSK M1GAS. 
The plasminogen activator doses were determined so as to produce the similar rates of pNA 
generation based on activity in solution i.e. in the presence of 100 nM Glu-Pg and 0.6 mM S-
2251, without fibrinogen. pNA generation was monitored by measuring absorbance change at 
405 nm at 30 s intervals for 90 min at 37 C.    
Rates were calculated as in section 2.2.4A. An R script (Colin Longstaff, personal 
communication, see appendix 2) was used to produce surface contour plots and heat maps 
to allow comparison and an overview of tPA, rSK H46a and rSK M1GAS activity across the 
fibrinogen/plasminogen matrix.  
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2.2.7 Investigating the effect of plasminogen concentration on fibrinolysis by rSK H46a and rSK 
M1GAS  
The fibrinolysis assay (section 2.2.4D and Figure 2.2D) was adapted to incorporate a range 
of plasminogen concentrations (0.0 - 1.6 µM Glu-Pg). The amount of tPA (included to allow 
comparison), rSK H46a and rSK M1GAS was adjusted to ensure similar activities were 
achieved for all the plasminogen activators with 100 nM Glu-Pg. As such, tPA (0.6 nM), rSK 
H46a (0.3 nM) and rSK M1GAS (0.02 nM) were used. A minimum of 3 independent 
experiments were carried out.  
2.2.8 Investigating the effect of tranexamic acid on plasminogen activation by rSK H46a and 
rSK M1GAS  
The solution assay (section 2.2.4A and Figure 2.2A) was adapted to include tranexamic acid 
(0 – 2.5 mM). 3 independent experiments with 4 replicates of each tranexamic acid 
concentration were carried out for a fixed SK dose. The SK concentration for each variant was 
determined such that similar rates of pNA generation were seen without tranexamic acid. As 
such, tPA (0.6 nM), rSK H46a (0.3 nM) and rSK M1GAS (0.02 nM) were used  
2.2.9 Investigating the combined effect of tranexamic acid and fibrinogen on plasminogen 
activation by rSK H46a and rSK M1GAS  
The solution assay with fibrinogen (section 2.2.4B and Figure 2.2B) was adapted to include 
12 fibrinogen concentrations (0 – 10 mg/ml) across the plate and 8 tranexamic acid 
concentrations (0 – 2.5 mM) down the plate; to produce a matrix of 96 different reactions. All 
reactions included 0.6 mM S-2251 and a fixed concentration of plasminogen activator. 3 
independent experiments were performed for each plasminogen activator with 100 nM Glu- 
and Lys- Pg. The plasminogen activator doses were determined so as to produce the similar 
rates of pNA generation based on activity in solution i.e. in the presence of 100 nM Glu-Pg 
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and 0.6 mM S-2251, without fibrinogen or tranexamic acid. As such rSK H46a (0.3 nM) and 
rSK M1GAS (0.02 nM) were used.  
2.2.10 Investigating the effect of tranexamic acid on fibrinolysis by rSK H46a and rSK M1GAS  
The fibrinolysis assay (section 2.2.4D and Figure 2.2D) was adapted to incorporate a range 
of tranexamic acid concentrations (0 – 2.5 mM). The amount of tPA (included to allow 
comparison), rSK H46a and rSK M1GAS was adjusted to ensure similar activities were 
achieved for all the plasminogen activators with no tranexamic acid. As such, tPA (0.6 nM), 
rSK H46a (0.3 nM) and rSK M1GAS (0.02 nM) were used. A minimum of 3 independent 
experiments were carried out.  
2.2.11 Investigating fibrinolysis by rSK H46a and rSK M1GAS of FXIIIa cross-linked fibrin  
The fibrinolysis assay (section 2.2.4D and Figure 2.2D) was adapted to incorporate FXIIa 
cross-linked fibrin. FXIII was pre-activated to FXIIIa via incubation with thrombin (100 nM) and 
5 mM CaCl2 solution for 30 min at 37 °C. Reactions were made with and without FXIIIa at a 
concentration of 2 IU/ml (i.e. twice the normal concentration in plasma).  
2.2.12 Investigating the effect of α2-antiplasmin on fibrinolysis by rSK H46a and rSK M1GAS 
The fibrinolysis assay (section 2.2.4D and Figure 2.2D) was adapted to incorporate α2-
antiplasmin at a fixed concentration of 20 nM. A minimum of 3 independent experiments were 
carried out.  
2.2.13 Investigating the effect of α2-antiplasmin on fibrinolysis of FXIIIa cross-linked fibrin by 
rSK H46a and rSK M1GAS 
The fibrinolysis assay (section 2.2.4D and Figure 2.2D) was adapted to incorporate FXIIa 
cross-linked fibrin and α2-antiplasmin (20 mM). FXIII was preactivated and used as described 
in 2.2.11.   
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2.3 Results 
2.3.1 Expression and purification of recombinant SK variants in E. coli 
Recombinant SK from S. equisimilis (rSK H46a) and S pyogenes (rSK M1GAS) were 
expressed in E. coli as N-terminal SUMOstar fusion proteins.  This system allows simple 
purification by Ni-affinity chromatography utilising the 6xHis tag within the SUMOstar fusion 
sequence. SK SUMOstar fusion proteins were cleaved by SUMOstar protease. The protease 
cleaves precisely at the junction between the tag and the SK sequence leaving no unwanted 
amino acids and preserving the N-terminal Ile essential for SK function.  
The final purification step removes the SUMOstar tag and protease by Ni-affinity leaving the 
purified SK in solution (Figure 2.4). Typically E.coli cultures yielded 200-500 g cleaved 
protein per litre of culture.  SDS-page of each variant under reducing conditions confirmed a 
discrete band, consistent with the expected size relative to MW markers, of 47 kDa. No other 
bands were present on the gel indicating good purity. For each variant several batches of 
protein were expressed and pooled and total protein concentration determined by amino acid 
analysis, sufficient to carry out all the studies in this project. Each combined batch was diluted 
to a working concentration to facilitate appropriate dilution regimes for the activity assays and 
stored as frozen aliquots to negate the effect of any batch to batch variation by preventing 
repeated freeze/thaw cycles. 
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Figure 2.4 SDS-PAGE of rSK H46a and rSK M1GAS to check for SUMOstar fusion 
protein cleavage and purification. Gels were loaded with 500 ng protein and stained with 
Coomassie reagent. Molecular weight markers were included in each gel for reference. A) and 
C) Indicates presence of rSK H46a and rSK M1GAS protein respectively (47 kDa) and cleaved 
SUMOstar tag (according to the manufacturer’s protocol 15-20 kDa) after incubation with 
SUMOstar protease. B) and D) Presence of rSK H46a and rSK M1GAS respectively after 
SUMOstar tag removed by Ni-NTA agarose column filtration. 
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2.3.2 The effect of fibrinogen and fibrin on plasminogen activation by rSK H46a and rSK M1GAS  
Four different assay systems were used to investigate the kinetic activities of rSK H46a and 
rSK M1GAS.  Plasminogen activation was measured in solution; in the presence of fibrinogen; 
in the presence of fibrin; and in a fibrinolysis assay. For each assay system, rSK H46a and 
rSK M1GAS potencies were calculated relative to the WHO 3rd IS for SK (00/464), in IU/ml, 
from multiple SK doses using a parallel line bioassay analysis. To compare SK activity 
between the different assay systems specific activities (expressed as IU/g protein) were 
calculated based on the protein concentration determined for each rSK preparation.   
2.3.2A Glu-Pg activation by rSK H46a and rSK M1GAS in solution  
To investigate SK activity in solution i.e. with no fibrin(ogen) present, the current EP method 
for assigning potencies to therapeutic SK was used. Initial plasminogen activation rates were 
measured against the chromogenic substrate for plasmin, S-2251. The results show rSK 
M1GAS has approximately 5-fold lower specific activity than rSK H46a, 12.4 IU/µg compared 
to 58.2 IU/µg respectively (Figure 3.2).  
2.3.2B Glu-Pg activation by rSK H46a and rSK M1GAS in presence of fibrinogen  
The solution plasminogen activation assay was adapted to investigate SK activity in the 
presence of fibrinogen (3 mg/ml). Potency estimates for rSK H46a and rSK M1GAS were 
calculated relative to the IS (00/464) in the same was as with the original assay, using initial 
plasminogen activation rates against S-2251.  
In the presence of fibrinogen, the specific activity determined for rSK H46a was found to be 
lower than in the solution assay (39.0 IU/µg and 58.2 IU/µg respectively).  Conversely, the 
specific activity of rSK M1GAS was higher in the presence of fibrinogen (20.2 IU/µg) compared 
to the solution assay (12.4 IU/µg) (Figure 3.2). When the activities of rSK H46a and rSK 
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M1GAS in fibrinogen were compared, rSK H46a was 2-fold higher than rSK M1GAS (39.0 
IU/µg vs 20.2 IU/µg), however this is smaller than the 5-fold difference observed in solution. 
The apparent inhibition of activity for rSK H46a may be explained by the competition between 
the chromogenic substrate and fibrinogen for the active site of plasmin. The higher activity 
observed for rSK M1GAS in the presence of fibrinogen appears to overcome any competitive 
inhibition to have an overall stimulatory effect.  
2.3.2C Glu-Pg activation by rSK H46a and rSK M1GAS in presence of fibrin 
The relative activities of rSK H46a and rSK M1GAS were investigated in the presence of fibrin. 
As with the solution and fibrinogen assays, initial plasminogen activation rates were 
determined using S-2251, however in this system the reaction occurs at the surface of a pre-
formed fibrin clot.  This approach is intended to be representative of the mechanism of action 
for therapeutic SK during thrombolytic therapy.  Fibrin clots were made in microtitre plates 
using physiological concentrations of fibrinogen (3 mg/ml) and thrombin (20 nM), incorporating 
plasminogen throughout.  The ionic strength of the buffer used in the reaction was optimised 
to ensure the clots were transparent; thus preventing clot turbidity from affecting absorbance 
readings at 405 nm.   
Specific activities for rSK H46a and rSK M1GAS were derived from potency estimates 
calculated relative to the WHO 3rd IS for SK (00/464).  The presence of fibrin appeared to have 
no measurable effect on the activity of rSK H46a (61.6 IU/µg) compared to the solution assay 
(58.2 IU/µg).  For rSK M1GAS however the activity in fibrin was calculated to be 74.0 IU/µg, 
which is approximately 7-fold higher than the specific activity of rSK-M1GAS calculated in the 
solution assay (12.2 IU/µg) (Figure 2.5).  
2.3.2D Effect of Glu-Pg activation by rSK H46a and rSK M1GAS on fibrinolysis  
The relative activities of rSK H46a and rSK M1GAS were investigated with Glu-Pg in a purified 
fibrinolysis assay system.  Fibrin clot lysis activity was measured by following absorbance 
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readings to monitor changes in clot turbidity corresponding to clot formation and lysis.  
Fibrinolysis rates were calculated as the time to 50% lysis from start of reaction.  Specific 
activities were determined for rSK H46a and rSK M1GAS, based on potency estimates made 
relative to the WHO IS (00/464), and  the activity of rSK-M1GAS (168.3 IU/µg) was calculated 
to be more than two-fold higher than rSK H46a (72.8 IU/µg).  
The relative activities of rSK-H46a and rSK M1GAS in the four assay systems is summarised 
in Figure 2.5 and Table 2.1.  While rSK H46a shows only small changes in activity in the 
presence of fibrin, and inhibition in the presence of fibrinogen, rSK M1GAS activation of 
plasminogen appears to be stimulated by fibrin. The presence of fibrin in the fibrin-bound 
plasminogen activation assay system shows a 7- fold increase in rSK M1GAS activity and 
there is up to a 15- fold increase in the fibrinolysis assay system compared to the solution 
assay where no fibrin(ogen) is present. rSK M1GAS activity is also stimulated in the presence 
of fibrinogen approximately 2- fold.  
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Figure 2.5 The effect of fibrinogen and fibrin on SK activity against Glu-Pg. Specific 
activity (IU/µg) of rSK H46a and rSK M1GAS were determined in solution (EP method), in the 
presence of fibrinogen, in the presence of fibrin and in a fibrinolysis assay using Glu-Pg 
relative to the WHO 3rd IS SK (00/464) to determine the effect of fibrin(ogen). Error bars show 
standard deviation of a minimum of 3 independent experiments (see Table 2.1). 
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2.3.3 Lys-Pg activation by rSK H46a and rSK M1GAS 
For each of the four assay systems, Glu-Pg was substituted with Lys-Pg, a more readily 
activated plasminogen form with an open conformation. Any relative differences between Glu- 
and Lys- Pg could shed light on the mechanism of action of the SK variants such as whether 
SK variants induce different conformational changes in plasminogen or alter fibrinogen 
binding.  
Lys-Pg activation and fibrinolysis rates were faster in all four assay systems than with Glu-Pg 
(data not shown); however the relative specific activities of rSK H46a and rSK M1GAS in IU/µg 
were comparable. The results for the solution plasminogen activation assay show rSK M1GAS 
has approx. 4-fold lower specific activity than rSK H46a; 54.6 IU/µg compared to 14.0 IU/µg, 
respectively. In the presence of fibrin (fibrin-bound plasminogen activation assay), rSK 
M1GAS activity increased, compared to in solution, to 67.0 IU/µg and was similar to rSK H46a 
59.2 IU/µg.  This equates to an approximate 5-fold increase in specific activity of rSK M1GAS 
in the presence of fibrin. In the fibrinolysis assay, rSK M1GAS shows approx. three-fold higher 
activity than rSK H46a (176.3 IU/µg vs. 60.4 IU/µg) (Table 2.1). 
Overall, the comparison of rSK H46a and rSK M1GAS activation of Glu- and Lys- Pg 
demonstrates that the differences seen are due to the binding of SK-Pg complexes with 
fibrinogen and fibrin.  
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Table 2.1 Effect of fibrin on SK activity against Glu-Pg and Lys-Pg. Specific activity (IU/µg) 
of rSK H46a and rSK M1GAS were determined for plasminogen activation in solution (EP 
method), in the presence of fibrinogen, at the surface of a fibrin clot and in a fibrinolysis assay, 
using Glu-Pg and Lys-Pg.  (N =) number of independent assays.  
 Glu-Pg Lys-Pg 
 rSK H46a rSK M1GAS rSK H46a rSK M1GAS 
 
Specific 
Activity 
(IU/µg) 
(N =) 
Specific 
Activity 
(IU/µg) 
 (N =) 
Specific 
Activity 
(IU/µg) 
 (N =) 
Specific 
Activity 
(IU/µg) 
 (N =) 
Solution 
plasminogen 
activation 
assay 
58.2 6 12.4 6 54.6 8 14.0 8 
Solution assay 
+ fibrinogen 
39.0 3 20.6 3 54.0 2 25.0 2 
Fibrin-bound 
plasminogen 
activation 
assay 
61.6 7 74.0 7 59.2 7 67.0 7 
Fibrinolysis 
assay 
72.8 5 168.3 5 60.4 7 176.3 7 
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2.3.4 Investigating the effect of fibrinogen concentration on plasminogen activation by rSK 
H46a and rSK M1GAS 
As demonstrated in Table 2.1 and Figure 2.5, fibrin(ogen) stimulates rSK M1GAS activation 
of Glu- and Lys-Pg. Fibrinogen is the soluble precursor of fibrin. It forms a homogeneous 
system, making it easier to study in activity assays than insoluble fibrin and as such is useful 
when investigating fibrin stimulation of plasminogen activation. 
The effect of fibrinogen on the activation of plasminogen by rSK H46a and rSK M1GAS was 
further investigated by determining plasminogen activation rates for Glu- and Lys- Pg across 
a fibrinogen concentration range. The aim was to understand the relative fibrinogen binding 
capacity of the SK variants in complex with plasminogen. Plasminogen and SK concentrations 
were kept constant to represent physiological concentration and ensure the rates of 
plasminogen activation by rSK H46a and rSK M1GAS were equivalent in solution (i.e. without 
fibrinogen).  
The height of the peak at the optimum fibrinogen concentration represents the stimulatory 
effect. For rSK M1GAS, fibrinogen binding is shown to be necessary for stimulation of 
plasminogen activation. Across the concentration range, Glu-Pg activation by rSK M1GAS 
was stimulated to a maximum of approx. 300% compared to in solution (Figure 2.6). In 
comparison, rSK H46a showed minimal stimulation up to physiological fibrinogen 
concentration (3mg/ml) of a 150%, and inhibition at this point and above.  
SK activation of Lys-Pg by rSK M1GAS showed the same profile, and maximal stimulation of 
activity at around physiological fibrinogen concentration of 3 mg/ml. (Figure 2.6). In contrast, 
the small stimulation of rSK H46a activity in the presence of Glu-Pg was lost in the presence 
of Lys-Pg, suggesting that Glu-Pg bound to fibrinogen undergoes a conformational change, 
making it more easily activated by SK. However, the open conformation of Lys-Pg means 
binding to fibrinogen does not undergo any increased activation when bound to rSK H46a, 
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and therefore the profile of Lys-Pg across the fibrinogen concentration represents the 
stimulation and inhibition by fibrinogen binding only.  
Subtracting the rates for rSK H46a activation of Lys-Pg from the other rates is therefore useful 
for demonstrating the extent to which the rSK variants are stimulated by fibrinogen across the 
concentration range (Figure 2.7).  When this subtraction is taken into account, there is no 
stimulation of rSK H46a by fibrinogen but rSK M1GAS still shows a 6–fold increase in activity 
with Glu-Pg and 5-fold with Lys-Pg, relative to in solution.  
As demonstrated in these experiments, rSK M1GAS stimulation displays a bell-shape curve 
of plasminogen activation against a log concentration of fibrinogen; typical of a template 
model. In a template model an increase in template concentration, in this instance fibrinogen, 
leads to an increase in plasminogen activation rates up to an optimum template concentration. 
Binding of the rSK M1GAS-Pg* complex and plasminogen to fibrinogen, brings activator and 
substrate into close proximity to facilitate activation. As the template concentration increases 
above the optimum, the activator and substrate are more likely to bind different template 
molecules and the stimulatory effect is lost. No such effect is seen for rSK H46a in the 
presence of fibrinogen.  
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Figure 2.6 The effect of fibrinogen on rSK H46a and rSK M1GAS activation of Glu- and 
Lys- Pg. rSK H46a and rSK M1GAS activity against Glu- and Lys– Pg by were measured over 
a range of fibrinogen concentrations (0 – 10 mg/ml). Rates are represented as relative activity 
(%) to that with no fibrinogen and plotted against a log fibrinogen concentration (mg/mL). Error 
bars show SEM of 4 replicates.  
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Figure 2.7 The stimulation of rSK M1GAS by fibrinogen. The stimulation of rSK H46a and 
rSK M1GAS was measured over a range of fibrinogen concentrations. The activity of rSK 
H46a in the presence of Lys-Pg was considered a baseline for conformational activation i.e. 
stimulation which could not be attributed to fibrinogen binding, and therefore subtracted from 
the rates for rSK H46a and rSK M1GAS activity with Glu-Pg, as well as rSK M1GAS activity 
with Lys-Pg. Rates are represented as relative activity (%) to that seen with no fibrinogen 
before subtraction of rSK H46a Lys-Pg activity, and plotted against a log fibrinogen 
concentration (mg/mL). Error bars show SEM of 4 replicates. 
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Fibrinogen is also known to be a template for plasminogen activation by tPA, which displays 
the characteristic bell-shaped curve across a fibrinogen range demonstrated above for rSK 
M1GAS (Thelwell and Longstaff, 2007).  A solution assay matrix of increasing fibrinogen 
concentration across the plate and increasing plasminogen concentration down the plate was 
used to further investigate the template model demonstrated by rSK M1GAS, and to compare 
activity of rSK H46a and rSK M1GAS with that of tPA.  
Increasing the plasminogen and/or fibrinogen concentration is seen to increase the rate of tPA 
activation of plasminogen, and to a much lesser extent rSK M1GAS, but changes in fibrinogen 
and plasminogen concentrations have very minimal effect on rSK H46a as demonstrated in 
the surface plots shown in Figure 2.8. rSK H46a activity reaches a maximum of 2.5-fold 
stimulation, but this is only at a plasminogen concentration much greater than seen in 
physiological conditions (1.6 µM). Maximal stimulation of rSK M1GAS is seen to be at around 
physiological fibrinogen (3 mg/mL), and is similar for tPA.  
In summary rSK M1GAS requires binding to fibrinogen to stimulate plasminogen activation. In 
contrast, rSK H46a shows equivalent activity in solution based and fibrin-based assay systems 
with inhibition in assays with fibrinogen.  
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Figure 2.8 The effect of plasminogen and fibrinogen concentration on plasminogen 
activation by tPA, rSK M1GAS and rSK H46a. 3D Surface contour plots (A for rSK M1GAS, 
B for tPA and C for rSK H46a) and corresponding heat maps (D, E and F) were generated to 
represent the activity, and allow comparison, of tPA, rSK H46a and rSK M1GAS, across a 
plasminogen/fibrinogen concentration matrix. The heat map isobars represent fold stimulation, 
with the fibrinogen concentration (0 – 15 mg/mL) along the X axis and the plasminogen 
concentration (0 – 1.6 µg/mL) along the Y axis. The colour gradient from white, through yellow 
and orange, to red represents maximal to minimal rate of stimulation, corresponding to height 
on the 3D surface contour plots.  
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2.3.5 Investigating the enzyme kinetics of plasminogen activation by rSK H46a and rSK M1GAS 
in a fibrin clot lysis assay 
Although fibrinogen is shown to stimulate rSK M1GAS activity, there is a greater stimulation 
in the presence of fibrin (Figure 2.5). As such, the effect of rSK H46a and rSK M1GAS on 
fibrinolysis was investigated further in a fibrinolysis assay. Varying the concentration of 
fibrinogen or thrombin used would alter the clot structure and fibrin formed, thereby affecting 
the stability of the clot, as well as making it difficult to interpret results. Instead, fibrinolysis by 
tPA, rSK H46a and rSK M1GAS was measured across a plasminogen concentration range. 
In all instances, the plasminogen activator concentration was adjusted to produce similar clot 
lysis times.  Figure 2.9 shows these results with data expressed as lysis rate (1/time to 50 % 
lysis) versus plasminogen concentration.  This allowed results to be fitted to the Michaelis 
Menten equation and provide estimates for the apparent KM and Vmax values which are 
summarised in Table 2.2. 
In this assay system the KM (0.08 – 0.11 µM) and Vmax (1.06 – 1.42 µM s-1) values did not differ 
significantly between the 3 plasminogen activators, but the amount of rSK M1GAS (0.02 nM) 
required for this activity was approximately 15 and 24-fold lower than the rSK H46a (0.3 nM) 
and tPA (0.6 nM) respectively. Normalising the Vmax/KM to account for the differences in 
concentrations gives values of 25.8 s-1 , 43.2 s-1 and 629.0 s-1 for tPA, rSK H46a and rSK 
M1GAS activity respectively (Table 2.2). Thus, in the presence of fibrin, rSK M1GAS on a 
mole for mole basis, is much more potent than rSK H46a or tPA. 
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Figure 2.9 The effect of plasminogen concentration on tPA, rSK H46a and rSK M1GAS 
mediated fibrinolysis.  Fibrinolysis by tPA, rSK H46a and rSK M1GAS was investigated 
across a plasminogen concentration range (0- 1.6 µM). Concentrations of each plasminogen 
activator were chosen to give similar activities at 100 nM Glu-Pg. Error Bars represent SEM 
of 4 replicates.  
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Table 2.2 Comparison of kinetic parameters for tPA, rSK H46a and rSK M1GAS 
mediated fibrinolysis. Kinetic parameters Vmax and KM, were determined for fibrinolysis by 
tPA, rSK H46a and rSK M1GAS. A normalised Vmax/KM value was determined for each variant 
to allow comparison based on the enzyme concentration (E0) necessary to produce similar 
kinetic rates.  
 
 Vmax (µM s-1) KM (µM) E0 (nM) 
Normalised 
Vmax/KM (s-1) 
tPA 1.28 0.08 0.60 25.8 
rSK H46a 1.06 0.08 0.30 43.2 
rSK M1GAS 1.42 0.11 0.02 629.0 
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2.3.6 The effect of tranexamic acid on SK H46a and rSK M1GAS activity. 
Tranexamic acid, a lysine analogue, inhibits plasminogen binding to fibrin(ogen) by competing 
for the lysine-binding sites in the plasminogen kringle domains.  It is useful in studying 
mechanisms of plasminogen activation by SK as it also interrupts the SK-plasminogen 
complex by disrupting SK-binding to the plasminogen kringle domains.  To investigate any 
differences in rSK H46a and rSK M1GAS binding to plasminogen through lysine-binding sites, 
the chromogenic solution assay (2.3.2A) was adapted to include a range of tranexamic acid 
concentrations and the results are shown in Figure 2.10.  The rSK concentrations were 
adjusted to give equivalent rates of activity in the absence of tranexamic acid, and the results 
were expressed as a percentage of this result for each SK.    The activity of rSK M1GAS was 
far more sensitive to low tranexamic acid concentrations than rSK H46a in solution, with a 
much sharper loss in activity across the concentration range.  
The effect of tranexamic acid on rSK H46a and rSK M1GAS activity was further investigated 
across a fibrinogen range in the presence of both Glu- and Lys-Pg (Figure 2.11). Here, once 
again, the activity of rSK M1GAS was more sensitive to lower tranexamic acid concentrations 
than rSK H46a, depicted by the comparative IC50 values of 14.5 µM for rSK M1GAS and 465 
µM for rSK H46a. 
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Figure 2.10 The relative effect of tranexamic acid on rSK H46a and rSK M1GAS activity 
in solution. Plasminogen activation by rSK H46a and rSK M1GAS was determined across a 
tranexamic acid concentration range (0 – 2.5 mM) using the chromogenic substrate for 
plasmin, S-2251. Activity is represented as % relative to plasminogen activation with no 
tranexamic acid present. Error bars represent the SEM of 4 replicates.  
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Figure 2.11 The combined effect of tranexamic acid and fibrinogen concentration on 
rSk H46a and rSK M1GAS. The rates of S-2251 substrate turnover by rSK H46a and Glu-Pg 
(top left), rSK H46a and Lys-Pg (top right), rSK M1GAS and Glu-Pg (bottom left), rSK M1GAS 
and Lys-Pg (bottom right) were investigated in a tranexamic acid (0-2.5 mM) and fibrinogen 
(0-10 mg/mL) concentration matrix.  
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Fibrinolysis with tPA, rSK H46a and rSK M1GAS was also investigated across the tranexamic 
acid concentration range (Figure 2.12). Whilst all three plasminogen activators showed the 
same sigmoidal curve, rSK H46a was less affected by increased concentration of tranexamic 
acid than tPA and rSK M1GAS, which were indistinguishable across the range. Here, the IC50 
for rSK H46a is 327 µM whilst for rSK M1GAS it is 133 µM. 
Whilst fibrinogen stimulates rSK M1GAS activity, this work has demonstrated there is a greater 
effect in the presence of fibrin (Figure 2.5). Figure 2.13 further demonstrates the difference 
fibrinogen and fibrin has on rSK M1GAS. Tranexamic acid is seen to have a much greater 
inhibitory effect on fibrinogen than fibrin; demonstrating that rSK M1GAS binding of fibrin is 
stronger than fibrinogen (IC50 133 µM vs. 14.5 µM respectively). In comparison, there is very 
little difference in the binding of rSK H46a to fibrinogen and fibrin (IC50 of 465 µM vs 327 µM). 
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Figure 2.12 The effect of tranexamic acid on tPA, rSK H46a and rSK M1GAS mediated 
fibrinolysis. Time to 50% fibrinolysis (s) by tPA, rSK H46a and rSK M1GAS was investigated 
across a tranexamic acid concentration range (0 - 2.5 mM). Concentrations of each 
plasminogen activator were chosen to give similar activities with no tranexamic acid present 
to facilitate comparison. Error Bars represent SEM of 4 replicates.  
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Figure 2.13 A comparison of the effect of tranexamic acid on rSK H46a and rSK M1GAS 
activity in the presence of fibrinogen and fibrin. The activity of rSK H46a and rSK M1GAS 
in fibrinogen and fibrin across a tranexamic acid concentration range was calculated relative 
to the corresponding activity in solution (i.e. no tranexamic acid present). The results were 
used to compare the relative effect of fibrinogen and fibrin on the two variants. 
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2.3.7 The effect of FXIII and α2-antiplasmin on fibrinolysis by rSK H46a and rSK M1GAS 
In physiological conditions, fibrin is cross-linked by activated FXIII (FXIIIa) to increase the 
stability of the fibrin clot and limit degradation (Chapin and Hajjar, 2015). FXIIIa has also been 
demonstrated to act as part of the innate immunity against S. pyogenes, actively trapping the 
bacteria in the fibrin clot by cross-linking the M1 protein to fibrin (Loof et al., 2011, Loof et al., 
2012). However, no studies have demonstrated the effect of FXIIIa and cross-linked fibrin on 
SK activation of plasminogen and subsequent fibrinolysis.  
To investigate this, plasminogen activation by rSK H46a and rSK M1GAS and the subsequent 
fibrinolysis of FXIIIa cross-linked fibrin was compared to that of untreated fibrin. Physiological 
concentrations of fibrinogen, thrombin and FXIIIa were used to ensure the fibrin formed was 
representative of that in bacterial invasion in vivo. FXIII was preactivated to FXIIIa by 
incubation with thrombin.  
Initially, studies with WHO 3rd IS SK (00/464) were used to determine the effect inclusion of 
FXIIIa has on clot lysis profiles. As seen in Figure 2.14, a different clot lysis profile was 
observed, compared to clots with no FXIII. This was represented by a lower maximum 
absorbance, indicating a change in clot turbidity as a result of the altered fibrin structure. The 
same assay set-up was replicated in the presence of rSK H46a and rSK M1GAS. However, 
despite the differing fibrin structure, the specific activities of rSK H46a and rSK M1GAS were 
unaffected, with time to complete lysis of FXIIIa cross-linked fibrin equivalent to that of 
untreated fibrin in all instances (Figure 2.15). 
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Figure 2.14 The effect of FXIIIa on clot formation absorbance at 405 nm. Typical clotting 
and lysis curves shown are for WHO 3rd IS SK (00/464) in the presence (A) or absence (B) of 
2 IU/ml FXIIIa over a range of SK concentrations (1,2,4 and 8 IU/ml) to show the change in 
maximum absorbance at 405 nm and hence change in fibrin clot structure through FXIIIa 
cross-linking.  
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Figure 2.15 The effect of FXIIIa cross-linked fibrin on rSK H46a- and rSK M1GAS- 
mediated fibrinolysis. Fibrinolysis mediated by rSK H46a and rSK M1GAS was investigated 
in the presence of activated FXIII. Lysis profiles for each variant with and without 2 IU/ml FXIIIa 
were determined by measuring absorbance at 405 nm. Typical profiles are shown here.   
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Under normal physiological conditions, FXIIIa cross-links α2-antiplasmin into fibrin clots to 
prevent clot degradation (Fraser et al., 2011).  As such, the effect of α2-antiplasmin on 
fibrinolysis facilitated by rSK H46a and rSK M1GAS was investigated.  
Fibrinolysis rates were determined for rSK H46a and rSK M1GAS in the presence of α2-
antiplasmin. Though the α2-antiplasmin was shown to increase fibrinolysis time, as with FXIIIa 
cross-linked fibrin there appeared to be no difference in effect on rSK H46a or rSK M1GAS 
activity (Figure 2.16).  
To further investigate the combined effect FXIIIa and α2-antiplasmin may have on rSK H46a 
and rSK M1GAS promotion of fibrin degradation, the fibrinolysis assay was replicated in the 
presence of both. This was compared concurrently to FXIIIa alone to investigate any changes 
in fibrinolysis by rSK H46a and rSK M1GAS. Again, as with α2-antiplasmin alone, fibrinolysis 
times were increased but there was no observed effect on rSK H46a and rSK M1GAS activity 
(Figure 2.17). 
Overall, rSK M1GAS does not appear to have any advantage with regard to fibrinolysis of 
FXIIIa cross-linked fibrin, when compared to rSK H46a. Furthermore, there is no protection 
from inhibition by the plasmin inhibitor α2-antiplasmin.  
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Figure 2.16 The effect of α2-antiplasmin (α2-AP) on rSK H46a- and rSK M1GAS- mediated 
fibrinolysis. Fibrinolysis mediated by rSK H46a and rSK M1GAS was investigated in the 
presence of α2-antiplasmin. Lysis profiles for each variant with and without α2-antiplasmin were 
determined by measuring absorbance at 405 nm. Typical profiles are shown here.   
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Figure 2.17 The combined effect of FXIIIa and α2-antiplasmin (α2-AP) on rSK H46a- and 
rSK M1GAS– mediated fibrinolysis. Fibrinolysis mediated by rSK H46a and rSK M1GAS 
was investigated in the presence of activated FXIII and α2-antiplasmin. Profiles of rSK H46a 
and rSK M1GAS mediated fibrinolysis of FXIII cross-linked fibrin with and without α2-
antiplasmin were determined by measuring absorbance at 405 nm. Typical profiles are shown 
here. 
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2.4 Discussion 
This work demonstrates that in contrast to the H46a SK used in the therapeutic SK, M1GAS 
SK is stimulated by fibrinogen, and to an even greater extent fibrin. Maximal stimulation of rSK 
M1GAS by fibrinogen in these assays is seen to be at around physiological fibrinogen (3 
mg/mL), and is similar for tPA, suggesting that fibrinogen binding is likely to regulate the 
activity of rSK M1GAS in vivo. 
The plasmin generated by rSK H46a and rSK M1GAS activity will bind both fibrinogen and the 
chromogenic substrate, S-2251, so competitive inhibition of S-2251 turnover will be present. 
With rSK H46a, these means a loss of activity compared to in solution, as demonstrated in 
Figure 2.5. Whilst this competitive inhibition is still present with rSK M1GAS, the stimulation 
through binding of fibrinogen more than overcomes the competitive inhibition resulting in a 
higher activity.  
The template effect, demonstrated by the studies with a fibrinogen concentration range 
(Figures 2.6 and 2.7) suggest that fibrinogen binds the M1GAS SK activator complex (SK-
Pg*) in addition to the substrate plasminogen, resulting in a ternary complex as hypothesised 
by McArthur et al. (McArthur et al., 2008). The binding may be via manipulation of binding 
sites on the plasminogen molecule during formation of the activator complex. Alternatively it 
may be via distinct sites on the SK molecule itself, but further studies would need to be 
conducted in order to accurately determine the mechanisms of binding.  
Overall, from the studies with FXIIIa cross-linked fibrin and α2-antiplasmin (Figures 2.15, 2.16 
and 2.17), the different mechanism of M1GAS SK identified in this chapter does not appear to 
offer any advantage over H46a SK with regard to the mechanism of pathogenesis proposed 
by Loof et al. (Loof et al., 2011, Loof et al., 2012).  
A difference between rSK H46a and rSK M1GAS activity is seen across a tranexamic acid 
range in solution which demonstrates that the complex formation of rSK M1GAS and 
plasminogen is more reliant on lysine binding sites than the rSK H46a-Pg complex (Figure 
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2.12). This also suggests that the differences between the SK variant activities in the presence 
of fibrinogen and fibrin across a tranexamic acid concentration range (Figure 2.13) is at least 
in part due to the effect of the lysine analogue on rSK M1GAS complex formation with 
plasminogen; not simply just the binding of the complex and plasminogen to fibrin(ogen). 
Despite this, the rSK M1GAS-Pg complex also exhibits stronger binding to fibrin than 
fibrinogen. This is presumably due to differences in binding sites for the rSK M1GAS-Pg 
complex with fibrinogen and fibrin, again through lysine binding sites. There is no observed 
difference in activity between rSK H46a plasminogen activation in the presence of fibrinogen 
and fibrin. 
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Chapter 3: Investigating the effect of rSK H46a and rSK M1GAS on plasmin   
3.1 Introduction 
As well as binding plasminogen, SK can also form an activator complex with plasmin (Pm), for 
which it has a higher affinity (Boxrud et al., 2000, Boxrud and Bock, 2000). Binding to plasmin 
is known to alter the enzyme specificity towards the activation site of plasminogen; promoting 
further plasmin generation (Bhattacharya et al., 2012). Some studies have looked at plasmin 
kinetics in complex with rSK H46a as well as the role of the N-terminus (Bean et al., 2005, 
Verhamme and Bock, 2008), but as with plasminogen less is known about the differences 
between SK variants.  Investigating the kinetics of plasmin in complex with rSK H46a and rSK 
M1GAS will aid understanding of the more complicated mechanism of plasminogen activation.  
Any differences in mechanism between rSK H46a and rSK M1GAS with plasmin may point to 
different mechanisms in the pathways of plasminogen activation.   
The crystal structure of human plasminogen has been determined (Law et al., 2012, Xue et 
al., 2012), as has the crystal structure of the catalytic domain of plasmin in complex with SK 
from group C H46a S. equisimilis (Wang et al., 1998), but no such equivalent for SK from 
group A M1 streptococci, such as S. pyogenes, is available. Though details of the molecular 
structure of the plasmin in complex with rSK M1GAS are lacking, it may be possible to model 
the structure by comparing sequences of rSK H46a and rSK M1GAS.  
Microplasmin (µPm) is the active site and linker sequence of plasmin only, lacking the kringle 
domains where many of the fibrinogen binding sites and SK interaction occurs (Takada and 
Takada, 1989a). This plasmin derivative is most like the catalytic domain used to determine 
the crystal structure of the complex with H46a S. equisimilis (Wang et al., 1998).  Kinetic 
studies using microplasmin may be more readily interpreted with reference to the crystal 
structure without potential interference of other domains in plasmin that are absent in 
microplasmin. In this chapter, the effect of H46a and M1GAS SK binding on plasmin and 
microplasmin activity was investigated. Initially solution based Michaelis-Menten kinetics were 
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employed to understand how the active site is manipulated by SK binding. The addition of 
fibrinogen and fibrin to the assays with plasmin provides information on the interaction of SK 
with the kringle domains and how this affects fibrin(ogen) binding and the kinetics of plasmin 
generation. 
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3.2 Experimental Procedures 
3.2.1 Materials and software  
3.2.1a Materials 
Buffer A - 0.5 M Tris pH 8.4 at 37 °C. Stored at 2-8 °C for 6 up to months. 
Buffer B – 10 mM Tris HCL 100 mM NaCl 0.01% Tween 20. Store at 2-8 °C for up to 1 week. 
Buffer C – Buffer B + 1mg/ml HSA. Store at 2-8 °C for up to 3 days.  
Blocking buffer – 0.05M Tris 0.1% Tween 20 pH 8.4 at 37 °C.   
All laboratory chemicals used to make buffers were from Sigma Aldrich, St Louis, Missouri, 
USA.  
Fibrinogen (Calbiochem, Merck Millipore, Billerica, Massachusetts, USA) - reconstituted in 
Buffer B to give stock solution of 50 mg/ml, and flash frozen in liquid nitrogen in small aliquots 
and stored at -40 °C. All dilutions for reactions were made using buffer B. 
WHO 3rd IS Plasmin (97/536) – reconstituted in 1 ml H2O, flash frozen in liquid nitrogen in 
small aliquots and stored at -40 °C. All dilutions for reactions were made in buffer C.  
Microplasmin (µPm) (Thrombogenics, Leuven, Belgium) – flash frozen in small aliquots in 
liquid nitrogen and stored at -40 °C. All dilutions for reactions were made using buffer C. 
WHO IS Thrombin (01/578) – flash frozen in small aliquots in liquid nitrogen and stored at -40 
°C. All dilutions for reactions were made using buffer C. 
rSK H46a, rSK M1GAS, rSK H46a (del1-59), rSK M1GAS (del 1-59) (see chapter 2) were 
flash frozen in liquid nitrogen and stored in small aliquots at -40 °C. All dilutions for reactions 
were made using buffer C. 
S-2251, H-D-Val-L-Leu-L-Lys-pNA (Chromogenix, Milan, Italy) – reconstituted in 15 ml H2O, 
to give a 3 mM stock solution. Stored at 2-8 °C, stable for several months.  
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Microtitre plates (Greiner,  Kremsmunster, Austria) – all microtitre plates were blocked with 
200 µL blocking buffer for 2 hours at 37 °C and washed 2x with 200 dH20 before use. 
3.2.1b Software 
GraphPad Prism (GraphPad Software, San Diego, California, USA) 
SoftMax Pro v5.0 (Molecular Diagnostics, Sunnydale, California, USA) 
Microsoft Excel (Redwood, Washington, USA) 
R Core Team (2012). R: A language and environment for statistical computing. R Foundation 
for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL: http://www.R-
project.org/. 
Combistats (EDQM, Strasbourg, France)  
3.2.2 Plasmin and microplasmin activity against S-2251 
3.2.2a Amidolytic activity of plasmin and microplasmin in solution 
Amidolytic activity of plasmin alone and plasmin in complex with rSK H46a, rSK M1GAS, rSK 
H46a del 1-59 and rSK M1GAS del 1-59 was determined in solution against the chromogenic 
substrate for plasmin, S-2251. KM and kcat values were then calculated for each complex. 
Amidolytic activity of microplasmin and the kinetic parameters kcat and KM were also 
determined against S-2251 alone and in complex with rSK H46a and rSK M1GAS. 
In all instances, 1.35 nM final concentration plasmin or microplasmin, diluted using buffer C, 
with and without a two-fold molar excess of SK was used.  A two-fold molar excess was 
determined as sufficient to complex all plasmin with SK by preliminary experiments where an 
increase in amidolytic rate was seen between a 1:1 and 1:2 Pm:SK ratio, but no further 
increase demonstrated for 1:3.  The Plasmin SK solutions were added to a range of eight S-
2251 concentrations (0.02 - 2.25 mM in final reaction mixtures), diluted in dH2O. All reactions 
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were 120 μl total volume and carried out in 96 well microtitre plates. All microtitre plates were 
incubated at 37 °C using a heated block. pNA generation was monitored by measuring 
absorbance change at 405 nm at 30 s intervals for 60 min at 37 C.   
Reactions were measured for 60 min with changes in absorbance at 405 nm corresponding 
to substrate hydrolysis and pNA generation. Plots of rates of absorbance versus time 
(mOD min-1) were created by plate reader software, SoftMax Pro v5.0, where substrate was 
< 10% depleted and therefore initial rates were at a maximum. The data were exported to 
Excel and initial rates of pNA generation (M s-1) were calculated using the extinction coefficient 
(ε) of a 1 M solution under these conditions of 2500 OD M-1. The extinction coefficient was 
determined under these experimental conditions following complete hydrolysis of a range of 
S-2251 concentrations with excess enzyme.  
Initial rates (Ms-1) were plotted against substrate (S-2251) concentration and fitted to the 
Michaelis-Menten equation in order to determine values for the kinetic parameters Vmax and 
KM (equation 4) using GraphPad Prism 5. Three independent experiments with two replicates 
for each variant per plate were carried out.  
𝑣 =
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑀 + [𝑆]
 (4) 
In this equation, v stands for velocity as a molar concentration of pNA generated per second 
and Vmax is the maximal velocity of the reaction. KM is the substrate concentration at which half 
the maximal velocity (Vmax) is achieved. [S] is the molar substrate concentration.  
𝑘𝑐𝑎𝑡 =
𝑉𝑚𝑎𝑥
𝐸0
 (5) 
kcat values were calculated as demonstrated in equation 5 with the total plasmin concentration 
representing the active enzyme E0, in this instance 1.35 nM calculated from the amount of 
active enzyme for the 3rd WHO IS for plasmin as determined by active-site titration (Longstaff 
and Gaffney, 1991). Activity of plasmin SK and microplasmin SK complexes was compared 
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using kcat/KM, the specificity constant. The microplasmin concentration was taken as advised 
on the manufacturer’s insert.  
3.2.2b Amidolytic activity of plasmin and microplasmin with fibrinogen 
The assay outlined above for determining the plasmin and microplasmin activity in solution 
alone and in complex with rSK H46a and rSK M1GAS was modified to study the complexes 
in the presence of fibrinogen (3 mg/mL).  
3.2.3 Fibrinolysis 
The following assays were used to measure fibrinolysis by plasmin in complex with rSK H46a 
and rSK M1GAS. 
3.2.3a Fibrinolysis assay with plasmin 
In order to measure fibrinolysis by plasmin in complex with rSK H46a and rSK M1GAS, fibrin 
clots were made in microtitre plate wells by adding a solution of fibrinogen (final concentration 
in reaction 2.8 mg/ml) (60 µl) to a 40 µl solution of thrombin (final concentration in reaction 20 
nM) and Pm-SK complex, or plasmin alone. Each assay contained 4 doses (3-25 nM) and 4 
replicates for each plasmin variant. As before, a two-fold molar excess of SK was used. All 
concentrations are for final reaction. 
Absorbance at 405 nm was measured for 5 hours to monitor changes in fibrin clot turbidity 
with increases in absorbance corresponding to clotting and subsequent decreases 
corresponding to lysis.  
The raw, kinetic data were exported from Softmax Pro plate reader software as a text file. An 
R program script (Silva et al., 2012), written by Colin Longstaff (Personal communication, see 
appendix 1) was used to determine the time at maximum absorbance (complete clotting) and 
time at lowest absorbance (complete lysis), to allow calculation of the time to 50% lysis (Figure 
2.2). The script is capable of determining several parameters from the raw kinetic data such 
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as max absorbance, time to max absorbance, time to complete lysis, time to any chosen % 
lysis.  Time to 50% lysis from start of reaction is a standard measure of fibrinolysis and as 
such was chosen in this instance as a parameter by which to compare the variants. Values for 
time to 50% lysis were then fitted to a parallel line bioassay using Combistats as outlined in 
section 2.2.4e.  
3.2.3b Physical fibrinolysis assay 
Fibrinolytic activity of plasmin, with and without a two-fold molar excess of SK was determined 
using an assay based on the European Pharmacopoeia method for determining lysis times of 
tPA (Alteplase) (Sands et al., 2004, Sands et al., 2002). Briefly, fibrin clots were made in glass 
tubes by adding a solution of 0.5 mL fibrinogen (final concentration in reaction 1.24 mg/mL) to 
0.1 mL thrombin (final concentration in reaction 20 nM) solution containing plasmin (6.3 nM or 
25 nM). After 30 s, clots were visible at which point a glass bead was added to each tube. 
Lysis was defined as the time taken for the bead to pass through the clot to reach the bottom 
of the tube. Timing started from when the fibrinogen solution and thrombin/plasmin solution 
were mixed and was timed using a stopwatch.  Assays contained 2 replicates and a range of 
concentrations for plasmin alone and in complex with rSK H46a and rSK M1GAS.  
Relative lysis times for plasmin in complex to rSK H46a and rSK M1GAS compared to plasmin 
alone were plotted in GraphPad Prism. To determine whether lysis times were significantly 
different (P <0.05) to plasmin alone, a student t test was performed in GraphPad Prism.  
3.2.4 Data Collection and analysis for microtitre plate assays 
All microtitre plate reactions were measured using a SpectraMax M5 plate reader and SoftMax 
Pro v5.0. All reactions were measured at 37 °C in 30 s intervals at 405 nm.  
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3.3 Results  
3.3.1 Amidolytic activity of plasmin in complex with rSK H46a and rSK M1GAS 
KM, kcat and kcat/KM were determined for plasmin and plasmin in complex with rSK H46a, rSK 
M1GAS to explore the mechanism of stimulation of plasmin activity. KM, kcat and kcat/KM were 
also determined for plasmin in complex with 1-59 deletion mutants of rSK H46a and rSK 
M1GAS to investigate whether N-terminal interactions of SK, known to be critical for 
plasminogen activation, are involved.  
Fitting to the Michaelis-Menten equation is shown in Figure 3.1. The values determined for 
KM, kcat and kcat/KM from this are presented in Table 3.1. Figure 3.3 shows kcat/KM for plasmin 
in complex with all the variants.  
 Both plasmin rSK H46a and plasmin rSK M1GAS complexes increased plasmin enzyme 
specificity constant (kcat/KM) against S-2251, ≈ 2-fold compared with kcat/KM plasmin enzyme 
activity alone (Figure 3.3). No increase in activity was seen for plasmin rSK H46a del 1-59 
complex and plasmin rSK M1GAS del 1-59 complex, both being comparable to plasmin. This 
indicates that the increase in activity is due to interaction between plasmin and the N-terminus 
of both rSK H46a and rSK M1GAS. Without the first 59 amino acids, the interaction between 
plasmin and SK is potentially lost, or ineffective.   
Though the rSK H46a and rSK M1GAS both show ≈ 2- fold increase in kcat/KM, their respective 
kcat and KM were significantly different, as seen in Table 3.1. The kcat value for plasmin rSK 
H46a complex was 2-fold higher than observed for all other plasmin rSK complexes and 
plasmin alone; whereas the KM for the plasmin rSK M1GAS complex was 0.20 mM compared 
to ≈0.40 mM for all other complexes. 
In summary, full-length H46a and M1GAS SK stimulate plasmin as shown by kcat/KM. In both 
instances, the N-terminal amino acids (1-59) are required. However, although H46a and 
M1GAS SK both stimulate plasmin activity to a similar extent closer examination of the KM and 
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kcat values show the mechanism to be different. H46a SK alters plasmin activity by increasing 
kcat, whereas M1GAS SK relies on improvements in KM for the substrate S-2251. 
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Figure 3.1 Representative fitting of amidolytic activity of plasmin in complex with rSK 
H46a and rSK M1GAS to Michaelis-Menten equation. Rates of amidolytic activity across a 
chromogenic substrate range were fitted to the Michaelis-Menten equation to determine 
values for the kinetic parameters Vmax and KM for plasmin alone and in complex with rSK H46a 
and rSK M1GAS and the N-terminal deletion mutants (not shown). Values shown are taken 
from one independent assay to represent typical profile.  
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Figure 3.2 The effect of rSK H6a, rSK M1GAS and N-terminal deletion mutants on 
plasmin activity. Enzyme specificity constant (kcat/KM) was calculated to compare the activity 
of plasmin alone and in complex with rSK H46a, rSK M1GAS and the 1-59 deletion mutants 
of each. Error bars show standard deviation of 4 independent experiments.  
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Table 3.1 Effect of SK on plasmin activity. Kinetic parameters Vmax, kcat, KM and kcat/KM (as 
calculated in GraphPad Prism) were determined for plasmin alone against S-2251, and in 
complex with the rSK H46a, rSK M1GAS and N-terminal truncated variants (del1-59). ± 
denotes SEM based on 4 independent assays.  *represents significantly different values (P 
<0.05) based on student t test against activity of plasmin alone. 
  
 
 
 
 
  
 Vmax (µM s-1) kcat (s-1) KM (mM) 
kcat / KM 
(mM-1 s-1) 
Plasmin (Pm) 0.03 ± 0.003 25.5 ± 1.9 0.39 ± 0.01 65.2 ± 5.5 
Pm rSK H46a 0.08 ± 0.005* 60.4 ± 3.8* 0.36 ± 0.01 169.6 ± 6.4* 
Pm rSK M1GAS 0.04 ± 0.003 27.8 ± 2.4 0.21 ± 0.06* 146.9 ± 22.4* 
Pm rSK H46a del 1-59 0.03 ± 0.003 25.0 ± 2.0 0.38 ± 0.02 66.4 ± 5.2 
Pm rSK M1GAS del 1-59 0.03 ± 0.002 25.6 ± 1.6 0.40 ± 0.02 64.4 ± 5.8 
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3.3.2 Effect of rSK H46a and rSK MIGAS on plasmin activity in presence of fibrinogen 
Plasmin activity in complex with rSK H46a and rSK M1GAS was investigated in the presence 
of fibrinogen to determine the effect of fibrinogen binding on plasmin amidolytic activity in 
complex with the two SK variants. All assays were carried out at physiological fibrinogen 
concentrations (3 mg/ml). Analysis of data is complicated by the action of fibrinogen as a 
competitive inhibitor of plasmin action on S-2251 and further effects of fibrinogen on 
complexes of rSK H46a or rSK M1GAS with plasmin need to be isolated. The mechanisms 
underpinning fibrinogen interactions with plasmin and rSK complexes were not explored in 
detail (KI values or type of inhibition were not determined).  The effects of fibrinogen are 
summarised by the kcat, KM and kcat/KM values for hydrolysis of S-2251 and these are presented 
in Figure 3.4, which can be compared with Table 3.1 showing kinetic parameters without 
fibrinogen.  As expected, as a competitive inhibitor, fibrinogen blocks the plasmin active site 
and increases KM for S-2251 (from 0.37 to 1.6 mM), but there is also a small decrease in kcat 
to 14.5 from 25.5 s-1.  Overall the effect of fibrinogen is to reduce kcat/KM to 17.9 M-1s-1, 13% of 
the value without fibrinogen. Interestingly, fibrinogen has a much weaker effect on plasmin in 
complex with rSK H46a and rSK M1GAS, as judged by kcat and KM values.  Figure 3.4 clearly 
shows stimulation of the kcat of the plasmin rSK M1GAS complex, which increases from 26.7 
to 64.7 s-1 and is thus achieves equivalent activity to plasmin rSK H46a, which itself is 
unaffected by fibrinogen. 
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Figure 3.3 The effect of rSK H46a and rSK M1GAS on plasmin activity in the presence 
of fibrinogen. A) Rates were fitted to the Michaelis-Menten equation to determine values for 
the kinetic parameters Vmax and KM for plasmin alone and in complex with rSK H46a and rSK 
M1GAS. Error bars show standard deviation of 3 replicates. B) Enzyme specificity constant 
(kcat/KM) was calculated to compare the activity of plasmin alone and in complex with rSK H46a, 
rSK M1GAS. Error bars show standard deviation of 3 independent assays.  
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Table 3.2 Kinetic parameters Vmax, kcat, KM and kcat/KM were determined for plasmin alone 
against S-2251, and in complex with the rSK H46a, rSK M1GAS in the presence of 
fibrinogen. ± denotes SEM of 3 independent assays.  * represents significantly different 
values (P <0.05) based on student t test against activity of plasmin alone. 
 
 
 
 
 
 
 
 
  
 Vmax (µM s-1) kcat (s-1) KM (mM) 
kcat / KM 
(mM-1 s-1) 
Plasmin (Pm) + 
fibrinogen 
0.01 ± 0.009 14.5 ± 4.2 1.6 ± 1.03 17.9 ± 7.1 
Pm rSK H46a + 
fibrinogen 
0.09 ± 0.003* 70.3 ± 5.7* 0.4 ± 0.01* 160.4 ± 15.7* 
Pm rSK M1GAS 
+ fibrinogen 
0.09 ± 0.004* 64.7 ± 12.6* 0.4 ± 0.07* 159.1 ± 5.0* 
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3.3.3 Effect of rSK H46a and rSK M1GAS on fibrinolysis with plasmin 
The relative effect of plasmin alone and in complex with rSK H46a and rSK M1GAS on fibrin 
clot lysis was investigated.  For plasmin alone it was difficult to obtain reproducible clot lysis 
curves and no linear dose response was seen as demonstrated in Figure 3.5.  It was therefore 
not possible to assign specific activity to the two rSK variants in complex with plasmin relative 
to plasmin alone against a fibrin substrate.  
When plasmin was in complex with rSK H46a and rSK M1GAS the reproducibility and linearity 
of the clot lysis curves improved (Figure 3.5), and it was possible to generate a dose response 
curve for each (Figure 3.6). Interestingly, the two complexes were found to be non-parallel. At 
low plasmin concentrations (3.1 nM) there was no observed difference between the activities 
of the plasmin rSK H46a complex compared to the plasmin rSK M1GAS complex (Figure 3.7).  
At higher concentrations (25 nM) however the plasmin rSK H46a complex was more effective 
producing faster clot lysis rates, up to nearly 3-fold faster than the plasmin rSK M1GAS 
complex (Figure 3.7).  
All of the assay systems used thus far to investigate SK activation of plasminogen and effect 
on plasmin activity have utilised optical density as a read-out when determining activity. 
However, determining plasmin activity in fibrinolysis using absorbance is only one approach 
and may be complicated by absorbance changes caused be fibrin rearrangements, which can 
also increase during early stages of fibrin degradation (Meh et al., 2001). To investigate the 
activity of plasmin SK complexes further, the fibrinolysis properties were measured using a 
physical fibrinolysis assay based on the current European Pharmacopoeial method for 
assigning potencies to therapeutic tPA (e.g. see (Sands et al., 2002, Sands et al., 2004). In 
this instance, clots are formed by the addition of thrombin to fibrinogen in the presence of 
plasmin and the SK variant. Fibrinolysis proceeds and time to complete lysis was recorded as 
the time the clot structure could no longer support the bead and therefore reaches the bottom 
of the tube. In this system, the activity of plasmin alone was seen to be more reproducible and 
at low concentrations (7 nM) the plasmin SK complexes were more effective producing faster 
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clot lysis rates compared to plasmin alone.  At higher concentrations (28 nM) there was no 
significant difference in lysis times between the two SK variants (Figure 3.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
100 | P a g e  
 
A) B) 
 
 
 
 
 
C)                                                                   D)         
 
 
 
 
 
Figure 3.4 Representative clotting and lysis curves showing effect of rSK H46a and rSK 
M1GAS on plasmin activity in fibrinolysis assay. Fibrinolysis was investigated by 
measuring absorbance at 405 nm in the presence of plasmin alone, and plasmin in complex 
with rSK H46a and rSK M1GAS. Typical lysis profiles of plasmin alone and in complex with 
rSK H46a and rSK M1GAS from replicates on a single 96-well plate at 25 nM (Figures A and 
B) or 3 nM (Figures C and D) plasmin. Whilst rSK H46a and rSK M1GAS showed good 
reproducibility at both concentrations of plasmin, fibrinolysis by plasmin alone was inconsistent 
between replicate wells.   
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Figure 3.5 The effect of rSK H46a and rSK M1GAS on plasmin activity in fibrinolysis 
assay as determined by absorbance at 405 nM. Time to 50% lysis was determined over a 
range of plasmin concentrations (3-25 nM) to determine the effect of rSK H46a and rSK 
M1GAS on plasmin activity and fibrinolysis. Fibrinolysis facilitated by plasmin alone was not 
reproducible or linear in response, so is not included here. Error bars denote SEM of 4 
replicates.  
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Figure 3.6 The effect of rSK H46a and rSK M1GAS on plasmin activity in a physical 
fibrinolysis assay. Time to lysis was measured at two plasmin concentrations (7 and 28 nM, 
panels A and B, respectively) to determine the effect rSK H46a and rSK M1GAS have on 
plasmin activity and fibrinolysis. Lysis times relative to plasmin alone were calculated to allow 
comparison between variants. Error bars show standard deviation of 4 independent 
experiments. 
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3.3.4 Microplasmin activity in complex with rSK H46a and rSK M1GAS 
Microplasmin consists of the catalytic domain and the linker region of plasmin only. As such it 
lacks the binding sites present in the kringle domains that associate with SK and/or 
fibrin(ogen). Studying the interaction of microplasmin with SK variants and comparing their 
activities in complex with plasmin is useful when studying the mechanism of SK bound plasmin 
as a way to understand the contribution of plasmin kringles and their interactions with SK and 
fibrin(ogen) to the relative differences in activity between rSK H46a and rSK M1GAS. 
Kinetic parameters were first determined for microplasmin activity in solution, alone and in 
complex with rSK H46a and rSK M1GAS. As demonstrated in Figure 3.8 and Table 3.2, there 
is no significant difference between the activity of microplasmin alone and in complex with rSK 
H46a and rSK M1GAS. From these data alone it is unclear whether there is effective plasmin 
complex formation with rSK H46a and rSK M1GAS, although the existence of a published 
crystal structure (Wang et al., 1998), suggests this is likely. However, the addition of fibrinogen 
alters the KM of plasmin more dramatically than that of the complexes as a result of the 
competition between the chromogenic substrate and fibrinogen for the plasmin active site. 
This demonstrates that the effect of fibrinogen on (micro)plasmin is independent of kringle 
binding. It also shows that both SK variants interact with the catalytic domain and ameliorate 
(micro)plasmin inhibition by fibrinogen. Interestingly, rates for microplasmin are faster than 
full-length plasmin in all cases.  
The activity of microplasmin (kcat / KM) shows little attenuation in complex with rSK H46a 
(258.0 mM-1 s-1in solution vs. 208.1 mM-1 s-1). Greater inhibition is seen with rSK M1GAS 
(326.6 mM-1 s-1 vs. 181.1 mM-1 s-1) bringing it closer to the activity seen with the plasmin rSK 
M1GAS complex. This suggests the differences in microplasmin binding of rSK H46a and rSK 
M1GAS is facilitated by different sites in the catalytic domain of plasmin, with rSK M1GAS to 
a greater extent.  
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Overall, microplasmin is less affected by fibrinogen than full-length plasmin. This is expected 
as the lack of kringles domains removes the majority of fibrinogen binding sites.   
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Figure 3.7   The effect of rSK H46a and rSK M1GAS on microplasmin activity. Rates were 
fitted to the Michaelis-Menten equation to determine values for the kinetic parameters Vmax 
and KM for microplasmin alone and in complex with rSK H46a and rSK M1GAS in solution (A) 
and in the presence of fibrinogen (B). Error bars show standard deviation of 3 replicates. C) 
Enzyme specificity constant (kcat/KM) was calculated to compare the activity of microplasmin 
alone and in complex with rSK H46a and rSK M1GAS in solution and the presence of 3 mg/mL 
fibrinogen. Error bars show standard deviation of 3 independent experiments.  
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Table 3.3 Effect of rSK H46a and rSK M1GAS on microplasmin activity. Kinetic 
parameters Vmax, kcat, KM and kcat/KM were determined for microplasmin alone against S-2251, 
and in complex with the rSK H46a, rSK M1GAS. ± denotes SEM of 3 independent 
experiments. * represents significantly different values (P <0.05) based on student t test 
against activity of microplasmin alone.  
 
*The table below contains selected data from Tables 3.1 and 3.2, represented again here to 
allow ease of comparison between microplasmin and plasmin. 
 Vmax (µM s-1) kcat (s-1) KM (mM) 
kcat / KM 
(mM-1 s-1) 
Microplasmin (µPm) 0.10 ± 0.006 76.8 ± 4.3 0.3 ± 0.02 250.9 ± 7.9 
µPm + fibrinogen 0.07 ± 0.005 52.5 ± 3.7 1.1 ± 0.02 48.2 ± 2.4 
µPm rSK H46a 0.11 ± 0.010 79.5 ± 7.5 0.3 ± 0.01 258.0 ± 27.2 
µPm rSK H46a + 
fibrinogen 
0.15 ± 0.006* 114.5 ± 4.2* 0.6 ± 0.06* 208.1 ± 14.1* 
µPm rSK M1GAS 0.10 ± 0.006 77.1 ± 4.8 0.3 ± 0.03 326.6 ± 32.1 
µPm rSK M1GAS + 
fibrinogen 
0.09 ± 0.001 65.5 ± 0.4 0.4 ± 0.02* 181.1 ± 11.8* 
 Vmax (µM s-1) kcat (s-1) KM (mM) 
kcat / KM 
(mM-1 s-1) 
Plasmin (Pm) 0.03 ± 0.003 25.5 ± 1.9 0.39 ± 0.01 65.2 ± 5.5 
Pm + fibrinogen 0.01 ± 0.009 14.5 ± 4.2 1.60 ± 1.03 17.9 ± 7.1 
Pm rSK H46a 0.08 ± 0.005* 60.4 ± 3.8* 0.36 ± 0.0y1 169.6 ± 6.4* 
Pm rSK H46a +   
fibrinogen 
0.09 ± 0.003* 70.3 ± 5.7* 0.40 ± 0.01* 160.4 ± 15.7* 
Pm rSK M1GAS 0.04 ± 0.003 27.8 ± 2.4 0.21 ± 0.06* 146.9 ± 22.4* 
Pm rSK M1GAS + 
fibrinogen 
0.09 ± 0.004* 64.7 ± 12.6* 0.40 ± 0.07* 159.1 ± 5.0* 
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3.4 Discussion 
Although in solution the kinetics of plasmin with an amidolytic substrate seem to follow simple 
kinetics, in the presence of fibrinogen or fibrin the system is much harder to study. As a first 
approximation, adding fibrinogen to plasmin and S-2251 would result in competitive inhibition 
and an increased KM, which is observed in the case of plasmin and microplasmin.  However, 
inhibition is more complicated and there may also be changes in kcat, indicating a mixed type 
of inhibition (see Tables 3.1, 3.2 and 3.3).  Further complexities are added when plasmin or 
microplasmin are in complex with SK, but there is a tendency for SK to shield the active site 
from competition with fibrinogen, and this is the case for both rSK H46a and rSK M1GAS.  In 
this way there may be an evolutionary advantage to shifting the specificity of plasmin away 
from fibrinogen and towards other substrates, including plasminogen, or in this case, S-2251.  
An unexpected feature of the results presented above is the increased activity of microplasmin 
compared with plasmin, but this may indicate the purpose of the kringle domain in plasmin are 
to limit unwanted proteolysis and focus activity towards fibrin or other substrates that bind 
plasmin through lysine binding sites.   
Another observation was the difficulty obtaining results when studying plasmin on its native 
substrate fibrin.  Results were non-linear over dose ranges on plasmin and rather 
irreproducible.  However, recent published work may explain these findings.  It is presumed 
that initial binding of plasmin to fibrin and proteolytic cleavage generates C-terminal lysines 
which attract further plasmin molecule, binding via kringle domains, to produce a clustering 
effect, which has been expressed at a macroscale level as fractal kinetic behaviour leading to 
increasing apparent KM during fibrinolysis (Varju et al., 2015). At higher plasmin 
concentrations, clustering may be less pronounced as plasmin spread along fibrin strands.  
Thus non-linear dose response ranges of plasmin on a fibrin substrate may be expected.  
Interestingly, this behaviour is largely supressed when plasmin is in complex with SK, 
suggesting SK significantly affects the interactions of plasmin kringles with C-terminal lysines 
during fibrinolysis. Further support for these ideas may come from the recently developed 
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WHO 4th IS Plasmin was prepared (Thelwell et al, 2015, in press). It was noted that none of 
the four standards for plasmin have used fibrin as a substrate, presumably because fibrin is a 
difficult substrate to study when measuring plasmin activity.  
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Chapter 4: Modelling the mechanism of M1GAS SK 
4.1 Introduction 
Understanding of streptokinase activation of plasminogen has almost exclusively focused on 
the Group C (GCS) S. equisimilis H46a SK variant which is used as a thrombolytic to treat 
myocardial infarction.  This strain of SK demonstrates no, or limited, binding and stimulation 
by fibrinogen, see chapter 2, e.g. Figure 2.8 for example (Chibber et al., 1985, Takada et al., 
1980) and presents the simplest mechanism of plasminogen to study.  However, other strains 
of SK across many streptococcal species, including the Group A (GAS) S. pyogenes M1 strain, 
display interactions with receptor bound fibrinogen and plasminogen and are typically 
associated with pathogenicity. Understanding the details of the mechanism of plasmin 
generation by SK variants from Streptococcal species associated with disease may provide 
insights into combating pathogenicity and treating infections (Sun, 2011).  Such studies will 
require inclusion of fibrinogen as a potential regulator of SK activity. 
The mechanism of action of SK as a plasminogen or plasmin binding protein, and plasminogen 
activator, has been outlined in chapters 2 and 3 and has been understood for some time 
(Gonzalez-Gronow et al., 1978).  More recently, Bock and co-workers have undertaken 
detailed studies on the various steps in the plasminogen activation process and developed 
the “trigger and bullet” model (Boxrud and Bock, 2004, Boxrud et al., 2004, Nolan et al., 2013).  
In this pathway, SK first binds plasminogen, generating an active site capable of converting 
free plasminogen to plasmin, providing the “trigger” step.  The plasmin thus formed has a 
higher affinity for SK than plasminogen and displaces it.  The plasmin M1GAS SK complex, 
the “bullet”, displays improved kinetics as a plasminogen activator, and this complex is 
responsible for subsequent plasmin generation.  As with most studies, the trigger and bullet 
mechanism was developed using an H46a SK variant with little or no binding capability for 
fibrinogen or fibrin.  It is of interest to explore the kinetics of plasminogen activation of a 
M1GAS SK, which does bind to fibrin and fibrinogen to better understand how plasminogen 
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activation is regulated.  Developing a model to explain the kinetic results of SK stimulated by 
fibrinogen is the subject of this chapter.  
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4.2 Experimental procedures 
M1GAS SK activity at 1.6 and 0.4 nM was simulated across a range of fibrinogen and 
plasminogen concentrations to replicate experimental data as closely as possible, and 
generate a matrix of kinetic data like that generated in a microtitre plate.  The specified range 
of fibrinogen was 53 nM to 30.3 µM, n=11 (log scale); and for plasminogen the range was 25 
nM to 1.6 µM, n=11, (linear scale). All simulations were performed using Gepasi, a computer 
program for simulating biochemical reactions (Mendes, 1993, Mendes, 1997). To facilitate 
comparison, 3D surfaces and contoured heat maps were fitted to the data using the Akima 
package in R (Akima, 1978). Curve fitting to the Michaelis-Menten equation of the data was 
accomplished using R and the Trellis package (Sarkar, 2008). 
The reactions involved in the pathways, present in the laboratory assays and used to simulate 
M1GAS SK activation of plasminogen are listed in Table 4.1 and represented in the model in 
Figure 4.2. Reaction 1 and 2 depict plasmin cleavage of the chromogenic substrate, S-2251, 
and pNA generation which are not shown in the model in Figure 4.2. The interaction between 
plasmin and fibrinogen, which will act as a competitive substrate for plasmin cleavage of S-
2251, is included in reaction 11. This model looks exclusively at initial rates so no reactions 
for the destruction of fibrinogen following plasmin generation are included. Simulations were 
typically followed for 600 s collecting 600, 1200 or 2400 time points. No significant differences 
were observed between various sampling rates. 
To begin modelling, values for the kinetic constants were either based on those determined in 
laboratory assays under the appropriate conditions, or taken from published values (see 
results). Kinetic parameters in the model were then adjusted manually to find optimal 
agreement between the data generated in laboratory assays and the simulation. Simulated 
data were treated in the same way as data from kinetic assays such that tables of time versus 
absorbance were generated and imported into R so rates of plasmin generation could be 
calculated from plots of absorbance versus time squared (see section 2.2.4A) up to a 
maximum absorbance chosen to limit substrate depletion to <20%.  A single R script was used 
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to determine rates of plasmin generation (pM s-1) from kinetic data and simulated data of rates 
of S-2251 hydrolysis and plot results (Colin Longstaff, personal communication, see Appendix 
2).   
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Table 4.1 Reactions required for Gepasi modelling. 
Reaction 
number 
Reaction Note 
1 E+S=ES 
The substrate S-2251 (S) forms a complex with the enzyme 
plasmin (E) 
2 ES-> E+P 
S2251 (S) is converted into pNA (P) by plasmin; thus 
releasing the enzyme (E) 
3 B+G=BG 
M1GAS SK (B) binds to plasminogen (G) to form a 
plasminogen activator complex (BG) 
4 BG+G=BGG 
The plasminogen activator complex (BG) binds a further 
plasminogen molecule (G) 
5 BGG-> BG+E 
Plasminogen (G) is converted to its active enzyme form, 
plasmin (E) and released from the activator complex (BG). 
6 G+F=GF Plasminogen(G) binds to fibrinogen (F) 
7 F+BG=FBG The activator complex (BG) binds to fibrinogen (F) 
8 GF+BG=GFBG 
The activator complex (BG) binds to plasminogen bound to 
fibrinogen (GF) to form a trimolecular complex (GFBG) 
9 G+FBG=GFBG 
Free plasminogen (G) binds the activator complex bound to 
fibrinogen (FGB) to form a trimolecular complex (GFBG) 
10 GFBG->E+FBG 
Plasminogen (G) is converted to plasmin (E) and released 
from the trimolecular complex (GFBG). The activator complex 
remains bound to fibrinogen (FBG). 
11 E+F=EF Plasmin (E) binds to fibrinogen (F) 
12 B+E=BE 
M1GAS SK (B) binds to plasmin (E) to form a plasminogen 
activator complex (BE). 
13 F+BE=FBE 
The plasminogen activator complex (BE) binds to fibrinogen 
(F) 
14 G+FBE=GFBE 
Free plasminogen (G) binds the activator complex bound to 
fibrinogen (FBE) to form a trimolecular complex (GFBE) 
15 GF+BE=GFBE 
The activator complex (BE) binds to plasminogen bound to 
fibrinogen (GF) to form a trimolecular complex (GFBE) 
16 GFBE->E+FBE 
Plasminogen (G) is converted to plasmin (E) and released 
from the trimolecular complex (GFBE). The activator complex 
remains bound to fibrinogen (FBE). 
17 BE+G=BEG The activator complex (BE) binds plasminogen (G) in solution 
18 BEG->BE+E 
The plasminogen (G) is converted to plasmin (E) and 
released by the activator complex (BE). 
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Table 4.2 Initial concentrations of metabolites included in modelling reactions.  
 
 
 
 
  
Metabolite  Initial Concentration 
S  0.24 mM 
G  
0.025, 0.183, 0.34, 0.50, 0.655, 
0.813, 0.970, 1.13, 1.29, 1.44, 
1.60 µM 
B  0.4 or 1.6 nM 
F  
0.052, 0.098, 0.186, 0.351,  
0.651, 1.26, 2.37, 4.49, 8.48, 
16.0,  30.3 µM 
E, ES, P, BG, BE, FBG, 
FBE, GFBG, GFBE, BEG, 
BGG, EF, GF 
 
0 
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4.3 Results 
Figure 4.1 presents a comparison between laboratory and simulated data for M1GAS SK 
activity across a fibrinogen/plasminogen concentration matrix, for which there is good 
agreement. M1GAS SK activation of plasminogen was simulated in Gepasi using the model 
in Figure 4.2. To facilitate comparison the data has been presented in Figure 4.1 as fitted 
surfaces (panels A and B), and as a contoured heat map, (panels C and D), which show results 
for kinetic data (panels A and C) and simulations (B and D) with 1.6 nM SK.  Panel E is a 
representation of the merged surfaces in panels A and C to illustrate the overlap of results.  
Panel F is a summary plot of apparent kcat/KM values from individual curve fits over a range of 
plasminogen concentrations, at each fibrinogen concentration.  In this case, good agreement 
is seen for kinetic data using 1.6 nM and 0.4 nM SK data (presented as points) and the results 
from simulated data which are presented as a curve, where 1.6 nM and 0.4 nM SK are 
overlapping.   
Curve fitting to the Michaelis-Menten equation using these data is presented in Figures 4.3, 
4.4, 4.5, and 4.6, corresponding to kinetic data for 1.6 nM, kinetic data SK, 0.4 nM, simulated 
data for 1.6 nM SK and simulated data for 0.4 nM SK, respectively.   The fitted parameters for 
kcat and KM from these curves and calculated values of kcat/KM are presented in Table 4.4 and 
4.5 for kinetic data and simulated data, respectively.  It was necessary to estimate and fix the 
KM for simulated data based on the fits to the kinetic data in order to complete batch fitting on 
the simulated data.  Visual inspection of kinetic data and simulated data (Figure 4.1) largely 
demonstrates excellent agreement and provides evidence to validate the model.  However, it 
is the case that some parameters could be changed slightly with compensation in other 
parameters to also provide a good fit.  Nevertheless, modifications to the parameters shown 
in Table 4.3 would be restricted to a narrow range.  It was not found possible to simplify the 
model presented in Figure 4.2 and still get the correct curves shapes shown in Figure 4.1 (A-
D), suggesting that the “trigger and bullet” mechanism is the minimal useful mechanism. Close 
examination of the Michaelis-Menten equation curve fits presented in Figures 4.3 to 4.6 
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suggests derived values for KM and Vmax (hence kcat) are robust, especially in the case of the 
results for the kinetic data.  There are some systematic deviations present in the curve fits for 
the simulated data (Figures 4.5 and 4.6), which may be improved with further optimisation of 
the model.  It should be noted that these curve fittings are an approximation of a more complex 
model since they assume idealised conditions of enzyme substrate interactions and 
adherence to a simple Michaelis-Menten model.  Fibrinogen is a complicating feature of the 
system that is likely to affect plasminogen activation over the concentration ranges used, 
therefore a simple Michaelis-Menten model is not truly accurate.  Thus the model illustrated 
in Figure 4.1 and Table 4.3 is a better approximation since it includes some additional 
interactions with fibrinogen. The simulated rate data do not include any noise, which is 
unavoidable in real kinetic data. It is therefore easier to identify systematic deviation in the 
simulated data, which may be masked in the curve fits of the actual kinetic data.   
 Association rate constants for all reactions with the exception of plasmin binding to M1GAS 
SK (reaction 12) are approximated to 107 M-1s-1 at 37 °C.  Many interactions of biological 
interest have association rate constants in the range 105 to 108 M-1 s-1 (0.1-100 µM-1 s-1) 
(Fersht, 1984) and it is common when fitting by numerical integration methods to begin with a 
fixed association rate constant and adjust KD or KM values by varying the dissociation rate 
constant e.g. (Kuzmic, 1996).  The formation of the plasmin M1GAS SK complex was assigned 
a rate constant of 108 M-1s-1 to reflect higher affinity and faster association (Boxrud et al., 2000, 
Boxrud et al., 2001).   Reported Biacore measurements at 25 °C determined association rate 
constants to be approximately 106 M-1s-1 for the SK-Pg* complex formation (Cook et al., 2012, 
Zhang et al., 2012), and for the SK-Pm* formation (Nolan et al., 2013). 
The kinetic constants for plasmin binding and cleavage of the chromogenic substrate, S-2251 
(reactions 1 and 2) were based on experiments described in chapter 3, whilst the binding of 
M1GAS SK to plasminogen (reaction 3) was best defined by a KD of 40 nM which fits well with 
published results by (Cook et al., 2012) and (Nolan et al., 2013).   
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The binding of the SK-Pg* complex to a further plasminogen molecule (reaction 4) and the 
subsequent generation of plasmin (reaction 5) were given a kcat of 0.04 and a KM of 0.6 µM as 
derived from fitting of Michaelis-Menten curves without fibrinogen.  This is approximately 7-
fold lower than results published (Boxrud and Bock, 2004) for H46a SK which is expected 
since M1GAS SK has been shown to be less effective without fibrinogen (KM was 0.27 µM and 
kcat 0.31 for Lys-Pg in (Boxrud and Bock, 2004).  In the model, when M1GAS SK complexes 
with plasmin, the KM was reduced by half to 0.3 µM, but the kcat was kept the same which is 
similar to the modest improvements in activity seen by (Boxrud et al., 2004).  
Upper limits of published KD values for fibrinogen binding to Lys-Pg are 8.3 µM (Lucas et al., 
1983), with lower estimates of 0.23 µM also available (Stewart et al., 1998). The value 
assigned here of 6.0 µM sits within this range. 
Reaction 8 represents the starting estimate from Michaelis-Menten fits at each fibrinogen 
concentration just as reaction 3 indicates the equivalent in solution.  The work on plasmin in 
this thesis (chapter 3) suggests fibrinogen can affect KM and kcat, but Michaelis-Menten fits of 
the data here indicate that the Vmax (and kcat) are much more affected than the KM.   
A 18-fold kcat increase from 0.1 s-1  to 1.8 s-1 for the generation of plasmin when the activator 
complex is in solution (reaction 5) or bound to fibrinogen (reaction 10) respectively accounts 
for most of the stimulation caused by fibrinogen in the assays systems. Some additional 
stimulation is seen with a small improvement in the KM to 0.25 from 0.6 µM.  
 An initial estimate for the binding of plasmin to fibrinogen (reaction 11) was based on the 
value published in (Longstaff and Whitton, 2004) but that assumed a simple competitive 
inhibition. As seen in chapter 3, this is not the case. Therefore, this is unlikely to be the true 
value, so may be a source of error and deviation at high fibrinogen concentrations.  
This binding of plasmin to SK (reaction 12) is tighter than the KD for SK-Pg* (reaction 3) and 
is similar to previously published Biacore measurements. (Cook et al., 2012, Nolan et al., 
2013, Boxrud et al., 2000).  The difference between these two values appears to be important 
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for the degree of curvature as plasminogen varies in the model to match the shape of the 
curves for laboratory data seen in Figure 4.1. 
The improvement between plasmin M1GAS SK complex and M1GAS SK-Pg* activity resulting 
from plasminogen binding is due to a decrease in KM (from 0.6 µM for plasminogen, reaction 
4,  to 0.3 µM for plasmin, reaction 17, without fibrinogen, and 0.6 µM for plasminogen to 50 
nM for plasmin with fibrinogen). There is no change in kcat, remaining consistent at 1.8 s-1 for 
both the plasminogen and plasmin complexes (reactions 10 and 16). This is in good 
agreement with laboratory data in chapter 3.  
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Table 4.3 Kinetic constants determined for chemical reactions in Gepasi modelling.  
Reaction 
number 
Reaction 
kon[a] 
(µM-1 s-1) 
koff 
(s-1) 
kcat 
(s-1) 
KD or KM 
(µM) 
1 E+S=ES 10 3680  368 
2 ES-> E+P   25.5  
3 B+G=BG 10 0.4  0.04 
4 BG+G=BGG 10 6  0.6 
5 BGG-> BG+E   0.1  
6 G+F=GF 10 60  6.0 
7 F+BG=FBG 10 60  6.0 
8 GF+BG=GFBG 10 2.5  0.25 
9 G+FGB=GFBG 10 2.5  0.25 
10 GFBG->E+FBG   1.8  
11 E+F=EF 10 5  5 
12 B+E=BE 100 0.01  0.0001 
13 F+BE=FBE 10 60  6.0 
14 G+FBE=GFBE 10 0.5  0.05 
15 GF+BE=GFBE 10 0.5  0.05 
16 GFBE->E+FBE   1.8  
17 BE+G=BEG 10 3  0.3 
18 BEG->BE+E 10  0.1  
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Figure 4.1 A comparison of lab-based and simulated M1GAS SK activation of 
plasminogen across a fibrinogen and plasminogen concentration matrix. Figures A) and 
C) illustrate data generated in the laboratory, whilst B) and D) show simulated data. E) is an 
overlay of the two to allow comparison, whilst F) compares lab values at two M1GAS SK 
concentrations with Gepasi simulated data for both. Axis in Figures A-D show plasminogen 
(Pgn) concentration in µM, fibrinogen (Fgn) concentration as log10 µM and rates of plasmin 
production in pM s-1.  In panel F fibrinogen concentration in µM is presented on a log scale. 
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Figure 4.2 A kinetic model to describe plasminogen activation by M1GAS SK. For clarity, 
some reactions listed in Table 4.3 have been omitted.  This are reactions 1 and 2 (E hydrolysis 
of S-2251), reactions 4 and 5 (E formation by BG without F binding) and reactions 17 and 18 
(E formation by BE without F binding). 
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Figure 4.3 Michaelis-Menten curve fits of kinetic data for 1.6 nM M1GAS SK activity 
across a fibrinogen concentration range. The values in the boxes above the curves denote 
the fibrinogen concentration (µM) with the Michaelis-Menten fits ordered from lowest Vmax 
(bottom left) to highest (top right). The y axis values are the plasminogen concentration (µM) 
and the z axis values denote rates of plasmin production in (pM s-1). 
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Figure 4.4 Michaelis-Menten curve fits of kinetic data for 0.4 nM M1GAS SK activity 
across a fibrinogen concentration range. The values in the boxes above the curves denote 
the fibrinogen concentration (µM) with the Michaelis-Menten fits ordered from lowest Vmax 
(bottom left) to highest (top right). The y axis values are the plasminogen concentration (µM) 
and the z axis values denote rates of plasmin production in (pM s-1). 
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Figure 4.5 Michaelis-Menten curve fits of simulated data for 1.6 nM M1GAS SK activity 
across a fibrinogen concentration range. The values in the boxes above the curves denote 
the fibrinogen concentration (µM) with the Michaelis-Menten fits ordered from lowest Vmax 
(bottom left) to highest (top right). The y axis values are the plasminogen concentration (µM) 
and the z axis values denote rates of plasmin production in (pM s-1). 
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Figure 4.6 Michaelis-Menten curve fits of simulated data for 0.4 nM M1GAS SK activity 
across a fibrinogen concentration range. The values in the boxes above the curves denote 
the fibrinogen concentration (µM) with the Michaelis-Menten fits ordered from lowest Vmax 
(bottom left) to highest (top right). The y axis values are the plasminogen concentration (µM) 
and the z axis values denote rates of plasmin production in (pM s-1). 
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Table 4.4 Summary of Michaelis-Menten curve fitting results for kinetic data using 1.6 
and 0.4 nM M1GAS SK. 
 M1GAS SK concentration (nM) 
 1.6 0.4 
Fibrinogen 
concentration (µM) 
Vmax 
(pM s-1) 
KM 
(µM) 
kcat 
(s-1) 
kcat/KM 
(µM-1 s-1) 
Vmax 
(pM s-1) 
KM 
(µM) 
kcat 
(s-1) 
kcat/KM 
(µM-1 s-1) 
0.00 79.4 0.65 0.05 0.08 8.3 0.29 0.02 0.07 
0.52 217.9 0.68 0.14 0.20 28.1 0.35 0.07 0.20 
0.79 242.1 0.61 0.15 0.25 31.1 0.27 0.08 0.29 
1.19 291.6 0.63 0.18 0.29 51.3 0.41 0.13 0.31 
2.66 318.7 0.44 0.20 0.45 58.4 0.35 0.15 0.42 
4.00 283.8 0.40 0.18 0.44 106.1 0.63 0.27 0.42 
6.00 311.9 0.48 0.20 0.40 95.7 0.64 0.24 0.37 
9.00 375.7 0.94 0.24 0.25 86.4 0.59 0.22 0.36 
13.50 244.0 0.62 0.15 0.25 78.4 0.73 0.20 0.27 
20.20 170.1 0.62 0.11 0.17 49.6 0.75 0.12 0.17 
30.30 108.9 0.59 0.07 0.12 31.2 0.66 0.08 0.12 
Min 79.4 0.40 0.05 0.08 8.3 0.27 0.02 0.07 
Max 375.7 0.94 0.24 0.45 106.1 0.75 0.27 0.42 
Ratio 4.7 2.34 4.70 5.83 12.8 2.81 
12.6
2 
5.86 
Average  0.60    0.51   
 
 
 
 
 
 
 
127 | P a g e  
 
Table 4.5 Summary of Michaelis-Menten curve fitting results for simulated data 
assuming 1.6 and 0.4 nM M1GAS SK. 
 M1GAS SK concentration (nM) 
 1.6 0.4 
Fibrinogen 
concentration (µM) 
Vmax 
(pM s-1) 
KM 
(µM) 
kcat 
(s-1) 
kcat/KM 
(µM-1 s-1) 
Vmax 
(pM s-1) 
KM 
(µM) 
kcat 
(s-1) 
kcat/KM 
(µM-1 s-1) 
0.05 68.1 0.50 0.04 0.09 17.2 0.50 0.04 0.09 
0.10 78.9 0.50 0.05 0.10 20.0 0.50 0.05 0.10 
0.19 98.3 0.50 0.06 0.12 24.9 0.50 0.06 0.13 
0.35 131.4 0.50 0.08 0.16 33.3 0.50 0.08 0.17 
0.66 183.1 0.50 0.11 0.23 46.5 0.50 0.12 0.23 
1.26 252.2 0.50 0.16 0.32 64.2 0.50 0.16 0.32 
2.37 320.1 0.50 0.20 0.40 81.6 0.50 0.20 0.41 
4.49 348.6 0.50 0.22 0.44 89.1 0.50 0.22 0.45 
8.48 307.3 0.50 0.19 0.38 78.9 0.50 0.20 0.39 
16.03 213.0 0.50 0.13 0.27 55.0 0.50 0.14 0.28 
30.30 117.0 0.50 0.07 0.15 30.4 0.50 0.08 0.15 
Min 68.1 0.50 0.04 0.09 17.2 0.50 0.04 0.09 
Max 348.6 0.50 0.22 0.44 89.1 0.50 0.22 0.45 
Ratio 5.1 1.00 5.07 5.13 5.2 1.00 5.19 5.19 
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5.4 Discussion 
The starting point for this work was the ‘trigger and bullet’ model for H46a SK activation of 
plasminogen proposed in (Nolan et al., 2013, Boxrud and Bock, 2004). A key difference 
between H46a SK and M1GAS SK is the interaction of fibrinogen so the model was adapted 
to incorporate the fibrinogen binding and stimulation of M1GAS SK demonstrated throughout 
this work.  This work used the basic model, laboratory data with ranges of plasminogen and 
fibrinogen and simulated results, to gain agreement between the kinetic data and the model 
to further our understanding of the mechanism of M1GAS SK.  
There is a strong agreement between the model and laboratory data but there are some 
parameters which are not known for certain and could be different, for instance the KD for 
plasmin and plasminogen with M1GAS SK. The values used in this model were taken from 
literature values (Cook et al., 2012, Zhang et al., 2012, Nolan et al., 2013) which have dealt 
primarily with group 2b strains. These share some characteristics with 2a SK variants of which 
S. pyogenes is a member (McArthur et al., 2008), however, future work into these interactions 
using Biacore could yield improves. Of further note, (Cook et al., 2012) binding studies were 
carried out at 25 °C, so the values will also differ slightly compared to at 37 °C, as used in this 
study.  
With S. pyogenes and Cluster 2a Streptococci, there is M1 expression and fibrinogen binding 
but no PAM expression and subsequently no direct plasminogen binding (typical of cluster 2b 
Streptococci) (McArthur et al., 2008). Seemingly, the bacteria’s interaction with fibrinogen is 
key to its mechanism of invasion, so it’s unsurprising that the SK would display fibrinogen and 
fibrin specificity. Without a capacity for direct plasminogen binding, which is less crucial in the 
blood considering the abundance of plasminogen (1.5 – 2.0 µM), there is a shift towards 
binding fibrinogen, another key haemostatic protein, as a way of localising plasmin activity to 
the cell surface. Any benefits of surface plasmin binding through surface-bound fibrinogen 
over direct PAM-plasmin binding are unknown. 
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The model shows how fibrinogen stimulates M1GAS activity in solution by binding SK and 
plasminogen to form a trimolecular complex, as hypothesized previously (McArthur et al., 
2008).  Stimulation of activity of the M1GAS SK-Pg* complex by fibrinogen is achieved by 
improvements in KM (0.6 to 0.25 µM) and kcat (0.1 to 1.8 s-1).  Similarly for the plasmin M1GAS 
SK complex, KM is improved (0.3 to 0.05 µM) and kcat (0.1 to 1.8 s-1), as shown in Table 4.1.  
These values also illustrate that most of the improvements seen when plasmin replaces 
plasminogen in the active complex with M1GAS are due to KM, which achieves its lowest value 
of 0.05 µM for plasmin M1GAS SK in the presence of fibrinogen.  Stimulation of kinetics is one 
way in which fibrinogen is deployed in regulating M1GAS activity and influencing pathogenesis 
(Cook et al., 2012), however accumulation of plasmin activity on the surface of the bacteria is 
also likely to be an important mechanism in promoting bacterial metastasis.  Thus the cluster 
2a bacteria have evolved to bind host fibrinogen molecules to their cell surface M1 receptor 
proteins to form the template for pericellular plasmin generation, as shown in Fig 1.3 (McArthur 
et al., 2008).  A different mechanism has been adopted by Cluster 2b bacteria which have 
PAM receptors able to bind and concentrate plasminogen, which may be tailored to 
environments with lower circulating plasminogen, explaining why PAM-expression is 
associated with skin infections (Svensson et al., 2002). 
The model outlined here only deals with the role of fibrinogen but fibrin is of great interest and 
seen to exhibit different binding and stimulatory effects on M1GAS SK, see chapter 2.  As the 
fibrin concentrations cannot be varied in a manner similar to that employed for fibrinogen, and 
there are diffusion issues with assay systems, modelling this in the same way as attempted 
with fibrinogen is more complicated. The heterogeneous nature of fibrin means that studying 
plasminogen activation at a solid liquid interface and modelling fibrinolysis is challenging.  
However, recent progress has been made in modelling fibrinolysis with tPA and similar 
approaches may be possible using SK (Bannish et al., 2014b, Bannish et al., 2014a, Longstaff 
and Kolev, 2015).  
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Chapter 5 Producing a recombinant SCG 
5.1 Introduction  
There have been several studies with SCG positive and SCG deficient strains of S. aureus to 
demonstrate the contributions of this virulence factor to pathogenesis (Cheng et al., 2010, 
DeDent et al., 2012, Cheng et al., 2009, Panizzi et al., 2011). However, very little is known 
about the mechanism of prothrombin activation with regard to bacterial virulence at the 
molecular level. There is also no clear understanding of why S. aureus expresses both a 
plasminogen activator (SAK) to promote fibrinolysis and SCG, a prothrombin activator which 
facilitates fibrin formation. 
The expression and purification of recombinant proteins is a useful tool for research. Bacterial 
systems, such as E. coli, typically give good protein yields and relative simplicity and ease of 
expression in comparison to other systems, such as mammalian (Baneyx and Mujacic, 2004, 
Malakhov et al., 2004, Thelwell and Longstaff, 2014). Work which served to demonstrate the 
potential of SCG as a ZAAP, and provide evidence for the “molecular sexuality” mechanism 
was carried out using recombinant truncated fragments of SCG. Native N-terminal sequences 
of S. aureus Tager strain SCG 1-325 as well as SCG 2-325, SCG 3-325 and SCG 147-325 
were expressed in E. coli using a His-tag system and a factor Xa cleavage site after the 
initiating ‘Met’ residue (Friedrich et al 2003). The same group has also expressed Met-SCG 
1-325 with a C-terminal His-tag (Panizzi et al 2006). Full-length GST-tagged SCG has been 
expressed in E. coli. A GST expression system was stated as being chosen since SCG 
seemed to undergo degradation during purification in a pET15b vector with a Strep tag 
(McAdow et al., 2012a). The GST tag system employed here used a PreScission (GE 
Healthcare) protease cleavage site, which does not allow purification of a recombinant protein 
with an intact, native N-terminal sequence, as removal of the tag leaves additional amino 
acids. This was not necessary for the work in (McAdow et al., 2012) as the focus was on the 
effect antibodies raised against SCG have on the ability for S. aureus to clot blood and 
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establish infection in a murine model, not the in vitro activity of the SCG protein. However, the 
N-terminal Ile1 residue on SK is critical for plasminogen activation (Wang et al., 2000) and an 
integral part of ZAAP “molecular sexuality” (Wang et al., 1999). Therefore, the recombinant 
expression strategies employed in this work were chosen to express a SCG protein with a 
preserved native N-terminal sequence, in order to investigate its potential as a prothrombin 
activator in manners analogous to those detailed above for SK. Following on from successful 
expression of SK in E. coli in a SUMOstar expression system (Chapter 2), the decision was 
taken to utilise this for SCG expression. SUMOstar has also been optimised for expression of 
recombinant proteins in P. pastoris and the initial cloning strategy is common between the two 
systems. As such, both strategies were explored in parallel.  
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5.2 Experimental procedures 
5.2.1 Materials, equipment and software 
One Shot TOP10 chemically competent E. coli cells, Zero Blunt TOPO PCR cloning kit, pCR 
– Blunt II-TOPO vector, Ampicillin, Zeocin, Blue Juice loading buffer, pGAPZα vector  
(Invitrogen, Merelbeke, Belgium) 
T7 Express LysY Competent high efficiency E. coli cells, Phusion High Fidelity DNA 
Polymerase Master Mix (New England BioLabs, Hertfordshire, UK). 
pE SUMOstar expression kit, pY SUMOstar expression kit, SUMOstar protease (LifeSensors, 
Pennsylvania, USA).  
QIAprep Spin Miniprep Kit, QIACUBE, QIAquick gel extraction kit, Empty columns (QIAGEN, 
Greater Manchester, UK) 
Nuclease free water, NanoDrop 2000 UV-Vis spectrophotometer, Rapid DNA ligation kit, 
aLICator LIC cloning and expression kit 2 (Thermo Scientific, Massachusetts, USA) 
All restriction digesion enzymes were FastDigest enzymes obtained from Thermo Scientific 
(Massachusetts, USA).  
Gel Red (Biotium, California, USA) 
rEK capture kit (Novagen, Wisconsin, USA) 
E-Gel® CloneWell™ 0.8% SYBR Safe™ gel s, E-Gel® iBase™ and Safe Imager system (Life 
Technologies, Renfrewshire, UK) 
Agarose,Glycerol, NiNTA Agarose (Sigma Aldrich, St Louis, Missouri, USA) 
AKTApurifier (GE Healthcare, Buckinghamshire, UK) 
S-2238 (H-D-Phe-Pip-Arg-pNA) (Chromogenix, Milan, Italy) – reconstituted in 15 ml H2O, to 
give a 3 mM stock solution. Stored at 2-8 °C, stable for several months.  
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Fibrinogen (Calbiochem, Merck Millipore, Billerica, Massachusetts, USA) - reconstituted in 
Buffer B to give stock solution of 50 mg/ml, and flash frozen in liquid nitrogen in small aliquots 
and stored at -40 °C. All dilutions for reaction set ups were in buffer B also. 
Prothrombin (Calbiochem, Merck Millipore, Billerica, Massachusetts, USA) - reconstituted in 
H20 to 1 mg/ml and flash frozen in liquid nitrogen in small aliquots and stored at -40 °C. All 
dilutions for reactions were in buffer C. 
5.2.2 Culture media and assay buffers 
YPD, YPDS and Low salt LB media were made according to recipes in the Invitrogen manual 
for pGAPZα A, B and C (MAN0000043). 
LB Media, made from LB media powder (Thermo Scientific, Massachusetts, USA) 
SOC medium (Invitrogen, Merelbeke, Belgium). Stored at 2 – 8 °C. 
TBE buffer, made from 10x TBE (Thermo Scientific, Massachusetts, USA) 
Buffer A - 0.5 M Tris pH 8.4 at 37 °C. Stored at 2-8 °C for 6 months. 
Buffer B – 10 mM Tris HCL 100 mM NaCl 0.01% Tween 20. Store at 2-8 °C for 1 week.  
Buffer C – Buffer B + 1mg/mL Human Serum Albumin (HSA). Store at 2-8 °C for 3 days.  
All laboratory chemicals used to make buffers were from Sigma Aldrich, St Louis, Missouri, 
USA.  
5.2.3 Bacterial strains and culture  
5.2.3A E. coli strains 
Commercially available chemically competent Top10 E. coli cells were used for initial 
transformation after cloning and plasmid maintenance. Protein expression was carried out in 
T7 Express LysY Competent high efficiency E. coli cells (New England Biolabs, Hertfordshire, 
UK) 
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 5.2.3B E. coli culture conditions 
Unless otherwise stated, E. coli cultures were routinely grown at 37 °C on LB-agar plates or 
in LB liquid culture with constant shaking. Culture media was supplemented with selective 
antibiotics as appropriate to the transformed plasmid (ampicillin (50 µg/mL) or zeocin in low 
salt LB (25 µg/mL)). For long term storage, E. coli cultures were stored at -80 °C in 2 ml 
aliquots containing 15% (w/v) glycerol. 
5.2.4 Yeast strains and culture 
5.2.4A P. pastoris strains 
Commercially available X-33 wild-type Pichia pastoris yeast strain (Thermo Scientific, 
Massachusetts, USA) were used for protein expression. 
5.2.4B P. pastoris culture conditions 
Successful transformants were plated on YPDS agar plates containing 100-1000 µg/mL 
zeocin and incubated statically at 30 °C for 2-3 days. Zeocin resistant colonies were grown on 
YPD plates containing 100 µg/mL zeocin to confirm presence of desired insert. Overnight 
colonies of P. pastoris necessary for electroporation and recombinant protein expression 
colonies of P. pastoris were grown in YPD media at 30 °C with shaking (300 rpm). Expression 
colonies were incubated for up to 72 hours.  
5.2.5 General methods for DNA manipulation 
5.2.5A Primer design and PCR amplification of staphylocoagulase from S. aureus Newman strain 
genomic DNA 
Primers were designed for the full-length mature peptide, based upon the staphylocoagulase 
sequence identified in (Baba et al., 2008) (accession code AP009351). Annealing 
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temperatures and secondary structures were verified using Thermo Scientific Multiple Primer 
Analyzer and Sigma Genosys DNA Calculator, available free online.  
All primers used in this study were synthesised by LifeTechnologies Invitrogen Custom DNA 
Oligo service to include any necessary sequences and restriction sites as detailed by the 
manufacturers guidance for the relevant expression vectors (Table 2.2).  
A PCR reaction was carried out using Phusion High Fidelity DNA Polymerase Master Mix 
according to manufacturer’s instructions. Briefly, 160 ng Newman strain S. aureus genomic 
DNA (kindly provided by Angelika Grundling at Imperial College, London) was used as a 
template with 0.5 µM of the respective primers (Table 2.2) in a 50 µL reaction containing 3% 
DMSO. Initial denaturation was carried out at 98 °C for 3 min followed by 35 cycles 
(denaturation at 98 °C for 10 s, and annealing and extension for 1 min at 72 °C) and a final 
extension period at 72 °C for 10 min.  
Agarose gel electrophoresis was used to confirm a single, discrete band of approximately 
1900 bp in size consistent with the predicted product of 1822 bp.  
5.2.5B TOPO cloning 
Where appropriate, a Zero Blunt TOPO PCR cloning kit was used to capture the successful 
SCG PCR amplification. A TOPO cloning reaction containing 2 µL PCR reaction (Table 2.3) 
and 10 ng pCR – Blunt II-TOPO vector was incubated at room temperature for 5 min according 
to manufacturer’s instructions. 5 µL of TOPO cloning reaction was added to one 50 µL vial of 
One Shot TOP10 chemically competent E. coli cells and incubated on ice for 30 min. The cells 
were heat shocked at 42 °C for 30 s, and returned to ice for 2 min before 250 µL SOC medium 
was added. The mixture was incubated for 60 min at 37 °C with shaking before 200 µL aliquots 
were plated on zeocin selective plates and incubated overnight at 37 °C. 
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5.2.5C Plasmid purification from E. coli 
Plasmid constructs (Table 2.3) were isolated from 5 mL overnight cultures containing the 
selective antibiotic of transformed One Shot TOP10 cells using the QIAprep Spin Miniprep Kit 
manually or using the automated QIACUBE standard miniprep protocol according to 
manufacturer’s instructions. 
5.2.5D Restriction enzyme digestion 
Restriction endonuclease digestion was used to confirm the presence of insert and to release 
inserts from construct ready for subcloning or cloning into expression vector. All restriction 
enzymes were FastDigest enzymes and digestion conditions set up according to 
manufacturer’s recommendations.  
Briefly, 500 ng DNA was incubated with 1 µL of each of the relevant restriction enzymes and 
3 µL FastDigest reaction buffer in a 30 µl reaction for 15 min at 37 °C. 1 µg of the 
corresponding vector (Table 2.3) was digested with 2 µL of the appropriate restriction enzymes 
in a 30 µL reaction containing 3 µL FastDigest buffer for 15 min at 37°C according to 
manufacturer’s instructions.  
5.2.5E Agarose gel electrophoresis and gel extraction. 
PCR products, restriction digests etc were visualised using agarose gel electrophoresis. 
Typically, E-Gel® CloneWell™ 0.8% SYBR Safe™ gel s and the E-Gel® iBase™ and Safe 
Imager system were used with DNA bands collected in nuclease free water via the collection 
wells.  Alternatively, a 1% agarose gel was cast with 0.5x TBE buffer including Gel Red. DNA 
samples were loaded with Blue Juice loading buffer and visualised under UV light. Where 
necessary, required bands were isolated from the gel with a scalpel and purified using 
QIAquick gel extraction kit according to the manufacturer’s instructions.  
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5.2.5F Determining DNA concentrations 
In all instances, DNA concentrations were measured using a NanoDrop 2000 UV-Vis 
spectrophotometer. 
5.2.5G DNA ligation and transformation of chemically competent E. coli 
Ligation of the SCG insert and corresponding vector was performed using Rapid DNA ligation 
kit according to manufacturer’s instructions. Typically 50 ng of digested vector was mixed with 
the required insert at a molar ratio of 1:3 in the presence of ligation buffer and Ligase for 5 min 
at 22 °C. 
5 µL of ligation reaction was added to one 50 µL vial of One Shot TOP10 chemically competent 
E. coli cells and incubated on ice for 30 min. The cells were heat shocked at 42 °C for 30 s, 
and returned to ice for 2 min before 250 µl SOC medium was added. The mixture was 
incubated horizontally for 60 min at 37 °C with shaking before 200 µL aliquots were plated on 
LB agar plates containing 100 µg/mL ampicillin and incubated overnight at 37 °C. 
5.2.5H Preparation and transformation of P. pastoris by electroporation. 
A 50 mL conical flask containing 5 mL YPD media was inoculated with P. pastoris and 
incubated overnight at 30 °C with shaking. 500 µL of the overnight culture was used to 
inoculate a 500 mL culture held in a 2 L baffled flask which was grown overnight at 30 °C with 
shaking until an OD600 of 1.3 to 1.5 was achieved. The cells were centrifuged at 1500 xg for 5 
min at 4 °C, and the pellet resuspended in 500 mL of sterile ice cold water (0 °C). Cells were 
centrifuged and resuspended a further 3 times, but in 250 mL sterile ice cold water and then 
20 mL and 1 mL of 1M sorbitol, respectively.  The final volume of cells were held on ice, and 
used immediately. 5 µg in 10 µL sterile water was mixed with 80 µL of the prepared cells in a 
0.2 cm electroporation cuvette held on ice, for 5 min. Cells were pulsed on P. pastoris settings 
using a Bio-Rad Gene Pulser MXCell electroporation machine (Bio-Rad Laboratories INC, 
Hertfordshire, UK), and 1 mL of 1M sorbitol (ice cold) added immediately to the cuvette. The 
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cells were then transferred to sterile 15 mL tube and incubated at 30 °C, statically, for 1-2 
hours. 10 – 200 µL were spread on YPD agar plates containing zeocin (100 µg/mL, 500 µg/mL 
or 1000 µg/mL) and incubated for up to 72 hours.  
5.2.5I DNA sequencing 
Purified plasmid DNA was sequenced by GATC Biotech (Constance, Germany) using 
sequencing primers (Table 5.4) designed according to specifications. The primers were 
designed to ensure sequencing of both strands. M13 primers, available in the lab, or aLICator 
sequencing primers provided in the aLICator expression kit, were included for sequencing of 
constructs. The results were aligned with source sequence and the sequence confirmed.  
5.2.6 Cloning strategies for SCG constructs 
5.2.6A Preparation of pE SUMOstar SCG and pY SUMOstar SCG 
A PCR reaction containing primers A and B amplified SCG from S. aureus and a Zero Blunt 
TOPO PCR cloning kit captured the successful PCR product which was used to transform 
chemically competent E. coli as detailed above.  TOPO-SCG constructs obtained via 
minipreps of overnight cultures of successful transformants were digested with BsmBI and 
XhoI to release the SCG insert. pE SUMOstar and pY SUMOstar were digested with BsmBI 
only. Ligation reactions containing the SCG insert and digested pE SUMOstar and pY 
SUMOstar vector were used to transform TOP10 cells. Successful pE SUMOstar constructs 
were purified from overnight cultures and used to transform T7 lysY cells ready for SCG 
expression.  
5.2.6B Preparation of pGAP Z α SUMO SCG and transformation of P. pastoris 
pY SUMOstar constructs were purified from overnight cultures of successful transformants. A 
restriction digest reaction with XhoI and XbaI was set up to obtain a SUMOstar SCG insert. 
XhoI and XbaI were also used to digest pGAPZ α vector isolated from E. coli glycerol stocks 
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provided by Craig Thelwell. A ligation reaction and transformation of chemically competent E. 
coli was performed and successful colonies used to make overnight cultures from which 
purified pGAPZ α SUMO SCG were obtained. Linearization of approx. 5 µg of construct was 
carried out via restriction digest with Avr II and used to transform competent P. pastoris cells 
by electroporation.  
5.2.6C Preparation of aLICator SCG 
A PCR reaction containing primers C and D amplified SCG from S. aureus, and confirmed by 
using the PCR product as a template to clone SCG with known primers. Overhangs were 
created on the successful purified PCR product by incubating 0.1 pmol PCR product with 1x 
LIC buffer, 1 µL of T4 DNA polymerase and nuclease free water in a 10 µL reaction according 
to manufacturer’s instructions. The mixture was vortexed, centrifuged briefly, and incubated 
at room temp for 5 min before the reaction was stopped with the addition of 0.6 µL EDTA. 1 
µL of the pLATE 51 vector was added to the mixture, vortexed and centrifuged briefly and held 
at room temp for 5 min to allow annealing to occur. The annealing mixture was used to 
transform chemically competent E. coli as detailed above. Successful transformants were 
purified from overnight cultures and used to transform T7 lysY cells ready for SCG expression. 
As part of the cloning strategy for using aLICator system with enterokinase cleavage, the SCG 
sequence checked to confirm that there were no enterokinase cleavage sites using REBASE, 
free online software from New England Biolabs.
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Table 5.1 Description of the primers used for PCR amplification of SCG from genomic S. aureus DNA in this research. 
Name Description Restriction sites Corresponding vector Sequence (5’ to 3’) 
A 
5’ end from start of 
mature peptide 
BsmBI 
pE SUMOstar, pY 
SUMOstar 
AACTACGTCTCAAGGTATAGTAACAAAGGATTATAGTGG
GAAATCACAAGTTAATG 
B 
3’ end to the stop 
codon 
XhoI 
pE SUMOstar, pY 
SUMOstar 
AACTCGAGTTATTTTGTTACTCTAGGCCCATATGTCGCA 
C aLICator/EK n/a aLICator 
GGTGATGATGATGACAAGATAGTAACAAAGGATTATAG
TGGGAAATCACAAGTTAATG 
D aLICator/EK n/a aLICator 
GGAGATGGGAAGTCATTATTTTGTTACTCTAGGCCCATA
TGTCGCA 
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Table 5.2 Description of the plasmids used in this research. 
Plasmid Name Source Description or use Antibiotic Resistance 
pCR-Blunt II-TOPO Invitrogen PCR cloning vector Kanamycin, Zeocin 
pCR-Blunt II-TOPO SCG Section 5.2.3-5.2.6 PCR cloning vector with SCG PCR product insert Kanamycin, Zeocin 
pE-SUMOstar LifeSensors 
Vector for T7 lac promoter based expression of 
SUMOstar fusion proteins in E. coli 
Ampicillin 
pE-SUMOstar SCG Section 5.2.3-5.2.6 
Vector construct for expression of N-terminal SUMOstar 
fusion of full-length SCG in E. coli 
Ampicillin 
pY-SUMOstar LifeSensors 
Vector for expression of SUMOstar fusion protein in P. 
pastoris 
Zeocin 
pY SUMOstar SCG Section 5.2.3-5.2.6 
Vector construct for expression of N-terminal SUMOstar 
fusion of full-length SCG in P. pastoris 
Zeocin 
pGAPZ α Invitrogen Vector for constitutive expression in P. pastoris Zeocin 
pGAPZ α SUMO SCG Section 5.2.3-5.2.6 
Vector construct for N-terminal SUMOstar fusion of full-
length SCG in P. pastoris with constitutive expression 
Zeocin 
aLICator pLATE51 Thermo Scientific 
Vector for expression of N-terminal 6xHis-tag proteins in 
E. coli with enterokinase recognition sites. 
Ampicillin 
aLICator pLATE51 SCG Section 5.2.3-5.2.6 
Vector construct for N-terminal 6xHis-tag full-length SCG 
in E. coli with enterokinase recognition site. 
Ampicillin 
 
 
 
142 | P a g e  
 
Table 5.3 Sequencing primers used to confirm successful SCG vector constructs in this 
research. 
Primer name Primer sequence 
Forward 1 GAGAGCACTGGATGATTTTC 
Forward 2 GCCAGTAGTAAAAGAAGAG 
Forward 3 GTGAATACAACGATGGAAC 
Reverse 1 GCTTTATCTTCTTCTGCTGC 
Reverse 2 GCTTTATCTTCTTCTGCTGC 
Reverse 3 TTTGCATGTGTTGTTACG 
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5.2.7 Recombinant protein expression and purification 
5.2.7A Expression of recombinant proteins in E. coli 
Expression of recombinant SCG was attempted using the SUMOstar fusion tag system and 
the aLICator system according to the protocol used to express recombinant SK variants in 
section 2.2.2. However in this instance the binding buffer used for AKTA purification contained 
20 mM imidazole. 
5.2.7B Expression of recombinant proteins in P. pastoris 
Expression of recombinant SCG was attempted using the SUMOstar fusion tag system for P. 
pastoris. 50 mL of YPD media was inoculated with an overnight culture from a successful 
transformant colony. Incubation was for up to 72 hours at 30 °C with shaking. 15 mL fractions 
of culture media was taken at 24, 48 and 72 hours and concentrated down to approx. 150 µL 
by 2x centrifugation in amicon tubes at 5000 x g for 20 min, at 4 °C. Concentrates were stored 
at -40 °C until analysis. 
5.2.7C Cleavage of SUMOstar fusion tag with SUMOstar protease 
Following dialysis overnight in 20 mM Tris-HCL, pH 8.0 containing 1.5 M NaCl), the SUMOstar 
fusion tag was cleaved using SUMOstar protease according to the manufacturer’s protocol. 
Cleavage was attempted from 4 - 16 hours at 22 - 30°C in the presence of 2 - 5 mM DTT and 
was confirmed by SDS-PAGE.  The SUMOstar tag and protease were bound to Ni-NTA 
agarose by mixing for 1 hour and the cleaved purified protein was recovered by filtration 
through an empty column. 
5.2.7D Cleavage of His-tag with enterokinase 
Protein eluates following AKTA purification were dialysed against 3 L cleavage buffer 
overnight.  Cleavage of the N-terminal tag with enterokinase was attempted with 2-4 units at 
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room temperature over several time courses (4-16 hours) with and without the presence of 
DTT (0- 5 mM). rEK was removed with a capture kit according to manufacturer’s instructions. 
The SCG prep was incubated with Ni-NTA agarose for 1 hour with mixing and ran through an 
empty column to bind and remove the cleaved HIS-tag.  
5.2.8 SCG activity 
5.2.8A SCG activity against S-2238, a chromogenic substrate for thrombin 
A reaction containing 50 µL of the SCG prep following rEK cleavage and removal, prothrombin  
(final concentration 1.4 µM) and the chromogenic substrate for thrombin S-2238 (final 
concentration 0.24 mM), was carried out in Buffer A. Absorbance at 405 nm was measured 
on a SpectraMax M5 plate reader (Molecular Diagnostics) at 30 s intervals for 2 hours at 37 °C. 
5.2.8B SCG activity against fibrinogen 
A reaction containing 50 µL of the SCG prep following rEK cleavage and removel, prothrombin 
(final concentration 1.4 µM) and fibrinogen (final concentration 3 mg/mL) was set up in Buffer 
A. Absorbance at 405 nm was measured on a SpectraMax M5 plate reader (Molecular 
Diagnostics) at 30 s intervals for 2 hours at 37 °C. 
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5.3 Results  
5.3.1 Expression and purification of SUMOstar fusion-tagged SCG  
5.3.1A E. coli 
Following on from the successful expression of SK variants (Chapter 2), the expression of 
SCG, another ZAAP, was attempted using the same SUMOstar fusion tag system. Successful 
cloning into the pE SUMOstar vector was verified by sequencing, and SDS-page gels 
demonstrated a band of an appropriate size (approx. 79 kDa) following the expression and 
purification strategy outlined in section 2.2.2 (Figure 5.1). As depicted in Figure 5.1 there are 
also several other bands, and at this stage it was not determined whether these were non-
specific contaminants or possibly truncated SUMOstar SCG. Gel electrophoresis of the 
purified SCG with a native N-terminal sequence following attempts to cleave the SUMOstar 
tag, using the SUMOstar protease, could not detect any protein (not shown). This suggests 
that potentially SUMOstar SCG was not expressed. A band of the appropriate size (79 kDa) 
for uncleaved SCG was detected by gel electrophoresis of the protein bound to the Ni-NTA 
agarose used for purification of the SUMOstar tag and protease following cleavage attempts. 
This demonstrates that the protein was potentially expressed but cleavage conditions were 
not optimal (Figure 5.2).  
SUMOstar protease activity has been shown to be protein specific. Cleavage of rSK H46a and 
rSK M1GAS in this project, which share 88.4% sequence homology, appeared to cleave at 
differing rates with rSK M1GAS cleavage taking approx. 4 hours, whilst rSK H46a required 
overnight incubation. To investigate whether the protein was expressed but insufficiently 
cleaved, increasing amounts of SUMOstar protease were trialled. DTT, which relaxes the 
protein structure by reducing disulphide bonds, was shown to be critical for SUMOstar 
protease cleavage of the SUMOstar tag for SK variants. As such, differing amounts of DTT 
were also attempted, as were a variety of cleavage times from 4 – 16 hours. SUMOstar 
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protease was also added in several stages to the prep, as there was some suggestion from 
optimisation of SK purification that the protease was inactivated after several hours. 
The presence of multiple bands of a similar size all bound to the NiNTA-agarose, suggested 
perhaps the protein was being cleaved resulting in a series of truncated SUMOstar-tagged 
SCG proteins. To attempt to improve expression conditions, various strategies were 
employed. Alternative culture media, Magic Media and Terrific Broth, (both Thermo Scientific, 
Massachusetts, USA) were also used. Magic Media allows recombinant protein expression 
without the need for IPTG induction, whilst Terrific Broth is a rich media intended to improve 
cell density and growth. Induction was also attempted at 30 °C, as lower temperatures can 
reduce proteolytic cleavage during expression of sensitive proteins, and is recommended for 
Magic Media expression. 
Incubation of the protein preps following SUMOstar protease cleavage attempts, with 
prothrombin and the thrombin chromogenic substrate, S-2238, could not detect any thrombin-
like activity. This may be because the protein was not expressed, or because the SCG 
remained uncleaved and inactive as a SUMOstar fusion protein. Unfortunately, none of the 
conditions tried improved yields of purified protein, and it was not possible to detect a cleaved 
native N-terminal sequence full-length SCG using SDS-page.  
Recombinant expression is specific to each individual protein, and it is very difficult to predict 
the optimal conditions for success. As such, the aLICator system for E. coli, an expression 
system which also enables preservation of the native N-terminal sequence in the final, purified 
protein was investigated alongside the SUMOstar strategies. This utilises a smaller, simpler 
N-terminal 6xHis tag for purification, and an alternative cleavage protease (enterokinase, rEK). 
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Figure 5.1 SDS-PAGE of SUMOstar SCG expression cultures following AKTA 
purification. SDS-page of 0.5 mL elution fractions (1-8) corresponding to a absorbance peak 
on the AKTApurifier chromatogram indicating protein detection. SCG expression cultures were 
run through a Ni-affinity column designed for purification of 6-His-tag bound recombinant 
proteins and eluted with an imidazole concentation gradient. The black arrow represents 
where a band of 79 kDa would run, representing the predicted weight of SUMOstar SCG.  
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Figure 5.2 SDS-PAGE of proteins bound to Ni-NTA agarose following SUMOstar 
protease cleavage. Following Ni-affinity purification on an AKTApurifier, protein eluates were 
incubated with SUMOstar protease to allow cleavage of the SUMOstar tag from the SCG 
protein. The protein eluates were the incubated with Ni-NTA agarose and run through a blank 
sample to column to remove SUMOstar protease, cleaved SUMOstar tag and uncleaved 
SUMOstar-SCG protein. Proteins bound to the column were eluted with 300 mM imidazole 
and subjected to SDS-page. Black arrow indicates predicted size (79 kDa) of SUMOstar SCG 
protein indicating poor cleveage with SUMOstar protease.  
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5.3.1B P. pastoris 
For SUMOstar tagged SCG expression in P. pastoris, successful cloning was also possible 
as determined by sequencing. An initial attempt at expression was conducted with 2 separate 
colonies, with a control (vector with no SCG) for comparison. Colony 1 was selected from a 
successful transformation plate containing 100 µg/mL zeocin. Colony 2 was selected from a 
successful transformation plate containing 500 µg/mL zeocin. Growth under higher antibiotic 
concentrations can be an indication that the plasmid DNA has integrated into multiple sites in 
the yeast genome during transformation, which can result in higher protein expression.  
Aliquots of the cultures were collected at 24, 48 and 72 hours for analysis. As seen in Figure 
5.3, gel electrophoresis of the culture media revealed an excess of proteins, so it was difficult 
to determine whether there was any difference between the control vector (no SCG) and the 
positive cultures. It was also difficult to conclude any differences in protein expression over 
the time course. As such, the culture supernatants were subjected to IMAC purification. 
Running the elution fractions through a gel revealed that there was no distinct band at 79 kDa, 
the expected size of the SUMOstar tagged SCG protein (Figure 5.4). Given that multiple 
strategies were pursued in parallel for this project, the optimisation of the expression of 
SUMOstar tagged SCG in P. pastoris was not continued beyond this point.  
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Figure 5.3 SDS-PAGE of SUMOstar SCG expression time course in P. pastoris. Culture 
samples were taken from a control vector only expression and two colonies which were 
successfully transformed with SUMOstar-SCG after 24, 48 and 72 hours expression at 30 °C. 
Black arrow indicates predicted band size of SUMOstar-SCG (79 kDa).   
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Figure 5.4 SDS-PAGE of SUMOstar SCG expression cultures from P. pastoris following 
AKTA purification using Ni-affinity. 0.5 ml elution fractions (1-9) corresponding to a peak 
on the AKTApurifier chromatogram indicating protein detection. Note the absences of a band 
at 79 kDa, the predicted weight of SUMOstar SCG, as indicated by the black arrow. 
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5.3.2 Optimising the expression and purification of recombinant SCG in E. coli using aLICator 
expression and rEK cleavage 
As well as attempts to express SCG using a SUMOstar fusion tag in E. coli or P. pastoris, the 
aLICator system (Thermo Scientific) was explored as a potential alternative.  This system 
allows purification via Ni-affinity chromatography utilising a 6xHis tag as with the SUMOstar 
systems, but cleavage of the N-terminal tag is achieved in this instance with enterokinase 
(rEK). This was a valuable approach to use alongside the SUMOstar systems given that the 
tag was much smaller, and therefore would offer different properties and restrictions to the 
fusion protein which may aid expression and correct protein folding. It may also alleviate the 
potential problem with truncations of SCG suspected in the E. coli expression of SUMOstar 
SCG. This is consistent with (McAdow et al., 2012) where a GST-fusion system was used to 
alleviate problems with protein degradation when a pET15b construct with a Strep tag was 
used. 
Following IMAC purification on the AKTA purifier system, SDS page visualisation showed a 
strong band of the correct size for tagged SCG, 64 kDa (Figure 5.5). The samples were 
subjected to rEK cleavage; initially for 4 hours with DTT. The protease was removed and the 
cleavage preps were incubated with prothrombin and a chromogenic substrate for thrombin 
(S-2238), to determine whether any thrombin-like activity was detectable. As demonstrated in 
Figure 5.6., an increase in absorbance at 405 nm and therefore SCG activity could be detected 
in the presence of S-2238 and prothrombin, but not in control reactions (A) S-2238 alone, B) 
S-2238 + prothrombin only, C) S-2238 + SCG prep only D) uncleaved SCG prep). 
Despite chromogenic activity, following 6xHis-tag cleavage and clean–up, visualisation of the 
purified SCG protein using SDS page was not possible; presumably due to low yield of cleaved 
protein (gel not shown).  
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Figure 5.5 SDS-PAGE of aLICator SCG expression cultures following AKTA purification. 
0.5 ml elution fractions (1-7) corresponding to a peak on the AKTApurifier chromatogram 
indicating protein detection. The band at 64 kDa corresponds to the predicted weight of 
aLICator SCG, indicated by the black arrow. 
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Figure 5.6 Chromogenic activity against S-2238 of an aLICator SCG protein prep 
following rEK cleavage. After tag cleavage with rEK, the aLICator SCG protein prep was 
incubated with prothrombin and S-2238, a chromogenic substrate for thrombin, and the 
absorbance of 405 nm measured to detect any SCG-like activity. S2238 was also incubated 
alone, with prothrombin, SCG, and prothrombin and the uncleaved prep as assay controls.  
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To attempt to optimise the 6xHis-tag cleavage and improve purified protein yields, a time 
course of rEK cleavage was employed. rEK was incubated with the SCG prep for 2, 4, 8 hours 
and overnight. Again, following removal of rEK, the samples were incubated with the 
chromogenic substrate S-2238 (Figure 5.7A) and also, in this instance, fibrinogen (Figure 
5.7B). Here, around 4 hours was determined as optimal, with overnight resulting in a loss of 
activity. Once more though, SDS page analysis following clean-up did not reveal a band for 
the purified, cleaved SCG protein (gel not shown).  
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Figure 5.7 A time course of rEK cleavage of aLICator SCG as determined by activity 
against the chromogenic substrate S-2238 (top) and fibrinogen (bottom). To optimise the 
conditions of tag cleavage with rEK, a time course was set up. Samples were taken from the 
cleavage prep after 2, 4 and 8 hours as well as overnight, and the rEK removed. The prep 
was then incubated with prothrombin and S-2238 or fibrinogen to detect any thrombin-like 
activity. 
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5.4 Discussion 
Despite several attempts, it was not possible to make a purified tag-free native N-terminal 
sequence SCG protein within the time frame of this project. The difficulties encountered with 
the expression strategies explored here could be attributed to cleavage of the N-terminal tags. 
The rSK variants H46a and M1GAS expressed using the SUMOstar system in this project 
share more than 88% sequence homology. Despite this, the efficiency of SUMOstar cleavage 
varied quite considerably. The SUMOstar tag appears to be susceptible to subtle differences 
in protein interactions, therefore it is perhaps not surprising that despite the system proving 
very successful for the expression of SK, it is seemingly not suitable for other ZAAP proteins, 
which share much less homology. There is a possibility that smaller, truncated SUMOstar-
SCG proteins may have been produced in the E.coli system, suggested by multiple bands 
around the predicted size for SUMOstar-tagged SCG. Appropriate stains could be employed 
to determine whether the bands on the gel contained the 6xHis-tag and therefore are SUMO-
SCG or a truncation.  
Though optimising the conditions was attempted to a certain extent, more could be done with 
attention to timing, temperature and the ratio of protease to protein. Attempts to cleave the 
aLICator 6xHis-tag showed loss of SCG activity when the protein was subjected to overnight 
incubation with rEK. This suggests non-specific cleavage of the protein, even though the 
sequence was checked for rEK recognition sites, and therefore alternative restriction 
endonucleases may need to be explored. 
The aLICator system was useful as the precut vector and rEK combination allowed the first 
codon of SCG to sit adjacent to the recognition sequence for rEK, which is also the point at 
which the protease cleaves. The unique SUMOstar protease also allows precise cleavage 
between the start of the protein of interest and the purification tag without leaving additional 
amino acids. Alongside the decision to attempt expression of SCG with the aLICator/rEK 
system following difficulties with the SUMOstar system, other vectors with alternative tags and 
cleavage approaches were considered. There are a large number of expression systems 
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which utilise N-terminal tags in addition to the SUMOstar and aLICator options explored in this 
work. However, the necessity to preserve the N-terminal Ile1 residue in this instance, severely 
limits vector options. Many vectors utilise restriction sites to allow insertion of the gene of 
interest into the expression vector adjacent to the recognition sequence for protease cleavage, 
but this often leaves additional amino acids. Many proteases typically employed in 
recombinant protein expression cleave within the recognition sequence also leaving additional 
amino acid residues attached to the final protein product. Such examples include thrombin, 
FXa and PreScission (GE Healthcare). Given that that this work intended to understand SCG 
interaction with the haemostatic system, specifically prothrombin and thrombin to promote 
fibrin formation, the use of coagulation factors in the expression and purification process were 
avoided. Commercial capture and removal kits for FXa and thrombin are available, but 
complete capture can never be guaranteed, so these options were considered less rigorously 
than others.    
C-terminal tags can be a useful alternative to N-terminal tags in many instances, but require 
the addition of an N-terminal methionine (Met) residue, or ‘start’ codon for protein translation. 
Cleavage of N-terminal ‘Met’ by bacterial enzymes in post- translational modifications is known 
to be inefficient and dependent on expression conditions such as temperature (Thelwell and 
Longstaff, 2014), therefore C-terminal tags are not a viable option for the expression of SCG 
with a native N-terminal sequence. Insufficient processing of N-terminal ‘Met’ residues would 
also be an issue with native, untagged SCG expression. The absence of a tag may or may 
not improve the expression of SCG. It also complicates the purification process, with reliance 
on techniques such as ion exchange chromatography, size exclusion chromatography, or 
potentially the more tailored, immobilised prothrombin, which would all require extensive 
optimisation.  
 A GST tag was used by (McAdow et al., 2012) to overcome SCG degradation during 
expression with alternatives including a pET15b/Strep tag system. Whilst the E. coli cells, used 
in this work are protease deficient, use of a GST tag or alternative expression strains could be 
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explored. There does not seem to be a GST tag vector system which allows conservation of 
the N-terminal sequence but mutagenesis could allow removal of extra bases to enable this 
as a viable option. 
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Chapter 6: Discussion 
6.1 Streptokinase and thrombolytics 
GCS S. equisimilis H46a SK has been used as a thrombolytic since 1980, and remains the 
most extensively used thombolytic worldwide (Armstrong and Collen, 2001). Scientific 
understanding of the mechanism is extensive but there has been no consideration for the 
properties of SK from other Streptococcal strains, such as GAS, until very recently. Even so, 
this new interest has been focused on the understanding of Streptococcal virulence, and there 
has also been little appreciation for the implications alternative SK variants could have for the 
therapeutic and its use in the treatment of myocardial infarction. This is the only mechanistic 
study to date comparing the mechanistic activity of GCS H46a SK with that of GAS SK from 
S. pyogenes, a cluster 2a M1 serotype strain. The work herein has demonstrated that MIGAS 
SK is stimulated by fibrinogen (Figure 2.5 and 2.7 and 2.8 as examples), and to an even 
greater extent fibrin (e.g. Figure 2.5 and Table 2.2). Furthermore, M1GAS SK displays 
characteristic similarities to the fibrin-specific physiological plasminogen activator, tPA, 
suggesting a similar template mechanism of action (Figure 2.6 and Figure 2.19). This 
discovery directly disputes one of the historically defining features of SK activation of 
plasminogen; a lack of fibrin specificity (Boyle and Lottenberg, 1997). This notion was based 
on studies which investigated H46a SK, used in the therapeutic for treatment of myocardial 
infarction, which displays no increase in activity in the presence of fibrinogen or fibrin, verified 
in Figure 2.5. Given the contrasting mechanisms of plasminogen activation demonstrated here 
between a single GCS and GAS SK, it is very likely there are many more SK variants with 
distinct mechanisms among Streptococci. 
The fibrin-independent mechanism of H46a SK has contributed significantly to the historical 
direction of thrombolytic design (Armstrong and Collen, 2001). It was the pursuit of fibrin 
specificity, lacking in H46a SK and uPA, the first generation thrombolytics, and the associated 
bleeding complications that often ensued, that drove the development of the second 
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generation alternatives including Alteplase (recombinant tPA) (Verstraete, 2000). It is possible 
that had M1GAS SK been chosen in place of H46a SK originally, the course of thrombolytic 
development may be significantly different. Second generation thrombolytics exhibited fibrin 
binding domains and as such were perceived to offer more fibrin targeted plasminogen 
activation (Verstraete, 2000). The GUSTO trial, an international randomised trial to compare 
demonstrated improvements compared to SK for incidences of haemorrhagic stroke and 
mortality with Alteplase (Investigators, 1993), and Alteplase largely replaced the use of SK in 
developed nations. However, in reality second generation thrombolytics were not as 
successful as initially hoped, with bleeding complications such as intracranial haemorrhage 
still a serious concern (Armstrong and Collen, 2001). The short half life of tPA, and less than 
optimal fibrin specificity encouraged the development of thrombolytic design further. Fibrin 
targeted activity remained the apparent best option for thrombolytic enhancement and as such 
also governed some of the rationale behind third generation therapeutics (Verstraete, 2000). 
One such example includes tenectaplase, a recombinant deletion mutant tPA with increased 
fibrin specificity, PAI-1 resistance and plasma half life (Armstrong and Collen, 2001). However, 
despite significant effort, fibrin specificity in laboratory assays, never transferred well to in vivo 
results and severe bleeding complications such as intracranial haemorrhage remain a genuine 
concern even with the third generation therapeutics (Dundar et al., 2003). 
There is an increasing incidence of cardiovascular disease in the developing world, and limited 
options for treatment (Feigin and Krishnamurthi, 2011). Due to the expense, tPA based 
thrombolytics not viable treatment options. SK is a cheaper and easily produced alternative 
that can be made in large quantities recombinantly with relatively inexpensive equipment 
(Thelwell, 2010, Thelwell and Longstaff, 2014, Butcher et al., 2013). Several trials have 
determined no benefit for the use of SK in the treatment of ischaemic stroke, but there remains 
support for further investigations into its use in ischaemic stroke to allow a cost-effective 
alternative for the developing world (Butcher et al., 2013, Feigin, 2007, Feigin and 
Krishnamurthi, 2011). SK variants, such as the fibrin-stimulated M1GAS SK in this project, 
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may offer more benefit than the current H46a SK, which exhibits no fibrin specificity, and could 
be explored as potential therapeutics. Furthermore, should a suitable alternative be identified, 
the nature of recombinant protein technology would enable movement to production of the 
new SK variant with minimal cost and effort. 
Typically fibrin specificity can be thought of as the stimulation of plasminogen activators in the 
presence of fibrinogen or fibrin compared to in solution. However, it has also been proposed 
that perhaps a more accurate assessment of fibrin specificity would be to compare the 
stimulation of plasminogen activators by fibrin in comparison to fibrinogen, as this may 
determine more accurately the likelihood of systemic activation in vivo (Bringmann et al., 
1995). Desmoteplase, by this definition exhibits good fibrin specificity, with significantly more 
activity in the presence of fibrin than fibrinogen (Bringmann et al., 1995). In this instance, 
M1GAS SK, and the fibrinogen stimulation it displays here (Figures 2.5 and 2.7 as examples), 
would not be a particularly good alternative for use as a fibrin targeted thrombolytic, as it would 
not be deemed truly fibrin specific. This does not discount the possibility that there may be 
many superior alternatives in the SK family with enhanced or ‘true’ fibrin specificity according 
to this definition. Perhaps exploring the mechanisms of other SK variants may provide some 
answers for rationale thrombolytic design to enhance targeted plasminogen activation, 
improve fibrin specificity and reduce unwanted bleeding complications. 
Treatment for myocardial infarction has largely moved beyond plasminogen activators with 
PCI being more commonly used in developed countries (Armstrong et al., 2003). However, 
the only approved treatment available for stroke is Alteplase (Longstaff and Kolev, 2015). 
Despite this, there is significant concern about the safety of Alteplase, and there is a need for 
safer alternatives. Recently an expert working group investigation from the Medicines and 
Healthcare products Regulatory Agency (MHRA) was initiated to assess efficacy and safety 
of the drug, given the increasing evidence from clinical trials (Independent expert review 
concludes alteplase is safe and effective for use within existing treatment guidelines, 2015).  
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6.2 Streptokinase and bacterial virulence 
Beginning to piece together the complexities of mechanistic differences between SK sheds 
new understanding on Streptococcal virulence. The SK from S. pyogenes, an M1 type Group 
A Streptococcal (GAS) strain displays a distinct plasminogen activation potential disparate 
from that of the SK S. equisimilis, a Group C streptococcal (GCS) strain, in the purified assay 
systems in this work. The key difference between rSK M1GAS and rSK H46a identified in this 
work is fibrin specificity, whereby rSK M1GAS demonstrates fibrin and fibrinogen localised 
activation. This is consistent with the expression of the fibrinogen receptor M1 on the bacterial 
cell surface (McArthur et al., 2008). Studies have demonstrated that M1, in particular its 
association with fibrinogen, has an important interplay with the haemostatic and innate 
immune systems. (Herwald et al., 2004) demonstrated that M1 binding with fibrinogen caused 
vascular leakage while work by (Macheboeuf et al., 2011) proposed an intricate association 
of M1 and fibrinogen molecules and demonstrated how it causes neutrophil activation. This 
compliments work that demonstates M1 binding of fibrinogen is involved in phagocytotic 
resistance (Anderson et al., 2014). It is also known that bacterial entrapment in fibrin clots by 
the human host is in part a result of FXIIIa cross-linking of the M1 protein to fibrin strands (Loof 
et al., 2011, Loof et al., 2012). Whilst this project has demonstrated that neither M1GAS SK 
nor H46a SK are affected directly by FXIIIa (see Figure 2.15), the interaction between 
fibrinogen, M1 and SK remains to be explored. Particularly, it would be interesting to determine 
the activation of plasminogen by rSK M1GAS in the presence of M1-bound fibrinogen to 
establish if that further modifies the mechanism, perhaps as binding of fibrin does compared 
to fibrinogen most apparent in Figures 2.5 and 2.13.  
M1 is one of several fibrinogen binding M proteins. It has been demonstrated that different 
serotypes of fibrinogen-binding M proteins bind via unique sequences to promote 
Streptococcal survival in blood (Ringdahl et al., 2000, Sun, 2006). Understanding how other 
M protein fibrinogen binding mechanisms influence SK activity could shed further light on the 
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Streptococcal survival observed here, and may help to understand why M1 is considered the 
M protein most associated with invasive infection (Steer et al., 2009). 
This work has focused on understanding the kinetics of rSK H46a and rSK M1GAS interaction 
with plasminogen and plasmin for the promotion of fibrinolysis, and proposed a kinetic model 
based on laboratory and simulated data with fibrinogen to make assumptions for the 
mechanism in the presence of fibrin  (Figure 4.2). This is an extension to compliment previous 
published work by Bock et al, who proposed the “trigger and bullet” hypothesis for H46a SK 
activation of plasminogen (Boxrud et al., 2001, Boxrud and Bock, 2004, Boxrud et al., 2004, 
Nolan et al., 2013). 
Both GCS and GAS are capable of producing the same breadth of infections in humans but it 
is GAS that are more commonly isolated in invasive infections (Ekelund et al., 2005, Cole et 
al., 2011). It seems possible that the differences in fibrin specificity between the GCS and GAS 
SK demonstrated in this thesis could at least in part explain the differences in pathogenicity; 
forming part of the necessary steps for establishing invasive disease. Specifically, it is possible 
to perceive that fibrin(ogen) specificity demonstrated by rSK M1GAS here would be greatly 
advantageous in escaping the fibrin clot in order to establish systemic infection.  
Plasminogen is abundant in the blood, and aside from plasminogen activators, GAS bacteria 
employ the use of several plasminogen binding receptors to promote their survival in the 
human host. Cluster 2b GAS express the cell surface molecule PAM which is shown to 
increase pericellular plasmin generation and bacterial virulence (Ringdahl et al., 1998, Sun et 
al., 2004), while cluster 1 GAS display the antiphagocytic GAPDH and SEN plasminogen 
binding receptors (Sun, 2006). Cluster 1 bacteria, typically isolated in pharyngeal infections, 
demonstrate higher solution SK activity than PAM expressing cluster 2b bacteria, the isolate 
commonly associated with skin infections. Work by (Zhang et al., 2012, Zhang et al., 2013) 
have begun to link these functional differences with structural differences, particularly in the β 
domain to better understand the distinct tissue tropism and virulence of GAS strains. 
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The findings in this work with regard to the mechanism of plasminogen activation by SK from 
pathogenic M1GAS bacteria complement an extensive body of research with regard to GAS 
and the importance of plasminogen in establishing infection. Work with transgenic mice with 
human plasminogen has demonstrated that SK is critical for GAS infection (Sun et al., 2004).  
The use of plasminogen is apparent throughout bacterial virulence. As mentioned before it is 
a key feature in Y. pestis, responsible for the bubonic plaque (Degen et al., 2007). 
Furthermore, Borrelia burgdorferi, responsible for Lyme disease, express the plasminogen 
binding receptor lipoprotein A on its cell surface, which enhances plasmin generation by 
physiological plasminogen activators uPA and tPA (Fuchs et al., 1994). A plasminogen 
knockout mouse model determined that host plasminogen was necessary for B. burgdorferi 
dissemination within the tick vector, and contributed to the establishment of disease within the 
host (Coleman et al., 1997). 
This work has focused on understanding the kinetics of rSK H46a and rSK M1GAS interaction 
with plasminogen and plasmin for the promotion of fibrinolysis, determining that rSK M1GAS 
is fibrin(ogen)-targeted. However, plasmin is a broad specificity protease, and its other 
substrates include the extracellular matrix, matrix metalloproteases and complement proteins 
(Lambris et al., 2008). Little attention has been paid to how SK binding of plasminogen and 
plasmin, to promote plasmin generation and alter protease function, could affect the activation 
of these substrates as well as the role this could play on bacterial virulence. An important part 
of innate mammalian immunity against invading pathogens is the complement cascade. As 
such, many bacteria have evolved means by which to evade this defence system, which has 
been comprehensively reviewed by (Lambris et al., 2008). In particular, S. aureus has been 
shown to promote the degradation of C3b and IgG through SAK plasmin generation 
(Lahteenmaki et al., 2001). It would be interesting to further our understanding of the role of 
SK in bacterial virulence by investigating the influence it has on the proteolysis of plasmin 
substrates, and if again a difference is seen for GAS and GCS variants, such as the fibrin 
stimulation seen by GAS SK in this work.  
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Understanding the mechanisms of bacterial virulence factors and their interaction with the 
human coagulation and fibrinolysis systems can enhance understanding of pathogenesis and 
identify potential new targets for antimicrobial action. The development of new antimicrobial 
technologies is an increasing pressing need, as demonstrated by incentives such as the 
Longitude prize which offers £10 million in funding for better diagnostic tests to ensure more 
effective use of antimicrobial agents (Longitude Prize Open, 2015). Microbial resistance to 
current antibiotics is increasing, and it is predicted that 10 million people could die every year 
by 2050, from infections caused by resistant microbial strains if no significant developments 
are made (O'Neill, 2014). Studies such as this, which provide detailed molecular 
understanding of the interplay between bacterial virulence factors and host proteins, could 
provide rationale for antimicrobial therapies. This work has demonstrated the fibrin specificity 
of the plasminogen activation by SK from S. pyogenes, commonly isolated from invasive 
infections (Ekelund et al., 2005, Steer et al., 2009). Interupting this interaction with fibrinogen, 
critical for M1GAS SK activity, could be a possible way of reducing the invasive potential of S. 
pyogenes to treat infection.  
It is important to be aware that in vitro data from purified assay systems does not always 
correlate well with the effect in living organisms. This is evident with the lack of success seen 
with the fibrin-targeted activity of second and third generation thrombolytics in vivo, despite 
laboratory assays demonstrating fibrin specificity for tPA, recombinant mutants and 
desmoteplase (Verstraete, 2000). Therefore there is always a possibility that the mechanism 
of M1GAS SK identified in this project could simply be an artefact in a far more elaborate story.   
6.3 Staphylocoagulase 
Though generation of a full-length native N-terminal sequence SCG protein was not feasible 
within the timeframe of this project, the need to further understand the mechanism of SCG 
activation of prothrombin is still a valuable aim. S. aureus expresses the plasminogen activator 
SAK, which serves to breakdown fibrin and the prothrombin activator SCG, which promotes 
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fibrin formation. There is currently no clear understanding why one bacterial strain would gain 
advantage from employing two seemingly opposing mechanisms.  
SCG is present in several Staphylococcal strains, which display a degree of genetic diversity 
and evolutionary disparity as described for SK. M1GAS SK and H46a SK share over 88.4 % 
sequence homology, yet this work has shown they display remarkably different mechanisms 
at the molecular level. It would interesting to investigate whether SCG variants offer 
mechanistic variations too. The benefit of plasminogen activators is apparent if the need is to 
escape the confines of a fibrin clot, in order to avoid neutrophils and their defence 
mechansisms such as neutrophil extracellular trap’s (NET’s), and establish invasive disease 
(Varju et al., 2015). Whereas, if the aim is to remain inconspicuous whilst travelling throughout 
the host with the intent to establish systemic infection, an invisibility shield of host 
fibrinogen/fibrin would prove valuable. One hypothesis regarding the role of staphylothrombin 
in pathogen invasion is as a protective coat to avoid detection by the host immune system 
(McAdow et al., 2012). As such, the need to effectively bind and cleave fibrinogen within close 
vicinity of the cell surface with a prothrombin activator, SCG, is understandable. It is also 
known that fibrinogen and SCG are critical component of abscess formation (Cheng et al., 
2009, Cheng et al., 2010, Cheng et al., 2011). This work has revealed that the fibrinogen 
network and SCG is generally at the host interface, further suggesting it is a protective feature. 
However, at a certain point, the breakdown of the abscess is essential to further promote 
infection, so it is possible that SAK plays a role here, breaking down the staphylothrombin 
product.  
6.4 Future work 
6.3.1 Streptokinase 
The model made in this work to explain the mechanism of M1GAS SK was derived in part 
from laboratory data, and in part from values taken from the literature. These numbers are 
unlikely to be completely representative of the assay conditions employed here, or the 
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specifics of the SK from S. pyogenes. Improvements could therefore be made to this work by 
conducting further experiments such as determining true binding kinetics with Biacore 
technologies, such as work carried out by (Cole et al., 2011). As mentioned earlier, this work 
looks at the simpler binding of fibrinogen and uses this understanding to make assumptions 
about fibrin interactions. Recently, work with tPA and fibrin has been carried out and similar 
efforts could be made with SK variants (Bannish et al., 2014b, Bannish et al., 2014a). Soluble 
fibrin analogues such as chloramine T or cyanogen bromide treated fibrinogen could also be 
used in purified assay systems such as in this study to further probe the difference in fibrin 
and fibrinogen stimuolation of M1GAS SK activation of plasminogen (Stief et al., 2001).  
Alongside the expression attempts for SCG, initial cloning work was done to produce 
fluorescent rSK M1GAS. This work was not completed within the time frame of the project, but 
the aim was to generate yellow fluorescent protein (YFP) recombinant M1GAS SK and use 
confocal microscopy to visualise the interaction and distribution of SK within fibrin clots, in a 
manner similar to work with tPA (Longstaff et al., 2011). 
The decision to investigate the mechanism of M1GAS SK from cluster 2a in this project was 
made because it is generally considered to be the most significant streptococcal variant with 
regard to human invasive disease (Cole et al., 2011, Ekelund et al., 2005). There is however 
a lot of merit in studying SK from other clusters or even more variants within cluster 2a. This 
may bring to light other interesting mechanistic variations, and provide rationale for 
improvements to thrombolytic therapies and antimicrobial technologies.   
6.3.2 Staphylocoagulase 
Successful expression of a full-length native N-terminal sequence SCG would need to occur 
to enable any mechanistic exploration. Should recombinant systems not allow this, an 
increasingly affordable option is to have the peptide construct synthesized, and would have 
been investigated if time had allowed. Kinetic studies similar those employed for the 
investigation of SK in this project could be used for SCG activation of prothrombin. Comparing 
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staphylothrombin fibrin formation with physiological fibrin formation initiated by thrombin may 
shed some understanding on the structure of the bacterial fibrin product.  
Of further interest would be the fibrinolysis of the staphylothrombin product by both 
physiological plasminogen activators, tPA and uPA, as well as bacterial plasminogen 
activators, SK and SAK. It could be that the fibrin is more suited to SAK and SK mechanisms, 
and resistant to physiological hydrolysis, but there have been no studies specifically 
comparing the fibrinolysis mechanisms of each plasminogen activator. It would also be 
valuable to compare fibrin formation by SCG to that of snake enzymes, which exhibit thrombin-
like activity. Examples include batroxabin and ancrod isolated from pit vipers. These snake 
enzymes make an easily digestible fibrin product, by unique cleavage of fibrinogen to promote 
fibrin formation, in order to deplete the host of fibrinogen and induce bleeding (Swenson and 
Markland, 2005, Markland, 1998).   
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Appendix 
Appendix 1: R script to produce clot lysis profiles and parameters for analysis of 
fibrinolysis assays in Chapters 2 and 3.  
Kindly provided by Colin Longstaff, personal communication.  
#Plate reader data is saved as .txt in Excel, here in C:\Tempdata\2013 folder, with a chosen 
name 
#Results are written to C:\Tempdata\2013\Results folder 
 
rm(list=ls()) #wipes all variables in 
memory 
 
## ADJUST SETTINGS IN 
SECTIONS 1-4 FOR YOUR DATA 
## ADDING A # MEANS THE 
LINE IS IGNORED 
## DELETING A # MEANS 
THE LINE WILL BE READ 
 
##1.  SELECT TARGET FILE 
target<- "C://Tempdata/sianclots.txt"  # A nice set of sample data 
#target<- "C://Tempdata//2013//June10Actilyse1.txt" # insert the name of the file saved in 
target directory 
plate1<- read.table(target, header=TRUE) 
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##OR Alternative file selection mechanism (seems not to work with 64 bit Windows!) 
#library (RODBC) 
#newtarget<- odbcConnectExcel(file.choose()) 
#plate1<-sqlFetch(newtarget,"Sheet1") 
#odbcClose(newtarget) 
 
attach(plate1) 
Names<-as.vector(names(plate1)) 
 
 
##2.  FILL IN THESE PARAMETERS TO DESCRIBE THE DATA SHEET 
nabsCols=2  #number of columns 
before absorbance readings 
absCols=96  #number of columns of 
absorbance readings-best stick to 96 if possible 
tint=30  #interval between 
readings in s 
delay=0  #optional delay to first 
reading 
RowNum=8  #For a normal plate will be 
8 but can be changed to generate a different layout of results 
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##3.  PLOTTING SETTINGS 
y0=0.065  #adjust this to make a 
sensible absorbance for 100% lysis for whole plate 
xtrim=0.5 #make "trim" a fraction to truncate the xscale on the plotted graphs (does not affect 
results) 
ytrim=1.2  #make "trim" a fraction to 
truncate the yscale on the plotted graphs (does not affect results) 
#J=1   #choose this if you 
want labels from the Headers included in wells in your plot, e.g. A1=1200 etc. 
J=0   #choose this if you 
just want the answer printed in the wells. e.g. 1200 
 
##4.  SELELCT THE RESULTS YOU WANT PRINTED ON THE PLOT AND IN THE 
CLIPBOARD 
## ALL THE OPTIONS ARE 
STORED IN FILES IN TEMPDATA\RESULTS (OR OTHER DIRECTORY AS SPECIFIED) 
#z<-1            #choose for max 
Abs 
#z<-2           #time to 
max Abs 
#z<-3  
   lyspoint=50    
#time to selected % lysis 
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#z<-4           
#time to selected %lysis from peak 
#z<-5           
#time to complete lysis 
z<-6           
#sum of abs, like area under curve to full lysis 
 
##The program goes to work! 
 
absCol1<-nabsCols+1 
dataCols<-absCols+nabsCols 
 
vect1<-absCol1:dataCols 
vect2<-absCol1:dataCols 
vect3<-absCol1:dataCols 
vect4<-absCol1:dataCols 
vect5<-absCol1:dataCols 
vect6<-absCol1:dataCols 
vectz<-absCol1:dataCols 
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Appendix 2: R script to produce surface contour and heat maps for kinetic and 
simulated data in Chapter 4 
Kindly provided by Colin Longstaff, personal communication. 
##Data are generated by gepasi 
##Read from a text file containing OD values plus other columns 
##Time is generated not read from the file 
 
rm(list=ls())  #wipes all variables in memory 
 
#setwd("Y:/Sian/Models") 
#setwd("T:/Sian/Models") 
setwd("C:/May 5") 
 
##REAL DATA OCT 3 
##FILL IN THESE PARAMETERS 
nabsCols=1     #number of columns before absorbance readings 
absCols=88    #number of columns of absorbance readings 
tint=30    #interval between readings 
delta=0.1   #delta in absorbance to calculate rate 
absRows=absCols   #number of rows in results = 8 for plate, 96 for whole 
plate 
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Bfact=3.56e4   #conversion factor for abs to pM/s 
 
xx3=c(30.3, 20.2, 13.5, 9.0, 6.0, 4.0, 2.66, 1.19, 0.79, 0.52, 0) 
#Lxx<-log10(xx) 
yy3=c(1.6, 0.8, 0.4, 0.2, 0.1, 0.05, 0.025, 0) 
xxx3<-rep(xx3,length(yy3)) 
yyy3<-rep(yy3, each=length(xx3)) 
Lxxx3<-(log10(xxx3 + 1)) 
 
absCol1<-nabsCols+1 
dataCols<-absCols+nabsCols 
vect3<-absCol1:dataCols 
 
 
targetO3<- "Data/OCT3.txt" 
plate13<- read.table(targetO3, header=TRUE) 
 
 
pointsnum<-length(plate13[,1])-1 
tend=pointsnum*tint 
 
Time<- seq(0,tend, by=tint) 
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tsq<-Time^2 
 
par(mfrow=c(8,11)) 
par(mar=c(0.2,0.2,0.2,0.2)) 
 
x0<- 0 
xend<- tend^2  #can be changed to a number make plots better 
y0<- 0   
yend<-delta 
cropx=.006  #crop the plotted x axis 
cropy=1  #crop the plotted y axis 
 
for(i in absCol1:dataCols){  
  yi<- plate13[,i] 
  yic<- plate13[,i]-plate13[1,i] 
  Yi<-yic[yic<delta] 
  Tsq<-tsq[1:length(Yi)] 
  regrCol<-lm(Yi~Tsq) 
  #plot(Tsq,Yi, col="red", pch=20,xaxt="n", yaxt="n", xlim=c(x0,cropx*xend), 
ylim=c(y0,cropy*yend)) 
  ##It is possible to change the plotting paramters here, x or y axis length etc 
  #abline(regrCol) 
  Res<-summary(regrCol) 
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  ODans<-Res$coef[2] 
  ans<-signif(1e12*ODans/Bfact, digits=4) 
  #legend(x0,yend,bty="n", ans) 
  #text(cropx*tend^2/2, cropy*yend*0.9, ans) 
  vect3[i-nabsCols]<-ans 
   
} 
mat3<- matrix(vect3, byrow=TRUE, nrow=absRows) 
platemat3<-matrix(vect3, byrow=TRUE, nrow=8) 
write.table(mat3, "clipboard", sep="\t", col.names=F, row.names=F) 
write.table(platemat3, "C:/Tempdata/plateRes3.txt", sep="\t", col.names=F, row.names=F) 
#print(paste(names(plate13[i]),"=", signif(Res$coef[2]*1e9, digits=4))) 
#Results are in plateRes3.txt and in clipboard for pasting into ExcelTimeplate 
#print(round(platemat3, digits=3)) 
 
 
nabsCols=1     #number of columns before absorbance readings 
absCols=88    #number of columns of absorbance readings 
tint=30    #interval between readings 
#delta=0.2    #delta in absorbance to calculate rate 
absRows=absCols   #number of rows in results = 8 for plate, 96 for whole 
plate 
Bfact=3.56e4   #conversion factor for abs to pM/s 
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xx4=c(30.3, 20.2, 13.5, 9.0, 6.0, 4.0, 1.77, 1.19, 0.79, 0.52, 0) 
yy4=c(1.6, 0.8, 0.4, 0.2, 0.1, 0.05, 0.025, 0) 
xxx4<-rep(xx4,length(yy4)) 
yyy4<-rep(yy4, each=length(xx4)) 
Lxxx4<-(log10(xxx4 + 1)) 
 
absCol1<-nabsCols+1 
dataCols<-absCols+nabsCols 
vect4<-absCol1:dataCols 
 
 
targetO4<- "Data/OCT4.txt" 
plate14<- read.table(targetO4, header=TRUE) 
 
 
pointsnum<-length(plate14[,1])-1 
tend=pointsnum*tint 
 
Time<- seq(0,tend, by=tint) 
tsq<-Time^2 
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par(mfrow=c(8,11)) 
par(mar=c(0.2,0.2,0.2,0.2)) 
 
x0<- 0 
xend<- tend^2  #can be changed to a number make plots better 
y0<- 0   
yend<-delta 
cropx=.01  #crop the plotted x axis 
cropy=1  #crop the plotted y axis 
 
for(i in absCol1:dataCols){  
  yi<- plate14[,i] 
  yic<- plate14[,i]-plate14[1,i] 
  Yi<-yic[yic<delta] 
  Tsq<-tsq[1:length(Yi)] 
  regrCol<-lm(Yi~Tsq) 
  #plot(Tsq,Yi, col="red", pch=20,xaxt="n", yaxt="n", xlim=c(x0,cropx*xend), 
ylim=c(y0,cropy*yend)) 
  ##It is possible to change the plotting paramters here, x or y axis length etc 
  #abline(regrCol) 
  Res<-summary(regrCol) 
  ODans<-Res$coef[2] 
  ans<-signif(1e12*ODans/Bfact, digits=4) 
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  #legend(x0,yend,bty="n", ans) 
  #text(cropx*tend^2/2, cropy*yend*0.9, ans) 
  vect4[i-nabsCols]<-ans 
   
} 
mat4<- matrix(vect4, byrow=TRUE, nrow=absRows) 
platemat4<-matrix(vect4, byrow=TRUE, nrow=8) 
write.table(mat4, "clipboard", sep="\t", col.names=F, row.names=F) 
write.table(platemat4, "C:/Tempdata/plateRes4.txt", sep="\t", col.names=F, row.names=F) 
#print(paste(names(plate14[i]),"=", signif(Res$coef[2]*1e9, digits=4))) 
#Results are in plateRes4.txt and in clipboard for pasting into ExcelTimeplate 
#print(round(platemat4, digits=3)) 
#print(round(platemat3, digits=3)) 
 
#######SIMULATED DATA 
 
simtint=0.5     #interval between readings 
#delta=.2   #delta in absorbance to calculate rate 
NumSets<-11   #take from gepasi set up 
NumTempl<-NumSets^2 
FirstRead<-1 
EndTime<-600  #take from gepasi setup 
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NumGroups<-NumSets*EndTime/simtint 
vect3s<-1:NumTempl 
#Bfact=3.56e4 #conversion factor for OD/s2 to pM/s 
 
#targetSO3<- "Sept 11 Pyo 1600 K.txt" 
targetSO3<- "May 5 Pyo 1600 K.txt" 
 
plate03s<- read.table(targetSO3, header=TRUE) 
plate13S<-na.omit(plate03s) 
#attach(plate13S) 
 
 
#OD<-X.OD  ##simple name change 
Time<-seq(0,EndTime,simtint) 
tsq<-Time^2 
 
tstart<-which(plate13S$OD==0) 
tlast<-tstart+EndTime 
Var13<-plate13S[,1] 
Var23<-plate13S[,2] 
vectempl3<-Var13[c(tstart)] 
vectempl13<-vectempl3[1:NumSets] 
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vectempl23<-Var23[seq(NumGroups, length(Var13), NumGroups)] 
write.table(vectempl13, "C:/Tempdata/Var13.txt", col.names=F, row.names=F) 
write.table(vectempl23, "C:/Tempdata/Var23.txt", col.names=F, row.names=F) 
SimF3<-rep(vectempl13,length(vectempl23)) 
SimG3<-rep(vectempl23, each=length(vectempl23)) 
SimFF3<-SimF3*1e6 
SimGG3<-SimG3*1e6 
LSimFF3<-(log10(SimFF3+1)) 
 
##Graphing  
par(mfrow=c(11,11)) 
par(mar=c(0.2,0.2,0.2,0.2)) 
 
x0<- 0 
xend<- EndTime^2  #can be changed to a number make plots better 
y0<- 0   
yend<-max(plate13S$OD) 
cropx=1  #crop the plotted x axis 
cropy=.1  #crop the plotted y axis 
 
for(i in 1:NumTempl){ 
  yi<- plate13S$OD[tstart[i]:tlast[i]] 
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  Yi<-yi[yi<delta] 
  Tsq<-tsq[1:length(Yi)] 
  regrCol<-lm(Yi~Tsq) 
  #plot(Tsq,Yi, col="red", pch=20,xaxt="n", yaxt="n", xlim=c(x0,cropx*xend), 
ylim=c(y0,cropy*yend)) 
  ##It is possible to change the plotting paramters here, x or y axis length etc 
  #abline(regrCol) 
  Res<-summary(regrCol) 
  ODans<-Res$coef[2] 
  ans<-signif(1e12*ODans/Bfact, digits=4) 
  #text(cropx*xend/2, cropy*yend*0.9, ans) 
  vect3s[i]<-ans 
} 
mat3s<- matrix(vect3s, byrow=TRUE, nrow=NumSets) 
write.table(t(mat3s), "clipboard", sep="\t", col.names=F, row.names=F) # large datasets 
Clipboard overflows 
write.table(mat3s, "C:/Tempdata/m.plateRes3.txt", sep="\t", col.names=F, row.names=F) 
#detach(plate13S) 
#Results are in m.plateRes3.txt and in clipboard for pasting 
#print(round(mat3s, digits=3)) 
 
 
#######SIMULATED DATA 2 
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simtint=0.5    #interval between readings 
#delta=.1   #delta in absorbance to calculate rate 
NumSets<-11   #take from gepasi set up 
NumTempl<-NumSets^2 
FirstRead<-1 
EndTime<-600  #take from gepasi setup 
NumGroups<-NumSets*EndTime/simtint 
vect4s<-1:NumTempl 
 
targetSO4<- "May 5 Pyo 400 K.txt" 
 
plate04<- read.table(targetSO4, header=TRUE) 
plate14S<-na.omit(plate04) 
#names(plate14) 
 
#OD<-X.OD  ##simple name change 
Time<-seq(0,EndTime,simtint) 
tsq<-Time^2 
##Make vectors for other variables 
##Note, these are not numbers that can be read 
##See accompanying file to generate real vectors from gepasi inputs 
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tstart<-which(plate14S$OD==0) 
tlast<-tstart+EndTime 
#vectempl<-X.F.i[seq(600, length(X.F.i), 600)]  #alternative route 
Var14<-plate14S[,1] 
Var24<-plate14S[,2] 
vectempl4<-Var14[c(tstart)] 
vectempl14<-vectempl4[1:NumSets] 
vectempl24<-Var24[seq(NumGroups, length(Var14), NumGroups)] 
write.table(vectempl14, "C:/Tempdata/Var14.txt", col.names=F, row.names=F) 
write.table(vectempl24, "C:/Tempdata/Var24.txt", col.names=F, row.names=F) 
SimF4<-rep(vectempl14,length(vectempl24)) 
SimG4<-rep(vectempl24, each=length(vectempl24)) 
SimFF4<-SimF4*1e6 
SimGG4<-SimG4*1e6 
LSimFF4<-(log10(SimFF4+1)) 
 
##Graphing  
par(mfrow=c(11,11)) 
par(mar=c(0.2,0.2,0.2,0.2)) 
 
x0<- 0 
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xend<- EndTime^2  #can be changed to a number make plots better 
y0<- 0   
yend<-max(plate14S$OD) 
#cropx=1  #crop the plotted x axis 
#cropy=1  #crop the plotted y axis 
 
for(i in 1:NumTempl){ 
  yi<- plate14S$OD[tstart[i]:tlast[i]] 
  Yi<-yi[yi<delta] 
  Tsq<-tsq[1:length(Yi)] 
  regrCol<-lm(Yi~Tsq) 
  #plot(Tsq,Yi, col="red", pch=20,xaxt="n", yaxt="n", xlim=c(x0,cropx*xend), 
ylim=c(y0,cropy*yend)) 
  ##It is possible to change the plotting paramters here, x or y axis length etc 
  #abline(regrCol) 
  Res<-summary(regrCol) 
  ODans<-Res$coef[2] 
  ans<-signif(1e12*ODans/Bfact, digits=4) 
  #text(cropx*xend/2, cropy*yend*0.9, ans) 
  vect4s[i]<-ans 
} 
mat4s<- matrix(vect4s, byrow=TRUE, nrow=NumSets) 
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write.table(t(mat4s), "clipboard", sep="\t", col.names=F, row.names=F) # large datasets 
Clipboard overflows 
write.table(mat4s, "C:/Tempdata/m.plateRes4.txt", sep="\t", col.names=F, row.names=F) 
#Results are in m.plateRes4.txt and in clipboard for pasting 
#print(round(mat4s, digits=3)) 
 
##Interperlation 
 
library(lattice) 
library(akima) 
gran<-25    # granularity of projection (number of tiles in surfaces) 
inter_data4<-interp(Lxxx4, yyy4, vect4,xo=seq(min(Lxxx4), max(Lxxx4), length = gran), 
yo=seq(min(yyy4), max(yyy4), length = gran),linear=T,duplicate=T) 
inter_data3<-interp(Lxxx3, yyy3, vect3,xo=seq(min(Lxxx3), max(Lxxx3), length = gran), 
yo=seq(min(yyy3), max(yyy3), length = gran),linear=T,duplicate=T) 
inter_sim3<-interp(LSimFF3, SimGG3, vect3s,xo=seq(min(LSimFF3), max(LSimFF3), length 
= gran), yo=seq(min(SimGG3), max(SimGG3), length = gran),linear=T,duplicate=T) 
inter_sim4<-interp(LSimFF4, SimGG4, vect4s,xo=seq(min(LSimFF4), max(LSimFF4), length 
= gran), yo=seq(min(SimGG4), max(SimGG4), length = gran),linear=T,duplicate=T) 
 
AY<-inter_data3 
BE<-inter_sim3 
max.z<-c(max(AY$z), max(BE$z)) 
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min.z<-c(min(AY$z), min(BE$z)) 
max.allz<-max(max.z) 
min.allz<-min(min.z) 
 
##GRAPHS 
##use this to generate a single big plot 
#FigMid<-c(0.1, 0.90, 0.1, 0.90)     
#par(fig=FigMid) 
#image(AY,  col=heat.colors(2500)) 
#contour(AY, nlevels=10, lwd=1, labcex=1.2, method="flattest", xlab="Fgn", ylab="Pgn", 
vfont=c("sans serif", "bold"),add=T)    #optional contours on heat map 
 
##These commands generate a 4 panel plot 
FigUL<-c(0.05,0.5,0.5,0.95) 
FigLL<-c(0.1,0.47, 0.1,.5) 
FigUR<-c(0.55,1, 0.5,0.95) 
FigLR<-c(0.6,.95, 0.1,0.5) 
 
#LEFT 
par(fig=FigUL) 
persp(AY, xlab="Fgn", ylab="Pgn", zlab="Rate", xlim=c(0,1.5), zlim=c(min.allz,max.allz), 
theta=-50, phi=20, col="lightblue") 
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#persp(AY, xlab="Fgn", ylab="Pgn", zlab="Rate", zlim=range(AY, finite=TRUE), theta=-40, 
phi=30, col="lightblue") 
#text(0,0.3, targetO3)    #include this line to print file names 
par(fig=FigLL, new=T) 
image(AY, xlim=c(0,1.5), col=heat.colors(2500)) 
contour(AY, nlevels=12, lwd=1, labcex=1.2, method="flattest", vfont=c("sans serif", 
"bold"),add=T)    #optional contours on heat map 
 
#RIGHT 
#PHI<-50 
par(fig=FigUR, new=T) 
#persp(BE, xlab="Fgn", ylab="Pgn", zlab="Rate", zlim=range(BE, finite=TRUE), theta=-40, 
phi=30, col="lightblue") 
BEpersp<-persp(BE, xlab="Fgn", ylab="Pgn", zlab="Rate", xlim=c(0,1.5), 
zlim=c(min.allz,max.allz), theta=-50, phi=20, col="pink") 
#BEpersp 
#text(0,0.3, targetO3)    #include this line to print file names 
 
par(fig=FigLR, new=T) 
image(BE,  xlim=c(0,1.5),col=heat.colors(2500)) 
contour(BE,  nlevels=10, lwd=1, labcex=1.2, method="flattest", vfont=c("sans serif", 
"bold"),add=T)   #optional contours on heat map 
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##These commants generate an spinning 3d plot and a snapshot of the final position 
##The  figure can be dragged and rotated by the mouse and new snapshots taken 
 
setwd("C://Tempdata") 
require(rgl) 
z2<-seq(11,71,1) 
dur<-z2 
for(ii in 1:length(z2)){persp3d(inter_data3,  xlab="Fgn", ylab="Pgn", zlab="Rate",   zlim=c(-10, 
300), theta=-60, phi=30, col="lightblue") 
                        play3d(spin3d(rpm=1), duration=dur-10 ) 
                      print(z2[ii]) 
                        snapshot3d(paste("Figdat",z2[ii],".png",sep=""))} 
##SHOULD BE AN EASIER WAY? 
#rgl.open() 
#movie3d(spin3d(), duration=3, convert=FALSE) 
 
 
 
